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CHAPTER I 
 
INTRODUCTION 
 
Peptide Delivery Barriers 
The therapeutic potential of peptides, proteins, and antibodies in applications ranging from cancer 
treatments to vascular pathologies has become more apparent as the fundamental etiology of these 
disease states becomes more comprehensively characterized [Wilson, 2009 #321;Alexander, 2005 
#120;Craik, 2013 #273;Ewing, 2011 #178;Gizard, 2008 #203;Ni, 2010 #263;Hata, 2005 #206]. However, 
major in vivo barriers exist to effective intracellular delivery of peptide-based, biomacromolecular 
therapeutics for specific applications: proteolysis of the peptide in the in vivo environment prior to or 
following cellular internalization, circumvention of non-specific binding and/or side-effects, translocation 
across the lipid bilayer that 
constitutes the cell membrane, 
escape from the intracellular 
endo-lysosomal and 
exocytosis trafficking 
pathways, and achieving an 
effective peptide dose within 
the intracellular micro-
environment where the 
therapeutic target is located 
(fig. 1.1) [5-8]. A wide array of 
approaches have been 
investigated to address these 
delivery barriers ranging from 
the utilization of drug delivery 
vehicles that improve 
Figure 1.1 - Intracellular peptide delivery barriers: 1) Biomacromolecular 
therapeutics like peptides must first translocate the cellular membrane and 
become internalized in the cell. 2) Once internalized, the therapeutic must 
escape from the endo-lysosomal pathway or consequently face degradation in 
lysosomes and/or trafficking for exocytosis out of the cell. 3) Finally, if a drug 
delivery vehicle is utilized to deliver the therapeutic then the vehicle must 
contain an inherent mechanism to release the therapeutic in order to avoid 
steric hindrance of bioactivity in the cytosol. Figure adopted with permission 
from [4]. 
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proteolytic resistance and in vivo half-life [9-11] to the use of electroporation, or cell-penetrant/fusogenic 
peptides to increase cellular internalization [12-14]. In addition to these approaches, the study and use of 
colloidal drug carriers such as liposomes, micelles, and nanoparticles to deliver biomacromolecular 
therapeutics has increased dramatically in the past decade [15-17].  These colloidal drug carriers are 
attractive because they can be modified to be multi-functional in terms of containing targeting moieties 
[18], cell penetrating and/or fusogenic peptides [19, 20], and environmentally responsive ‘smart’ polymers 
that can facilitate escape from the endo-lysosomal trafficking pathway or trigger site-specific, release of 
the therapeutic payload  [21-25]. Despite the advances made in overcoming these delivery barriers, 
substantial synthetic and functional limitations still exist in terms of multi-functional drug carriers that 
simultaneously address the key delivery barriers of stability, cellular uptake, escape from the endo-
lysosomal pathway, and an effective means to ‘un-package’ or release the desired therapeutic into the 
proper intracellular micro-environment. 
 
The Role of p38/MAPK Signaling in Vein Graft Failure 
Cardiovascular disease (CVD) is the leading cause of death in the United States, with coronary 
heart disease responsible for more than 50% of CVD-related mortality (i.e., causing 1 of every 6 deaths) 
[26]. In terms of financial burden, the direct and indirect cost of coronary heart disease in the US were 
~$200 billion in 2009, with a projected price increase of 100% between 2013 and 2030 [26] Coronary 
artery bypass grafting with autologous conduits remains the standard treatment for multi-vessel coronary 
heart disease. However, almost half of saphenous vein grafts fail within the first 18 months due to intimal 
hyperplasia (IH) [27]. Although intimal hyperplasia occurs normal physiologic conditions in the closing of 
the ductus arteriosus[28], pathologic intimal hyperplasia (also known as accelerated intimal hyperplasia) 
occurs in a variety of disease states, specifically in the context of vascular bypass grafting with 
autologous vein. Vein graft intimal hyperplasia is characterized by the migration and proliferation of 
smooth muscle cells into the intima and is associated with excess deposition of extracellular matrix [29]. 
This process results in the formation of a highly cellular lesion (i.e., neointima) that reduces vascular 
lumen area and ultimately leads to thrombosis and/or complete occlusion. No therapeutic approaches are 
sufficient to inhibit IH and improve graft patency in humans.  Antithrombotic and antiplatelet agents, such 
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as warfarin, clopidogrel, and aspirin, have little or no effect on IH [30].  Two large clinical trials tested 
delivery of an E2F transcription factor decoy, designed to prevent smooth muscle proliferation, to 
coronary and peripheral vascular vein grafts, but these trials were unsuccessful at preventing graft failure 
[27, 31]. 
One of the underlying causes of IH is activation of the p38 mitogen activated protein kinase (p38 
MAPK) pathway in vascular smooth muscle cells (VSMCs) owing to mechanical and biochemical stresses 
experienced by the graft during harvest as well as during post-transplant adaptation to arterial pressure 
(i.e., vein graft arterialization) [32]. p38 MAPK activates multiple pro-inflammatory and pro-fibrotic 
effectors implicated in IH (fig. 1.22) [33-35]. However, inhibitors of p38 MAPK have failed clinical trials 
because of the adverse effects associated with blocking this pleotropic, upstream mediator [36]. p38 
phosphorylation of MK2 triggers its 
translocation from the nucleus to the 
cytosol [37]. Activated MK2 signals 
through downstream targets such as 
heat shock protein 27 (HSP-27), 
heterogeneous nuclear 
ribonucleoprotein A0 (hnRNP A0), and 
cyclic AMP response element binding 
protein (CREB) to promote VSMC 
migration [38],
 
proliferation [39], and 
inflammatory cytokine production 
[35]—which combined lead to graft IH 
and failure. Although logical 
therapeutics, small molecule inhibitors 
of MK2 have failed to gain FDA 
approval owing to lack of specificity and solubility [40]. A highly specific, cell-penetrating peptide-based 
MK2 inhibitor (MK2i) has been developed [41] that is currently in phase I clinical trials for treatment of 
idiopathic pulmonary fibrosis and shows potential to reduce IH in vein transplants [42]. However, like 
Figure 1.2 - P38/MAPK signaling cascade: Overview of the p38 
MAPK-MK2 pathway that is activated in vascular smooth muscle 
cells during surgical resection and transplantation resulting in a 
pathological, synthetic vascular smooth muscle cell phenotype. 
From [2], reprinted with permission from AAAS. 
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many intracellular-acting biologics, MK2i bioavailability within the cytoplasm (where activated MK2 is 
localized) is limited by sequestration/degradation within late endosomes and early lysosomes [8].  
The Role of HSP20 and MK2 in Vasospasm 
 
Vasospasm refers to the pathological constriction of human vascular tissue that can lead to 
downstream tissue ischemia and, ultimately, tissue necrosis. The clinical burden of vasospasm can be 
highlighted in two areas: 1) Coronary vasospasm (both acute vasospasm following coronary artery 
bypass grafting and Prinzmetal’s angina) and 2) subarachnoid hemorrhage-induced symptomatic cerebral 
vasospasm. There are approximately 1.6 million coronary artery bypass procedures performed annually 
in the United States [43], and acute coronary vasospasm occurs in 1-8% of all patients undergoing to 
coronary artery bypass grafting [44]. Treatment of coronary vasospasm includes immediate, invasive 
intracoronary administration of vasodilators such as nitroglycerin or verapamil [45]. Coronary vasoaspasm 
also occurs outside the context of coronary bypass grafting and is referred to as Prinzmetal’s, or “variant” 
angina [46]. The prevalence of Prinzmetal’s angina ranges from ~4% of patients undergoing coronary 
angiography in the United states [47] to ~30% of patients in Japan [48]. Again, treatment involves 
administration of vasodilators (i.e., nitrates such as nitroglycerin and calcium channel blockers such as 
verapamil) and β-blockers and high doses of aspirin are contraindicated. Similarly, the current treatments 
for symptomatic cerebral vasospasm following subarachnoid hemorrhaging are also limited. 
Subarachnoid hemorrhages (SAH) affect 30,000 people annually and cause up to 7% of all strokes [49]. 
Nearly all cases of SAH are due to rupture of a cerebral aneurysm, and 40-50% of post-SAH mortality is 
attributed to symptomatic vasospasm (i.e., delayed cerebral ischemia) [50]. Current therapeutic 
approaches (i.e. triple H therapy [51]) have yielded no significant improvement in mortality rates. Since 
cerebral perfusion pressure is directly proportional to mean arterial pressure systemically-delivered 
vasodilators are avoided as they result in systemic hypotension, thereby exacerbating cerebral ischemia. 
Thus, there exists a significant clinical need for therapeutic interventions for vasospasm that avoid 
systemic effects by selectively targeting vasospastic vessels.  
At the ultrastructural level, vasospasm is mediated by the contraction of vascular smooth muscle. 
Smooth muscle contraction is caused by the sliding of actin and myosin filaments past each other within 
smooth muscle cells. As a result, actively depolymerizing or destabilizing actin filaments results in 
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inhibition of smooth muscle contraction and enhancement of relaxation as the myosin filaments no longer 
have an intact substrate to bind to and utilize to generate force. Thus, the destabilization of actin filaments 
in smooth muscle may be a promising therapeutic approach to preventing and treating vasospasm. 
Vasospasm is associated with a down-regulation of heat shock protein 20 (HSP20, also known as 
HSPB6) and concomitant increases in the expression and phosphorylation of heat shock protein 27 
(HSP27, also known as HSPB1). Both HSP20 and HSP27 have been shown to be key regulators of actin 
dynamics and contraction in smooth muscle [38, 52]. HSP20 is activated through nucleotide-dependent 
protein kinases and is thought to interact with with the 14-3-3 scaffolding protein leading to the 
dissociation, dephosphorylation, and activation of the actin disassembly protein cofilin [52] (fig. 1.3). 
Activation of MAPKAP Kinase II (MK2) by p38 MAPK is also believed to contribute to vasoconstriction 
through the formation of filamentous actin (F-actin) stress fibers within smooth muscle cells.  MK2 
phosphorylates HSP27, which associates with filamentous actin to prevent actin depolymerization and 
inhibit tissue vasorelaxation [34, 53]. Activated MK2 also phosphorylates LIM kinase which 
phosphorylates and deactivates cofilin, thereby inhibiting actin depolymerization[33]. Thus, both HSP20 
and MK2 play key roles in actin dynamics and represent promising targets to treat and prevent 
vasospasm[54]. In fact, a peptide mimetic of phosphorylated HSP20 (p-HSP20) was recently developed 
and shown to prevent SAH-induced macrovascular vasospasm in a non-craniotomy model of SAH-
induced vasospasm[55] and a MK2 inhibitory peptide (MK2i), derived from a sequence shown by Hayess 
and Benndorf to inhibit MK2 in vitro[41], was optimized[40] and shown to enhance sodium nitroprusside 
induced vasorelaxation of vascular smooth muscle[56]. However, sequestration and accumulation of both 
the p-HSP20 and MK2i peptides in the endo-lysosomal trafficking pathway remains a fundamental barrier 
to achieving optimal bioactivity on the actin regulatory machinery located in the cytoplasm[8]: previous 
studies have required extremely high doses to achieve therapeutic bioactivity, limiting the practicality of 
clinical translation. 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Translational Approach to Intracellular Peptide Delivery 
 
Peptide based biomacromolecular therapeutics have significant potential for use in a variety of 
clinical applications ranging from cancer treatment to cardiovascular disease. In comparison to small-
molecule drugs, peptide based therapies are advantageous in terms of specificity, potency, and 
biocompatibility. However, major in vivo barriers exist to effective intracellular delivery of 
biomacromolecular therapeutics for translational applications. Many delivery platforms have been 
Figure 1.3 - The role of MAPKAP Kinase 2 (MK2) and Heat Shock Protein 20 (HSP20) in actin mediated 
regulation of smooth muscle tone: MK2 is activated by cellular stress (e.g. mechanical trauma, cytokines, 
ROS, etc.) through p38 MAPK. Activated MK2 activates a number of downstream effectors: 1) phosphorylation of 
heat shock protein 27 (HSP27) results in capping of filamentous actin thereby inhibiting actin depolymerization 
and vasorelaxation. 2) phosphorylation of Lim Kinase (LIMK) results in phosphorylation and deactivation of cofilin 
which prevents actin degradation and inhibits vasorelaxation. The MK2 inhibitory peptide (MK2i) binds to MK2 
preventing the activation of these downstream effectors and promoting vasorelaxation. HSP20 is phosphorylated 
by cyclic nucleotide-dependent protein kinases (PKA and PKG) resulting in binding to and displacement of 
phosphorylated coflin from the 14-3-3 protein. This displacement causes cofilin to become dephosphorylated and 
activated by phosphatases such as slingshot, resulting in depolymerization of filamentous actin. The phospho-
HSP20 peptide mimetic (p-HSP20) recapitulates the activity of phosphorylated HSP20, ultimately leading to 
vasorelaxation. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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developed and studied to increase in vivo stability and facilitate cellular uptake and endosomal escape, 
but these approaches are typically costly, involve complex synthesis schemes, can be cytotoxic, and can 
suffer from relatively limited therapeutic enhancement. The overall goal of this project is to develop a 
simple, biocompatible drug delivery platform to enhance intracellular delivery of therapeutic 
peptides by enhancing cellular uptake, facilitating endosomal escape and cytoplasmic release of 
the drug payload thereby increasing the duration of therapeutic efficacy.  
Cell penetrating peptides (CPPs), which are generally cationic and interact with the negative 
charge of cell membranes, are commonly conjugated to biologic therapeutics such as peptides, DNA, and 
siRNA to increase cell uptake. The use of CPPs can significantly increase cellular uptake of therapeutics, 
however, CPPs do not address the delivery barrier of escaping the endo-lysosomal trafficking pathways 
subsequent to cellular internalization. The cationic nature of CPPs makes them amenable to electrostatic 
complexation with anionic polymers for the development of novel drug delivery systems. Electrostatic 
complexation of therapeutics into a nanomedicine is desirable in that it circumvents the need for chemical 
conjugation of the therapeutic to the carrier which can result in steric hindrance of the therapeutic 
payload’s bioactivity. Furthermore, complex synthesis schemes that are characteristic of colloidal drug 
carriers (e.g. liposomes and micellar constructs) usually suffer from poor yields due to the need for 
multiple rounds of synthesis and purification necessary to achieve the desired product. As a result, the 
development of a simple, cost-effective platform to address the delivery barriers that 
biomacromolecules face will allow for the translation of highly-specific and potent biologic 
therapeutics and research tools for a wide range of applications. The following specific aims are 
designed to test the hypothesis that endosomolytic nano-polyplexes can serve as a general platform 
technology for the intracellular delivery of CPP-based therapeutic peptides for a variety of applications in 
in vitro, ex vivo, and in vivo mechanistic studies, with strong potential for translation toward treatment of 
human disease. 
Specific Aim 1: Synthesize and characterize a library of nano-polyplexes (NPs) formulated with a 
MAPKAP Kinase 2 inhibitor peptide (MK2i-NPs). An MK2i cell penetrating peptide will be formulated with 
an anionic, endosomolytic polymer at a range of charge ratios (CRs). The size, polydispersity, surface 
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charge, and pH-responsive behavior of the resulting nano-polyplexes (NPs) will be characterized to 
determine optimal conditions for formulation of a nanomedicine with ideal physico-chemical properties. 
Specific Aim 2: Assess uptake, retention, endosomal escape, and bioactivity of an optimized MK2i-NP 
formulation in relevant in vitro models. Flow cytometry will be performed to compare the cellular uptake 
and retention of fluorescently labeled MK2i-NPs vs. free peptide. Microscopic analysis of fluorescently 
labeled MK2i uptake in conjunction with an endo-lysosomal dye will be used to verify enhanced 
endosomal escape of NPs compared to the peptide alone. The bioactivity and duration of efficacy of the 
MK2i-NPs will be compared to the free peptide through functional readouts relevant to IH in human 
coronary artery vascular smooth muscle cells (HCAVSMCs).  
Specific Aim 3: Assess the therapeutic efficacy of MK2i-NPs ex vivo in human saphenous vein and in 
vivo in a rabbit vein graft interposition model. MK2i-NP vessel penetration and peptide retention will be 
assessed in human saphenous vein (HSV) explants. The ability of MK2i-NPs to inhibit intimal hyperplasia 
(IH) will be evaluated ex vivo in human saphenous vein (HSV) explants. Western blot analysis of protein 
expression will be used to verify underlying therapeutic mechanisms. The ability of MK2i-NPs to prevent 
IH and improve vein graft patency will be evaluated in vivo in a rabbit jugular vein graft interposition 
model. Immunohistochemical analyses will be utilized to assess the effect of MK2 inhibition on vascular 
smooth muscle cell phenotype both ex vivo and in vivo. 
Specific Aim 4: Assess nano-polyplexes as a platform technology. Nano-polyplex formulations will be 
optimized for two therapeutic CPPs and applied to prevent and treat vasospasm. The uptake and 
retention of the optimized NPs will be assessed through flow cytometry and endosomal escape will be 
assessed through subcellular fractionation. The bioactivity of each NP formulation will be assessed in 
vitro through the analysis of F-actin stress fiber formation in vascular smooth muscle cells and ex vivo 
through smooth muscle physiology studies performed on viable human vascular tissue explants. 
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CHAPTER II 
 
DEVELOPMENT, OPTIMIZATION, & CHARACTERIZATION OF MK2I-NPS 
 
Introduction 
Therapeutic peptides are generally modified with a cell penetrating peptide 
sequence to promote cell internalization via endocytosis and/or micropinocytosis 
n[54, 57-59]. However, CPP-modified peptides suffer from poor bioactivity due to 
entrapment in endosomal vesicles that are trafficked for lysosomal degradation or 
exocytosis as opposed to cytoplasmic peptide release [5, 7, 8, 58, 60, 61]. We and 
other have shown that co-delivery of an endosomolytic polymer with a CPP-
internalized therapeutic increases cytoplasmic delivery and bioacitivity [7, 21, 62-65]. Poly(ethylacrylic 
acid) (PEAA) was first described for pH-dependent disruption of lipid vesicles [66, 67], and the related 
polymer PPAA was subsequently shown to have membrane disruptive properties in a pH range that is 
ideally tuned for endosomal escape and intracellular delivery [68, 69]. Early endosomes are continuously 
acidified through ion exchange and ATP-dependent proton pumps in the vesicle membrane [70-72], and 
in this environment, the pendant carboxylic acid moieties on PPAA (fig. 2.1) become more protonated / 
deionized. This deionization reversibly transitions PPAA into a more hydrophobic, membrane-interactive 
conformation that results in disruption of the endosomal membrane and enables cytoplasmic delivery of 
endosomal cargo. The pKa of the pendant carboxylic acids is roughly 6.7, so at higher pH values, such as 
physiologic pH, the carboxylic acid groups are predominately deprotonated / ionized, conferring a net 
negative charge to the polymer. In contrast, the pKa of certain amino acid side chains that typically 
constitute CPPs, namely arginine and lysine, is much higher (pKa~10-12.5 depending on amino acid). As 
a result, peptides that contain a high number of these polar side chains such as CPPs are primarily 
protonated and cationic at physiologic pH. Consequently, CPP-based peptide therapeutics can be 
electrostatically complexed at an intermediate pH between the pKa of cationic amino acid side chains of 
CPPs and anionic carboxylic acids on PPAA.  
Figure 2.1 - PPAA 
chemical structure 
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This generalizable electrostatic complexation approach will be utilized for the formulation of nano-
polyplexes with a cell permeant peptide inhibitor of MAPKAP Kinase 2 (Table 2.1). The MK2i peptide will 
be made through solid phase peptide synthesis with standard Fmoc chemistry, purified by RP-HPLC, and 
verified via ESI-MS. Poly(propylacrylic acid) will be synthesized through RAFT polymerization utilizing 4-
cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) as the chain transfer agent. Polyplexes 
will be formed by mixing the PPAA homopolymer with the MK2i peptide in aqueous buffer with a defined 
pH between the pKa values of the primary amines present on MK2i and the carboxylic acid moieties in 
the PPAA polymer. To determine an optimal nanoparticle formulation, a library of nano-polyplexes (NPs) 
will be prepared at a range of charge ratios (i.e. CR = ([NH3
+
]MK2i/[COO
-
]PPAA) from 10:1 to 1:10. 
Peptide Sequence MW Function 
MK2i (MMI-0100) YARAAARQARAKALARQLGVAA 2283.67 MAPKAP Kinase II inhibitor 
 
 
To provide a vehicle control for biological studies, non-endosomolytic MK2i-NPs (NE-MK2i-NPs) 
will be formulated with poly(acrylic acid) (PAA, fig. 2.2), a structurally similar polymer 
that does not have a pH response in a physiologically relevant range due to the pKa 
of the carboxylic acid group being lower (pKa~4.3) than the pH range encountered in 
the endo-lysosomal pathway. MK2i peptide will be fluorescently labeled with an 
amine-reactive Alexa-488 or Alexa-568 succinimidyl ester for the formulation of 
fluorescent MK2i-NPs for uptake studies. 
MK2iNP size and surface charge based on ζ-potential will be analyzed through dynamic light 
scattering (DLS) analysis. An optimal charge ratio will be chosen based upon three criteria: 1) 
consistently yields a unimodal particle size distribution with hydrodynamic diameter in the nanometer size 
range, 2) minimal size, and 3) minimal polydispersity. Optimized MK2i-NP size and morphology will be 
further characterized through TEM analysis of uranyl-acetate counterstained samples. DLS analysis of 
pH-dependent MK2i-NP size will be used to verify NP dissociation in acidic, endosomal conditions. pH-
dependent membrane disruptive activity (i.e. endosomolytic potential) will be assayed through a red blood 
Table 2.1 - MK2i peptide. Red amino acid abbreviations indicate the presence of polar amino groups in the amino 
acid side chain that potentiate electrostatic interaction with PPAA:  R (arginine), K (lysine) - primary amines (strong 
base); N (asparagine), Q (glutamine) - amides (weak bases). 
Figure 2.2 - PAA 
chemical structure  
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cell hemolysis assay at pH values mimicking physiologic (pH 7.4), early endosomal (pH 6.8), late 
endosomal (pH 6.2), and lysosomal (pH 5.6) pH values. 
 
Methods  
Materials 
All reagents were purchased from Sigma and were of analytical grade unless otherwise stated. 
PD10 desalting columns were purchased from GE healthcare. Diethyl propylmalonate was purchased 
from Alfa Aesar (Ward Hill, MA). All monomers were filtered through a basic alumina column to remove 
inhibitors prior to use in polymerizations. Dioxane was distilled prior to use in polymerizations.  2,2’-
Azobis(2-methylpropionitrile) (AIBN) was recrystallized twice from methanol prior to use. 
 
Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) 
The RAFT chain transfer agent ECT was synthesized following protocols previously described by 
Convertine et al. [64] and adapted from Moad et al. [73]. Briefly, Ethanethiol (76 mmol, 4.72 g) was 
reacted with carbon disulfide (79 mmol, 6.0 g) in the presence of sodium hydride (79 mmol, 3.15 g) in 
diethyl ether for 1h. The resulting sodium S-ethyl trithiocarbonate was further reacted with iodine (25 
mmol, 6.3 g) to obtain bis(ethylfulfanyl-thiocarbonyl) disulfide, which was further refluxed with 4,4’-
azobis(4-cyanopentanoic acid) in ethylacetate for 18 h.  The crude ECT was purified by column 
chromatography using silica gel as the stationary phase and a gradient of ethyl acetate:hexane (40:60 to 
70:30) as the mobile phase. 
1
H NMR (400MHz, CDCl3):  1.36 t (SCH2CH3);  1.88 s (CCNCH3);  2.3–
2.65 m (CH2CH2);  3.35 q (SCH2CH3). 
 
Synthesis of 2-propylacrylic acid (2-PAA) 
The synthesis of 2-PAA was adapted from existing methods developed by Ferrito et al. [74]. 
Briefly, diethyl propylmalonate (200 mmol, 40.45 g) was stirred in 1M KOH in 95% ethanol and acidified 
with HCl to yield 2-carbopropoxybutyric acid, which was reacted with diethylamine (200 mmol, 14.62 g) 
and formalin (200 mmol, 16.11 g) at room temperature for 24h, followed by reflux at 60°C for 8 hours.  
Following acidification with sulfuric acid, the resulting 2-propylacrylate was extracted 3x with diethyl ether 
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and dried over magnesium sulfate. The pure 2-propylacrylate was then refluxed in 2M KOH for 20 h to 
yield   2-propyl acrylic acid, which was extracted 3x with diethyl ether, dried, and vacuum distilled under 
vacuum to yield a colorless oil. 
1
H NMR (400 MHz, CDCl3)  0.97 t (CH3CH2);  1.55 m (CH3CH2CH2);  
2.31 t (CH3CH2CH2);  5.69-6.32 q (CH2=C);  12 s (CCOOH). 
  
Synthesis and characterization poly(propylacrylic acid) (PPAA) and poly(acrylic acid) (PAA) 
The ECT chain transfer agent (CTA) was utilized in the RAFT polymerization of a poly(2-
propylacrylic acid) homopolymer (PPAA) that was carried out in bulk under a nitrogen atmosphere at 
70°C for 48 hours using AIBN as the free radical initiator. The reaction mix was put through three freeze-
vacuum-thaw cycles and purged with nitrogen for thirty minutes prior to polymerization. The molar ratio of 
CTA to AIBN was 1 to 1 and the monomer to CTA ratio was set so that a degree of polymerization (DP) of 
190 would be achieved at 100% conversion. Following polymerization, the resultant polymer was 
dissolved in DMF and precipitated into ether 5 times before drying overnight in vacuo. The RAFT 
polymerization of a poly(acrylic acid) homopolymer (PAA) was carried out in distilled dioxane under a 
nitrogen atmosphere at 70°C for 18 hours using AIBN as the free radical initiator and ECT as the CTA. 
The reaction mix was purged with nitrogen for thirty minutes prior to polymerization. The molar ratio of 
CTA to AIBN was 5 to 1 and the monomer to CTA ratio was set so that a DP of 150 would be achieved at 
100% conversion. Following polymerization, the resultant polymer was dissolved in dioxane and 
precipitated into ether 5 times before drying overnight in vacuo.  Gel permeation chromatography (GPC, 
Agilent) was used to determine molecular weight and polydispersity (Mw/Mn, PDI) of the PPAA and PAA 
homopolymers using HPLC-grade DMF containing 0.1% LiBr at 60°C as mobile phase. Molecular weight 
calculations were calculated with ASTRA V software (Wyatt Technology) and were based on calculated 
dn/dc values for PPAA determined through injection of serial dilutions of the polymer in conjunction with 
off-line refractive index monitoring.  
 
Synthesis cell permeant MAPKAP Kinase 2 inhibitory peptide (MK2i) 
A cell penetrant MK2 inhibitor peptide (MK2i, sequence YARAAARQARAKALARQLGVAA, MW = 
2283.67) was synthesized on a PS3 3 channel serial peptide synthesizer (Protein Technologies, Inc. 
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Tucson, AZ) utilizing standard Fmoc Chemistry. N-methylpyrrolidone (NMP, Fischer Scientific) was 
utilized as a solvent in all peptide syntheses. HCTU was used as an activator (Chempep, Wellington, FL) 
in the presence of N-methylmorpholine. All amino acids were double coupled in order to maximize yield 
and purity. Peptides were cleaved/deprotected in Reagent B: TFA/Phenol/H2O/triisopropylsilane 
(88/5/5/2).  Successful peptide synthesis was verified through LC-MS analysis on a Waters Synapt ESI-
MS. Peptides were then further purified by reverse phase HPLC on a Waters 1525 binary HPLC pump 
outfitted with an extended flow kit, a Waters 2489 UV/Visible detector and a phenomenex Luna C18(2) 
AXIA packed column (100A, 250 x 21.2  mm, 5 micron). A) HPLC grade water with 0.05% formic acid and 
B) HPLC grade acetonitrile were used as the mobile phases and the peptide was purified utilizing a 90% 
A to 90% B gradient over 25 minutes (16 mL/min). Acetonitrile was removed from purified fractions with a 
rotary evaporator and the purified fractions were then frozen, lyophilized, and peptide purity was verified 
through electrospray ionization mass spectrometry (ESI-MS) on a Waters Synapt ESI-MS. 
 
MK2i nano-polyplex (MK2i-NP) synthesis and characterization 
PPAA was dissolved in 1 M NaOH and diluted into a phosphate buffer (pH 8) to obtain a stock 
solution. MK2i was dissolved in phosphate buffer (pH 8). The MK2i peptide and PPAA polymer were 
mixed at a range of CRs from [NH3
+
]:[COO
-
] = 10:1 to 1:10 to form MK2i-NPs. The resulting polyplexes 
were syringe filtered through 0.45 µm PTFE filter, and the hydrodynamic diameter and ζ-potential were 
characterized on a Malvern Zetasizer Nano-ZS. 
A CR of 1:3 was then chosen as the optimal formulation and used in subsequent studies. Nano-
polyplexes formulated at the same CR with the non-endosomolytic polymer PAA (i.e., NE-MK2i-NPs) 
were analyzed by DLS and used as a vehicle control in all subsequent studies. MK2i-NPs were visualized 
through transmission electron microscopy (TEM) imaging. TEM samples were prepared by inverting 
carbon film-backed copper grids onto a droplet of aqueous polyplex suspensions (1 mg/mL) and blotted 
dry. All samples were then counterstained with 3% uranyl acetate. Samples were desiccated in vacuo for 
2 h prior to TEM imaging. The pH-dependent size changes of polypexes at a CR of 1:3 were then 
quantified by DLS analysis at various pH values in PBS. 
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PH-dependent membrane disruption hemolysis assay 
In order to assess the polyplexes’ potential for enhancing endosomal escape, a red blood cell 
hemolysis assay was utilized as previously described [75]  to measure the capacity of polyplexes to 
cause pH-dependent disruption of lipid bilayers. Briefly, following approval by Vanderbilt Medical Center’s 
Institutional Review Board, whole human blood from an anonymous donor was drawn and plasma was 
aspirated following centrifugation of the red blood cells. The remaining erythrocytes were washed three 
times with 150 mM NaCl and re-suspended into phosphate buffers corresponding to physiologic (pH 7.4), 
early endosome (pH 6.8), early/late endosome (pH 6.2), and late endosome/lysosomal (pH 5.8) 
environments. The polyplexes and peptides (1-40 μg/mL), PBS (negative control), or 1% Triton X-100 
(positive control) was added to the erythrocyte suspensions and incubated at 37 °C for 1 hour. Intact 
erythrocytes were pelleted via centrifugation, and supernatant was carefully transferred to a new 96-well 
plate. The hemoglobin content within the supernatant was then measured via absorbance at 541 nm. 
Percent hemolysis was determined relative to Triton X-100 and PBS controls. 
 
Results 
Polymer synthesis and characterization 
RAFT polymerization was used to synthesize a poly(propylacrylic acid) and poly(acrylic acid) 
homopolymers that were subsequently analyzed by gel permeation chromatography [calculated PPAA 
dn/dc = 0.087 ml/g DP = 193 (GPC), PDI = 1.47 (GPC) (fig. 2.3 A); calculated PAA dn/dc = 0.09 ml/g DP 
= 150 (GPC), PDI = 1.27 (GPC) (fig. 2.3 B). Polymer purity and molecular weight were then verified 
through NMR spectroscopy utilizing D6MSO as a solvent. (PPAA DP = 190 (H
1
 NMR) (fig. 2.3 C); PAA 
DP = 106 (H
1
 NMR) (fig. 2.3 D). 
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Peptide synthesis and purification 
The Purity of the HPLC-Purified MK2i peptide was verified through electrospray ionization mass 
spectrometry (MK2i MW = 2283.67 g/mol, (fig. 2.4). 
Figure 2.3 - Polymer characterization. GPC chromatograms of (A) poly(propylacrylic acid) (PPAA) [degree of 
polymerization = 193, PDI =1.471, dη/dC = 0.087 (ml/g)] and (B) poly(acrylic acid) (PAA) [degree of 
polymerization = 150, PDI = 1.27, dη/dC = 0.09 (ml/g)] polymers in DMF. The trace shows UV absorbance at the 
characteristic absorption peak of the trithiocarbonate moiety (310 nm) present in the 4-cyano-4-
(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) chain transfer agent utilized in the polymerization.
 1
H 
NMR spectrum of (C) poly(propylacrylic acid) (PPAA) and (D) poly(acrylic acid) (PAA) in D
6
MSO. Molecular 
weight was determined by comparing the area of peaks associated with the chain transfer agent (i.e. peaks c,d 
for PAA and peak b for PPAA) to peaks associated acrylic acid/propylacrylic acid (i.e. peak a for PAA and peak c 
for PPAA): PAA degree of polymerization = 106, PPAA degree of polymerization = 190. From [2], reprinted with 
permission from AAAS. 
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MK2i nano-polyplex (MK2i-NP) synthesis and characterization 
NPs were formed by simple mixing of the poly(acrylic acid) (PAA) or poly(propylacrylic acid) 
(PPAA) homopolymers with the MK2i peptide in PBS at pH 8.0, which is between the pKa values of the 
primary amines present on the MK2i peptide and the carboxylic acid moieties in the PPAA polymer; this 
ensures optimal solubility and net charge on both the cationic peptide and anionic polymers (fig. 2.5 A). 
PPAA was utilized in the lead MK2i-NP formulation because of its well-defined pH-dependent membrane 
disruptive activity (schematically illustrated in fig. 2.5 B) [21, 76, 77] and previous safe use in animal 
models [78, 79]. PAA was utilized as a vector control as it is an anionic polymer with structural similarity to 
PPAA but lacks pH-responsiveness in a physiologically relevant range due to its lower pKa (pKa~4.3) 
(fig. 2.5 C). 
To determine optimal nanoparticle formulation conditions, a library of MK2i-NPs was prepared at 
a range of charge ratios [i.e. CR = ([NH3
+
]MK2i:[COO
-
]PPAA)], and the size distribution and particle surface 
charge were characterized. MK2i-NP ζ-potential was directly proportional to the CR, with an apparent 
isoelectric point at CR ~ 2:1 (fig. 2.5 D). A CR of 1:3 was chosen as the optimal formulation as this ratio 
yielded a unimodal size distribution with minimal particle size and polydispersity (table 2.2). Non-
endosomolytic MK2i nano-polyplexes (NE-MK2i-NPs) were formulated with PAA as a vehicle control for 
biological studies. NE-MK2i-NPs prepared at CR=1:3 with PAA had size and ζ-potential statistically 
Figure 2.4 – MK2i peptide characterization. Electrospray-ionization mass spectrometry (ESI-MS) mass 
spectrum for the HPLC-purified CPP-MK2i fusion peptide. sequence: YARAAARQARA-KALARQLGVAA, MW = 
2283.67 g/mol. The mass spectrum shows three major peaks each corresponding to the fragmentation of the full 
peptide sequence. From [2], reprinted with permission from AAAS. 
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equivalent to the endosomolytic MK2i-NPs. Interestingly, optimized NPs formulated at a CR of 1:3 yielded 
a negative surface charge (ζ-potential = -11.9 mV), indicating that the cationic peptide is primarily 
packaged into the core of the nanoparticles and that the anionic polymer PPAA is the primary component 
exposed at the surface of the NPs in aqueous environments. 
 
 
 
 
MK2i-NP unpackaging under endolysosomal conditions was assessed at a range of pHs 
revealing that the MK2i-NPs dissociated as the pH was lowered from extracellular pH toward the pKa of 
the carboxylic acids (pH~6.7) on PPAA, which also correlates to early endosomal conditions [80] (fig. 2.5 
E). It is hypothesized that at the lower pH, the PPAA polymer becomes protonated/deionized, and the net 
positive charge on the peptide causes electrostatic repulsion and disassembly of the MK2i-NPs. NP 
Figure 2.5 - MK2i-NP synthesis and characterization. (A) MK2i-NP synthesis scheme. (B) MK2i-NPs 
hypothesized mechanism of endosomal escape. (C)  Treatment comparison summary: Endosomolytic MK2i-NPs 
formulated with poly(propylacrylic acid), non-endosomolytic (NE) NE-MK2i-NPs formulated with poly(acrylic acid). 
MK2i-NPs and NE-MK2i-NPs are made with the MK2i peptide with the sequence shown (red = modified TAT 
mimetic cell penetrating peptide sequence, green = MK2 inhibitory sequence). (D) Zeta potential of polyplexes 
prepared at different charge ratios ([NH
3
+
]/[COO
-
]). Alexa denotes NPs formulated with an Alexa-488 conjugated 
MK2i peptide. NE denotes NE-MK2i-NPs. Data are represented as mean ± SEM (n = 3 independent 
measurements). (E) DLS analysis of pH-dependent MK2i-NP disassembly. From [2], reprinted with permission 
from AAAS. 
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disassembly under early endosome-like conditions reduces the likelihood that peptide bioactivity and/or 
PPAA endosomal membrane disruptive function is sterically hindered by polymer-peptide interactions. 
NH2:COOH Z-ave diameter (nm) 
10:1 10.32 ± 2.63* 
2:1 52.1 ± 46.86* 
1:1 970.6 ± 662.4 
1:1.5 465.1 ± 138.4* 
1:2 474.2 ± 32.59 
1:3 118.8 ± 26.76 
1:4 607.4 ± 285.2* 
1:5 213.0 ± 67.95* 
1:10 21.57 ± 9.89* 
1:3 (Alexa) 168.5 ± 24.63 
1:3 (NE) 113.7 ± 14.47 
1:3 (NE Alexa) 197.4 ± 12.85 
 
 
 
 In order to verify DLS results, uranyl acetate counter-stained nano-polyplexes (at a charge ratio 
= 1:3) were imaged using transmission electron microscopy. TEM images revealed particle sizes in 
agreement with results from DLS analysis (fig. 2.6). 
 
Table 2.2 – MK2i nano-polyplex library characterization. Size summary of MK2i-NPs prepared at different 
charge ratios ([NH
3
+
]/[COO
-
]) as determined by DLS analysis. Asterisks (*) indicate multimodal size distributions 
(multiple peaks present). 1:3 (Alexa) polyplexes were formulated with an Alexa488-conjugated MK2i peptide to 
use in cellular uptake studies. 1:3 (NE) polyplexes were formulated with a non-endosomolytic (NE) poly(acrylic 
acid) polymer that does not exhibit pH-dependent membrane disruptive activity in the endosomal pH range as a 
vehicle control. Data are mean ± peak width. From [2], reprinted with permission from AAAS. 
Figure 2.6 - NP size and morphology. Dynamic light scattering analysis of (A) MK2i-NP and (B) NE-MK2i-NP 
size distributions. (C) Representative TEM images of uranyl acetate counterstained MK2i-NPs. Scale bar = 100 
nm. From [2], reprinted with permission from AAAS. 
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In order to verify that the pH-responsive behavior of the PPAA polymer is maintained when 
electrostatically complexed with the MK2i peptide a red blood cell hemolysis assay was used to measure 
pH-dependent membrane disruption activity of polyplexes at pH values mimicking physiologic (pH 7.4), 
early endosome (pH 6.8), early/late endosome (pH 6.2), and late endosome/lysosomal (pH 5.8) 
environments (fig. 2.7). 
 
 
 At physiologic and even early endosomal pH, no significant red blood cell membrane disruption 
was observed even at polymer concentrations as high as 40 μg/mL. However, as the pH was lowered to 
late endosomal values, a significant increase in hemolysis was observed, with greater membrane 
disruption at pH 5.8 compared to 6.6. The hemolytic behavior of the polymer was directly proportional to 
polymer concentration, with over 90% erythrocyte lysis occurring at 40 μg/mL polymer in pH 5.8 buffer. 
This switch-like transition to a membrane disruptive conformation at late endosomal pH combined with 
negligible membrane disruptive activity in the physiologic pH range demonstrates the desired functionality 
of the polyplexes and further indicates their potential as non-toxic, endosomolytic intracellular delivery 
vehicles. Interestingly, the polyplexes demonstrated less hemolytic capacity than the pH responsive 
Figure 2.7 - pH-dependent red blood cell membrane disruption. Red blood cell hemolysis assay shows that 
MK2i-NPs have similar, albeit slightly masked, pH-dependent and dose-dependent membrane disruptive activity to 
the PPAA polymer but NE-MK2i-NPs and the MK2i peptide alone do not. 
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polymer alone, indicating that the formation of an electrostatic complex with the MK2i peptide slightly 
masks the membrane-disruptive activity of the polymer. This finding is consistent with the pH-dependent 
size changes monitored by DLS, which evinced polyplex dissociation at early endosomal pH values (i.e. 
pH 6.8), indicating that as the endosomal pH decreases the polyplexes will first dissociate and 
subsequently disrupt the endosomal membrane. This behavior is advantageous in that it effectively “un-
packages” the therapeutic peptide from the electrostatic complexes prior to cytoplasmic release, ensuring 
that peptide bioactivity is not hindered due to steric hindrance from the pH-responsive polymer. 
 
Discussion 
Methods to enable the efficient intracellular delivery of peptide-based therapeutics are a 
potentially high-impact but relatively unmet need.  This shortcoming is primarily due to multiple delivery 
barriers that exist in terms of delivering biomacromolecular therapeutics, each of which must be 
addressed to optimize bioactivity.  The data presented herein demonstrate the successful synthesis and 
optimization of electrostatically complexed, pH-responsive nanoparticles that are ~100 nm in size and 
show pH-responsive unpackaging and membrane disruptive behavior ideal for endosomal escape and 
intracellular pay-load delivery. 
The RAFT synthesized PPAA polymer serves as the key component of this nanotechnology 
platform for intracellular peptide delivery. The carboxylic acid groups present in the PPAA repeating unit 
has a pKa ~6.7, causing it to become protonated and membrane-disruptive at pH values encountered in 
the endo-lysosomal pathway as shown in fig. 2.7. [62]. These carboxylic acid groups are deprotonated at 
pH values above the pKa of 6.7, rendering the polymer anionic at slightly basic pH values. This anionic 
behavior allows for electrostatic complexation with cationic peptides due to the presence of primary 
amines in specific amino acid side chains (pKa ~9-12 depending on the amino acid) and results in well-
defined nano-polyplexes as shown in figs. 2.5 and 2.6. Furthermore, the electrostatic complexation of a 
cationic therapeutic and the anionic ‘smart’ polymer is reversible, allowing for ‘de-complexation’ and 
release of the peptide once the PPAA polymer becomes protonated due to electrostatic repulsion as 
shown in 2.5A. Most peptide based therapeutics, as well as many nucleic acid, protein and small 
molecule based therapeutics, utilize a cell penetrating peptide to facilitate cellular uptake, and the majority 
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of these cell penetrating peptides are cationic in nature (e.g. oligoarginines, oligolysines, TAT, penetratin, 
etc.) [12, 13, 81, 82]. As a result, this approach has the potential to serve as a platform technology for the 
intracellular delivery of a wide range of therapeutics for a myriad of applications.  
  
Conclusion 
The utilization of RAFT polymerization enabled the synthesis of a relatively monodisperse 
endosomolytic, pH-responsive poly(propylacrylic acid) homopolymer and a control non-endosomolytic 
poly(acrylic acid) homopolymer. Solid-phase peptide synthesis utilized in conjunction with reverse phase 
HPLC yielded a pure MK2i peptide. These components were utilized to formulate pH-responsive, 
endosomolytic MK2i nano-polyplexes (MK2i-NPs) and control, non-endosomolytic nano-polyplexes (NE-
MK2i-NPs). MK2i-NPs demonstrated ideal pH-responsive behavior both in terms of pH-responsive 
decomplexation to allow for payload release after cellular internalization and in demonstrating switch-like, 
pH-dependent membrane disruptive activity (whereas the control NE-MK2i-NPs did not). As a result, two 
separate NP formulations have been synthesized, characterized, and optimized for further study as 
peptide-delivery carriers in vitro. 
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CHAPTER III 
 
MK2I-NP UPTAKE, RETENTION, ENDOSOMAL ESCAPE, & BIOACTIVITY 
 
Introduction 
It is widely reported in literature that peptides, as well as other biomacromolecular therapeutics, 
suffer from poor uptake as they are not inherently membrane permeable [83]. Thus, many therapeutic 
biologics are modified with cell penetrating peptide sequences to increase peptide uptake and bioactivity.  
However, the choice of CPP sequence significantly influences peptide potency, and CPPs can cause 
nonspecific effects independent of the therapeutic sequence.  The original MK2 inhibitory peptide 
sequence was discovered and optimized as a substrate peptide based on the sequence surrounding the 
serine 86 phosphorylation site of heat shock protein 27 (13). Testing various MK2 inhibitory peptides 
revealed that the inclusion of many CPP sequences caused nonspecific kinase inhibitory activity that was 
associated with cytotoxicity in vitro (12).  These findings led to the discovery that the CPP sequence 
utilized in the current studies (i.e., YARAAARQARA, a modified version of the HIV transactivator of 
transcription, or TAT, cell penetrating peptide) produces optimal specificity against MK2 and motivated 
our goal of developing a translational delivery technology to enhance the therapeutic potential of this 
optimized MK2i peptide. The optimized MK2i-NP formulation formulated with this cell permeant MK2i 
peptide yielded a nanoparticle with a negative surface (ζ-potential of -11.9 ± 3.2 mV). Current approaches 
to non-specifically increase cellular uptake are almost universally focused on imparting a positive charge 
to the drug formulation in order to interact with the inherent negative charge of the cellular membrane [19, 
58, 84]. In order to ensure that formulation into a negatively charged nanoparticle does not hinder cellular 
uptake, cellular uptake studies will be performed to compare uptake of free peptide to the MK2i-NP and 
NE-MK2i-NP formulations. Furthermore, since multiple cell-types are present in vein grafts, cell type-
specific uptake will be investigated through the quantification of MK2i uptake in both vascular smooth 
muscle and endothelial cells. 
MK2i-NPs evinced ideal membrane disruptive activity as demonstrated through a red blood cell 
hemolysis assay. However, the lipid bilayer that constitutes the membrane of red blood cells is merely a 
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biological model and does not accurately replicate the endosomal membrane. Thus, endosomal escape 
will be further investigated and verified in vitro through colocalization studies using microscopic analysis 
of fluorescently labeled MK2i-NP uptake in conjunction with an endosomal dye over time. Escape from 
endosomal trafficking is a promising approach to extending the duration of efficacy of peptide-based 
therapeutics as it circumvents trafficking for lysosomal degradation and/or trafficking for exocytosis. To 
this end, the intracellular retention of MK2i when delivered in an endosomolytic NP formulation will be 
measured over time following treatment removal in vascular smooth muscle cells. 
NP formulation is designed to optimize uptake, retention, and endosomal escape of the MK2i 
peptide; hence, it is hypothesized that NP formulation will concomitantly increase MK2i bioactivity and 
duration of therapeutic efficacy. MK2 inhibition has demonstrated promise in inhibiting cell migration and 
inflammatory cytokine production which are both hallmarks of IH pathogenesis. As a result, the ability of 
MK2i-NPs to inhibit inflammatory cytokine production and migration will be assessed in both vascular 
smooth muscle and endothelial cells. To assess the duration of therapeutic efficacy, inflammatory 
cytokine production will be assessed over time following treatment removal in cells stimulated with an 
inflammatory agonist. Furthermore, due to the inherent membrane disruptive activity of PPAA, there is 
potential that NP formulation may have deleterious effects on cell viability. Consequently, cell viability will 
be assessed in cells treated with a range of concentrations of the NP formulations to ensure 
biocompatibility. 
 
Methods 
Cell culture 
Primary HCAVSMCs and HUVECs were obtained from Lonza; HCAVSMCs were cultured in vascular cell 
basal medium (ATCC) supplemented with a vascular smooth muscle cell growth kit, 1% penicillin-
streptomycin and plasmocin (5 µg/mL)]. HUVECs were cultured in endothelial basal medium (Lonza) 
supplemented with an EGM-2 bullet kit, 1% penicillin-streptomycin and plasmocin (5 µg/mL). 
 All cultures were maintained in 75cm
2
 polystyrene tissue culture flasks in a 37°C and 5% CO2 
environment with cell culture media refreshed every other day. Cells were grown to 80-90% confluence 
prior to being harvested and passaged. All cells were seeded at a density of 20,000-30,000 cells/cm
2
, as 
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required for each specific experiment.  Only cells from early passages (numbers 3-8) were used in 
experiments. 
 
Microscopic analysis of MK2i-NP uptake and intracellular trafficking 
An amine-reactive Alexa-488 succinimidyl ester was dissolved in DMSO and mixed at a 1 to 3 
molar ratio with the MK2i peptide in 100 mM sodium bicarbonate buffer (pH 8.3). Unreacted fluorophore 
and organic solvent were removed using a PD-10 miditrap G-10 desalting column, and the fluorescently 
labeled peptide was lyophilized. PPAA and PAA polymers were mixed with fluorescently labeled MK2i 
peptide at a CR 1:3 and syringe filtered through a 0.45 µm PTFE filter to form fluorescent MK2i-NPs and 
control NE-MK2i-NPs, respectively. Fluorescent MK2i-NPs, NE-MK2i-NPs, or MK2i peptide alone were 
applied to HCAVSMCs grown on Lab-Tek II 8-well chambered coverglass at a concentration of 10 µM 
MK2i peptide in low serum media for 2 hours. Cells were then washed 2x with PBS, and subsequently 
incubated in fresh medium for an additional 0, 2, 4, 10, or 22 hours. For the final two hours of incubation, 
50 nM Lysotracker Red DND-99 was added to each well in order to visualize acidic endo/lysosomal 
vesicles. Cells were then washed with 0.1% Trypan blue to quench extracellular fluorescence followed by 
2 additional washes with PBS. Cells were then imaged using a LSM 710 META confocal fluorescence 
microscope with ZEN imaging software. Gain settings were kept constant for all images acquired. 
All images were processed using imageJ and colocalization was analyzed using Just Another 
Colocalization Plugin (JACoP) [85]. Mander’s overlap coefficients were then calculated for n ≥ 3 separate 
images for each treatment group to quantify colocalization. To determine treatment effects on the size of 
the compartments where the peptide was found, the free hand selection tool in ImageJ was used to 
outline n ≥ 50 individual intracellular compartments for each treatment group, and the area of each was 
quantified and averaged. 
 
Flow cytometric quantification of MK2i-NP uptake and intracellular retention 
HCAVSMCs or HUVECs were grown to 80-90% confluence, harvested, and seeded at 20,000 
cells/well in a 24 well plate and allowed to adhere overnight in low serum media (DMEM, 1% FBS, and 
1% P/S). Fluorescent MK2i peptide, MK2i-NPs, and NE-MK2i-NPs were synthesized as noted above for 
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microscopy analysis, and HCAVSMCs were treated at a concentration of 10 µM MK2i for 2 hours. 
Following treatment, cells were washed with PBS, washed with CellScrub buffer for 10 minutes at room 
temperature to remove extracellular polyplexes and/or peptide, washed 2x in PBS, and given fresh 
complete growth media. ECs were immediately harvested and VSMCs were incubated for an additional 0, 
12, 24, 72, or 120 hours. Cells were then washed with PBS, trypsinized, and resuspended in 0.1% Trypan 
blue in PBS for analysis on a FACSCalibur flow cytometer BD CellQuest Pro software (v 5.2). Data was 
exported and analyzed with FlowJo software (V 7.6.4). All samples were run in triplicate. 
The intracellular MK2i half-life (𝑡1/2) was calculated by exponential decay nonlinear regression 
analysis of intracellular peptide fluorescence at 0 and 5 days following treatment removal using the 
exponential decay function [where 𝑁= intracellular fluorescence and 𝜆 = the decay rate]: 
𝑁(𝑡) = 𝑁𝑜𝑒
−𝜆𝑡                                                                                       (𝑒𝑞. 1) 
And calculating the 𝑡1/2 from the decay constant of each exponential decay function as follows: 
𝑡1/2 =
ln(2)
𝜆⁄                                                                                       (𝑒𝑞. 2) 
 
Boyden chamber chemotaxis assay 
HCAVSMCs or HUVECs were seeded in a 24 well plate at a density of 30,000 cells/well in low 
serum media and allowed to adhere overnight. Cells were treated for 30 mins with MK2i-NPs, NE-MK2i-
NPs, MK2i peptide, or PBS. For 5 day post-treatment migration assays VSMCs were washed 2x with PBS 
and then cultured in fresh medium for 5 days with the media being replaced every 2 days. Following 
treatment or 5 days of post-treatment incubation, each well was washed 2x with PBS , trypsinized, 
resuspended in 100 μl low serum growth media, and plated onto 6.5-mm, 8-μm pore polycarbonate 
inserts (Corning) in a 24-well plate with 600 μl low serum growth media containing either 50 ng/ml PDGF-
BB (VSMCs) or 25 ng/ml VEGF (ECs) in the lower chamber. Cells were allowed to migrate for 8 hours, 
and then cells on the upper side of each insert were gently removed with a cotton swab. Cells on the 
lower side of each insert were then fixed and stained using a Modified Giemsa Differential Quik Stain Kit. 
After staining, 4 images were taken from the four quadrants of each insert, and the number of cells per 
high-power field were quantified in ImageJ by thresholding each image and manually counting the cells.  
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Scratch wound chemokinesis assay 
 HCAVSMCs were seeded in Lab-TEK II 8-well chambered coverglass at a density of 20,000 
cells/well in 250 μl low serum growth media and allowed to adhere overnight to achieve a nearly confluent 
(90-95%) monolayer. Cells were treated with MK2i-NPs, NE-MK2i-NPs, MK2i peptide or PBS -/- for 30 
minutes. Following treatment, scratch wounds were made with a 10 uL pipette tip through the middle of 
each cell monolayer. The media was then replaced with low serum growth media containing a CellTracker 
Green BODIPY dye for 30 minutes to enable visualization of migrating cells. Following treatment with the 
dye, media was replaced with low serum growth media containing 50 ng/ml PDGF-BB (or with PBS for 
the negative control). Scratch wound areas were then imaged at 24 hours using a Nikon Eclipse Ti 
inverted fluorescence microscope with NIS Elements imaging software. Wound closure was calculated 
with ImageJ software by quantifying the scratch wound area around the periphery of migrating cells 
normalized to the original scratch wound area. Scratch wound assays for each treatment group were 
performed in 3 independent experiments. 
 
Cell proliferation assay 
To confirm that VSMC migration results were not influenced by treatment effects on cellular 
growth rates, a cellular proliferation assay was performed. HCAVSMCs were seeded at 10,000 cells/well 
in a 96-well plate in low serum media and allowed to adhere overnight. Cells were treated for 30 minutes 
with MK2i-NPs, NE-MK2i-NPs, MK2i peptide or PBS. Each treatment was then aspirated and replaced 
with 100 μl low serum growth media ± 50 ng/ml PDGF-BB. After 24 hours of incubation, a CellTiter 96 
Aqueous Non-Radioactive Cell Proliferation Assay (Promega) was performed according to the 
manufacturer’s protocol.  
 
MK2i-NP cytotoxicity in stimulated HCAVSMCs 
The CytoTox-ONE Homogenous Membrane Integrity assay (Promega) was used to assess the 
cytotoxicity of MK2i, MK2i-NP, and NE-MK2i-NP treatments according to the manufacturer’s instructions. 
Briefly, HCAVSMCs from early passage were grown to 80-90% confluence in a 75 cm
2
 tissue culture flask 
in a 37°C/5% CO2 incubator prior to harvest. 200 µL of cell suspension (at 10,000 cells/well) was seeded 
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onto 96-well plates to yield an approximate 70% confluence per well. Cells were allowed to adhere to the 
plate overnight. Cells were stimulated with either 10 μM angiotensin-II or 20 ng/ml TNF-α for 4 hours 
followed by treatment with MK2i-NPs, MK2i, or NE-MK2i-NPs for 2 hours. Following treatment, cells were 
aspirated and 200 µL of fresh medium was added to each well. After 24 hours of incubation in fresh 
media cells were washed 2x with PBS and re-suspended in 100 µL lysis buffer. Each well was then 
supplemented with 100 µL Lactate dehydrogenase (LDH) substrate and incubated at RT for 10 minutes 
prior to the addition of 50 µL stop solution. LDH-induced fluorescence (excitation 550 nm, emission 600 
nm) was then quantified with a TECAN Infinite M1000 Pro plate reader and used to determine cell viability 
compared to untreated control groups. 
 
Inflammatory Cytokine Analysis 
In order to evaluate the ability of MK2i-NPs to inhibit Interleukin-6 (IL-6) production, HCAVSMCs 
were cultured and seeded onto a 96-well plate using the methods described in the LDH cytotoxicity assay 
above. Cells were treated with 20 ng/mL tumor necrosis factor-α (TNFα) for 4 hours followed by treatment 
with MK2i-NPs or MK2i alone for 2 hours. Following treatment, each well was aspirated and 
supplemented with fresh medium. After 12 and 24 hours, 100 µL of supernatant was collected and frozen 
at -80°C until cytokine analysis could be performed. 
Similarly, to evaluate the ability of MK2i-NPs to inhibit TNFα production, HCAVSMCs were 
cultured and seeded onto a 96-well plate using the methods described in the LDH cytotoxicity assay 
above. Cells were treated with 10 μM ANG II for 4 hours followed by treatment with MK2i-NPs, NE-MK2i-
NPs, or free MK2i peptide alone for 2 hours. Following treatment, each well was aspirated and 
supplemented with fresh medium. After 12 and 24 hours, 100 µL of supernatant was collected and frozen 
at -80°C until cytokine analysis could be performed. 
To longitudinally assess the duration of NP effects on production of the inflammatory cytokine 
monocyte chemoattractant protein 1 (MCP-1) in vascular cells, HCAVSMCs and HUVECs were treated in 
low serum media with MK2i-NPs, MK2i, or NE-MK2i-NPs for 2 hours. Following treatment, each well was 
aspirated and supplemented with fresh medium. After 3 or 5 days cells were stimulated with TNFα (20 
28 
ng/ml) for 24 hours. Following stimulation 100 µl of supernatant was collected and frozen at -80°C until 
cytokine analysis could be performed.   
Human IL-6 (cat # 900-K16), Human TNFα (cat # 900-K25), and Human MCP-1 (cat # 900-K31) 
ELISA development kits (Peprotech; Rocky Hill, NJ) were used to measure cytokine levels in supernatant 
collected from treated cells. For both assays 9 standards were prepared according to the manufacturer’s 
protocol. 40 µL of supernatant was diluted with 60 µL diluent; quadruplicates of each sample were used. 
Absorbance at 405 nm with wavelength correction at 650 nm was monitored for 1 hour with readings 
taken every 5 minutes. Concentrations of IL-6 and TNFα were determined through extrapolation from a 4 
parameter logistic fit of the standard curve. All data were then normalized to cell viability determined 
through a LDH-based cytotoxicity assay (Promega). Data are expressed as mean ± SEM. 
 
Statistics 
Statistical analysis was performed with one-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test to validate statistical significance of mean differences between experimental 
groups. Analyses were done with OriginPro 8 software or Minitab 16 software. Statistical significance was 
accepted within a normal-based 95% confidence limit (α=0.05). Results are presented as arithmetic mean 
± SEM graphically, and p-values are included within figures or in the figure legends.  
 
Results 
MK2i-NP uptake and Intracellular retention 
Measurement of MK2i uptake and intracellular retention over a 5 day period after treatment 
removal in human vascular smooth muscle cells (VSMCs) revealed that MK2i-NPs significantly increased 
peptide internalization by over an order of magnitude and increased intracellular MK2i retention over 5 
days after treatment removal (fig. 3.1).   
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Interestingly, MK2i-NPs showed an increase in peptide-associated fluorescence over the first 72 
hours of incubation following treatment/washing. It was verified that this effect was not due to delayed 
internalization of MK2i-NPs bound to the outer membrane of the cells (fig. 3.2) but that this increase in 
fluorescence is due to an Alexa-488 self-quenching mechanism[86]; increased fluorescence over time 
may be due to diminished quenching as the MK2i is unpackaged from the NPs intracellularly.   
Figure 3.1 - MK2i-NP formulations increase cellular uptake and extend intracellular retention. (A) 
Representative flow histograms of MK2i internalization when delivered as a free peptide, via MK2i-NPs, and via 
NE-MK2i-NPs. (B) Flow cytometric quantification of HCAVSMC uptake and retention of fluorescently labeled 
MK2i, MK2i-NPs, and NE-MK2i-NPs. Data are mean ± SEM, n =3. P values determined via single factor ANOVA. 
From [2], reprinted with permission from AAAS. 
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Because NE-MK2i-NP uptake was equivalent to the free peptide, these data indicate that 
differences in cell internalization are due to NP composition and independent of particle morphology and 
charge. Notably, enhanced peptide delivery via the MK2i-NP formulation was also detected in analogous 
studies on endothelial cells suggesting that this is not a cell type-specific observation (fig. 3.3). 
Furthermore, considering that uptake was similar between separate cell types further suggest that 
increased internalization may be the result of a non-specific interaction/uptake mechanism or potentially 
mediated through a specific cell receptor present on both vascular smooth muscle and endothelial cells.  
Figure 3.2 - MK2i-NP membrane binding. MK2i-NP internalization is not affected by membrane 
bound NPs as shown by minimal differences in MK2i-NP uptake in VSMCs that either had 
extracellular fluorescence quenched by trypan blue and/or were extensively washed with cell scrub 
buffer to remove any extracellular NPs following treatment removal. 
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  Half-life calculations (fig. 3.4 A) showed that MK2i-NPs increased the intracellular half-life of the 
MK2i peptide by over an order of magnitude from 4 days to 58 days. However, it must be noted that these 
calculations may be skewed by the increase in intracellular fluorescence in cells treated with MK2i-NPs 
after treatment removal, which is why half-life calculations were performed solely on 0 and 5 day time 
points after the amount of MK2i fluorescence decreased below initial uptake levels. Considering that 
increased fluorescence over time may be due to diminished fluorescent quenching as the MK2i is 
unpackaged from the NPs intracellularly further supports that Increased peptide intracellular half-life 
following delivery via MK2i-NP formulations is likely due to decreased rate of peptide degradation in the 
endolysosomal pathway and/or the rate of exocytotic recycling out of the cell [87]. In addition to 
increasing uptake and intracellular retention, NP formulation also increased the percentage of treated 
cells positive for internalization following treatment (fig. 3.4 B and C). Furthermore, the percentage of 
VSMCs positive for internalization of the free MK2i peptide decreased over time (from 52% to 4% over 5 
days) whereas VSMCs treated with the NP formulation stayed relatively constant (from 88% to 96% over 
Figure 3.3 - MK2i uptake in endothelial cells. (A) Flow cytometric quantification and (B) representative flow 
histograms of endothelial cell uptake of fluorescently labeled MK2i, MK2i-NPs, and NE-MK2i-NPs. Data are 
mean ± SEM, n =3. P values determined via single factor ANOVA. From [2], reprinted with permission from 
AAAS. 
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5 days). These findings further support that formulation into endosomolytic NPs increases the intracellular 
half-life of the MK2i peptide and shows potential to increase the duration of MK2i therapeutic efficacy. 
 
 
 
 
To elucidate the mechanism responsible for the observed increase in MK2i intracellular retention, 
microscopy/colocalization studies were used to assess endosomal escape of MK2i-NPs. Imaging and 
quantification of MK2i-NP endosomal escape in VSMCs demonstrated that MK2i-NP formulation 
significantly reduced MK2i endolysosomal colocalization (fig. 3.5 A). Longitudinal quantification of 
Figure 3.4 - MK2i uptake and intracellular retention. (A) Quantification of intracellular MK2i half-life (𝑡
1/2
) by 
exponential decay nonlinear regression analysis of intracellular peptide fluorescence at 0 and 5 days following 
treatment removal. (B) Longitudinal quantification and (C) Representative flow histograms and subsets used to 
calculate the percentage of HCAVSMCs positive for MK2i internalization following removal of treatment with free 
MK2i, MK2i-NPs, or NE-MK2i-NPs. Data are mean ± SEM, n =3. * P<0.01, ** P<0.001 vs. MK2i, Ɨ P<0.01, ƗƗ 
P<0.001 vs. NE-MK2i-NPs. P values determined via single factor ANOVA.  From [2], reprinted with permission 
from AAAS. 
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MK2i/Lysotracker colocalization following treatment revealed significantly reduced MK2i/lysotracker 
colocalization for the MK2i-NP treated cells, and MK2i delivered via the NP formulation showed 
decreased colocalization over time, suggesting an active endosomal escape mechanism (figure 3.5 B). 
Interestingly, quantification of compartment size revealed that NE-MK2i-NP or MK2i treated cells showed 
MK2i localization within smaller vesicles representative of endosomes, whereas MK2i delivered via MK2i-
NPs was found within larger compartments, potentially representative of the cytosol or disrupted vesicles 
(fig. 3.5 C). 
 
 
  
  
In order to assess the in vitro therapeutic efficacy and cytocompatibility of NPs compared to the 
free MK2i peptide, TNFα and ANG II-stimulated HCAVSMCs were treated with a range of MK2i-NP or 
MK2i peptide concentrations for 2 hours and incubated in fresh media for 24 hours. Following incubation, 
Figure 3.5 - MK2i-NPs reduce endo-lysosomal colocalization of MK2i. (A)  Representative confocal 
microscopy images of Alexa-488 labeled MK2i (green) colocalization (yellow) with Lysotracker (red). Scale bars = 
20 μm. (B) Quantification of MK2i Alexa-488 labeled MK2i colocalization with Lysotracker red in HCAVSMCs 24 
hours after 2 hours of treatment determined via calculation of Mander’s coefficients. Data are mean ± SEM (n≥3 
separate images). P values determined via one way ANOVA. (C) Quantification of intracellular compartment size 
of  HCAVSMCs treated with Alexa-488 labeled MK2i. Data are mean ± SEM (n≥50 separate intracellular 
compartments per treatment group). P values determined via one way ANOVA. From [2], reprinted with 
permission from AAAS. 
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supernatant was collected for cytokine analysis and an LDH assay was used to quantify cell viability. 
None of the treatments displayed significant cytotoxicity at any of the concentrations tested (fig. 3.6).  
  
 
 
Figure 3.6 - Cell viability in treated HCAVSMCs. Cell viability in HCAVSMCs stimulated with a) 10 
μM ANG II or b) 20 ng/ml TNFα for 6 hours, treated for two hours with MK2i-NPs, NE-MK2i-NPs, or 
the MK2i peptide alone (concentrations in figure legends) and cultured for 24 hours in fresh media as 
determined by an LDH cytotoxicity assay. NT = No treatment, data are mean ± SEM, n = 4. No 
statistically significant differences were observed. From [2], reprinted with permission from AAAS. 
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Subsequent to verification 
of cell viability, ELISAs 
were performed on 
collected supernatants to 
quantify IL-6 secretion and 
TNFα production in TNFα 
and ANG II-stimulated 
HCAVSMCs, respectively. 
Both IL-6 and TNFα are 
inflammatory cytokines 
that are activated 
downstream of MK2 and, 
thus, provide an indirect 
measure of MK2 inhibition 
[88-90]. MK2i-NPs were 
found to significantly 
inhibit TNFα production in 
ANG-II stimulated 
HCAVSMCs at all 
concentrations in a dose-
dependent manner 
compared to the untreated 
control (fig. 3.7A). In fact, 
MK2i-NPs were found to 
inhibit TNFα production at 
a 10-fold lower dose than 
the free peptide (10 µM 
Figure 3.7 - MK2i-NP formulation enhances MK2i bioactivity in vitro. (A) 
Quantification of ANG-II-induced TNFα production in HCAVSMCs. Data are 
mean ± SEM (n = 4 technical replicates). P values determined via one way 
ANOVA. (B) Quantification of TNFα-induced IL-6 production in HCAVSMCs. Data 
are mean ± SEM (n = 4 technical replicates). P values determined via one way 
ANOVA. From [2], reprinted with permission from AAAS. 
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MK2i-NPs vs. 100 µM free MK2i). MK2i-NPs were also found to significantly enhance MK2i-mediated 
inhibition of IL-6 production compared to the MK2i peptide alone (fig. 3.7 B). Interestingly, measurement 
of TNFα secretion in ANG II-stimulated HCAVSMCs proved to be a more robust readout of NP activity 
relative to inhibition of IL-6 production in response to TNFα. As expected based upon uptake and 
endosomal escape studies, NE-MK2i-NPs made with a poly(acrylic acid) as a vehicle control did not 
demonstrate any enhancement in MK2i mediated inhibition of TNFα production. 
In addition to inflammatory processes, vascular smooth muscle cell migration into the intima is 
also integral in the pathogenesis of IH [91]; Thus, both Boyden transwell chemotaxis and scratch wound 
chemokinesis assays were performed in treated HCAVSMCs in the presence of the chemoattractant 
platelet derived growth factor (PDGF). The Boyden transwell chemotaxis assay demonstrated that MK2i 
inhibition significantly inhibited VSMC chemotaxis (fig. 3.8).  
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In agreement with MK2i-NP inhibition of TNFα production, MK2i-NPs were found to equivalently 
inhibit directional VSMC migration at an order of magnitude lower dose than the free MK2i peptide. To 
further investigate the effects of MK2i-NPs on vascular smooth msucle cell migration, a scratch wound 
chemokinesis assay was performed (fig. 3.9). Similar to results yielded by chemotaxis assays, 
chemokinesis was also inhibited by MK2i and MK2i-NPs were able to inhibit migration at a significantly 
(i.e., >10-fold) lower dose than the free MK2i peptide. These results suggest that MK2 inhibition not only 
Figure 3.8 - MK2i-NPs inhibit VSMC chemotaxis in vitro. Quantification and representative images of 
HCAVSMC migration immediately after treatment removal determined via a Boyden transwell migration assay. 
Data are mean ± SEM (n = 3 technical replicates from 2 separate experiments). P values determined via one 
way ANOVA. From [1], reprinted with permission from AAAS. 
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inhibits directional vascular smooth muscle cell migration but also inhibits vascular smooth muscle cell 
motility. 
 
 
 
 
In light of the significant effects of MK2i on cell migration, a proliferation assay was performed to 
ensure that inhibition of migration was not attributable to treatment effects on cell proliferation. The same 
treatment protocol and time points from the scratch wound migration assay were utilized for analysis of 
cellular proliferation with and without the addition of PDGF-BB. None of the treatments were found to 
produce significant effects on HCAVSMC proliferation although PDGF appeared to slightly increase 
proliferation and MK2 inhibition trended towards dose dependent inhibition of migration  (fig. 3.10). 
Figure 3.9 - MK2i-NPs inhibit VSMC chemokinesis in vitro. Quantification and 
representative images of HCAVSMC migration immediately after treatment removal 
determined via scratch wound migration assay. Scale bars = 100 µm, all images are of 
cells in the presence of PDGF. Data are mean ± SEM (n = 3). P values determined via 
one way ANOVA. From [1], reprinted with permission from AAAS. 
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Endothelial cells as well as vascular smooth muscle cells displayed increased uptake of the MK2i 
peptide when formulated into NPs, motivating inquiry into the effects of MK2 inhibition in endothelial cells. 
In order evaluate MK2i-NP effects on endothelial migration, a Boyden transwell migration assay was 
performed on endothelial cells in the presence of the chemoattractant vascular endothelial growth factor 
(VEGF) revealing that MK2 inhibition reduced cellular migration independent of cell type (fig. 3.11). 
Furthermore, it appears that MK2i-NPs were more effective at inhibiting migration in endothelial cells as 
well as vascular smooth muscle cells.  
 
 
 
 
 
 
Figure 3.10 - Cell proliferation assay. Cell proliferation in HCAVSMCs treated for 30 minutes with MK2i peptide 
alone, MK2i-NPs, or NE-MK2i-NPs and cultured for 24 hours in fresh media with (+) or without (-) 50 ng/mL 
PDGF-BB. NT = no treatment, n = 4. No statistically significant differences were found. P values determined via 
one way ANOVA. From [1], reprinted with permission from AAAS. 
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Because the intracellular half-life of MK2i was significantly higher when delivered via MK2i-NPs, 
in vitro bioactivity assays were also carried out at 5 days post-treatment to assess the impact of the NP 
formulation on longevity of peptide therapeutic action. A 5 day time point was chosen as it is outside the 
calculated intracellular half-life of MK2i (i.e., 3.2 days), indicating that the bioactivity of the free peptide will 
be significantly reduced compared to MK2i-NPs. Indeed, investigation of Inhibition of VSMC migration 5 
days post-treatment via a Boyden transwell chemotaxis assay revealed that MK2i-NPs sustained 
inhibitory activity at all concentrations whereas free MK2i or NE-MK2i-NPs showed no significant effects 
(fig. 3.12).  
Figure 3.11 - MK2i effects on endothelial migration.  
Quantification and representative images of HUVEC migration immediately after treatment removal determined via 
a Boyden transwell migration assay. Data are mean ± SEM (n = 3 technical replicates from 2 separate 
experiments). P values determined via one way ANOVA. From [2], reprinted with permission from AAAS. 
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In order to further investigate the effect of NP formulation on the duration of MK2i bioactivity, the 
ability of MK2i-NPs to sustain inhibition of inflammatory cytokine production was also investigated. In 
accord with intracellular half-life calculations for the MK2i-NP formulation compared to the free MK2i 
peptide, the ability of the free MK2i peptide to inhibit TNFα-stimulated production of monocyte 
chemoattractant protein-1 (MCP-1, which attracts inflammatory cells and is implicated in vein graft IH [92]) 
Figure 3.12 - MK2i-NPs prolong inhibition of VSMC migration in vitro. Quantification and representative 
images of HCAVSMC migration 5 days after treatment removal determined via a Boyden transwell migration 
assay. Data are mean ± SEM (n = 3 technical replicates). P values determined via one way ANOVA. From 
[2], reprinted with permission from AAAS. 
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was significantly decreased at 5 days post-treatment in vascular smooth muscle cells (fig. 3.13 A) 
whereas MK2i-NPs demonstrated sustained inhibitory bioactivity at 5 days post-treatment. To clarify if this 
prolonged duration of 
bioactivity is cell type 
dependent the TNFα-
stimulated production of 
MCP-1 in endothelial 
cells was also 
investigated at 3 and 5 
days after treatment 
removal (fig. 3.13 B). 
MK2i-NPs were found to 
significantly inhibit 
endothelial MCP-1 
production compared to 
both untreated and MK2i 
treated cells at both time 
points, further 
corroborating the 
intracellular half-lives 
calculated for the free 
peptide compared to the 
NP formulation. 
 
 
 
 
 
Figure 3.13 - Vascular smooth muscle and endothelial MCP-1 production over 
time. Quantification of MCP-1 production relative to untreated controls in both (A) 
vascular smooth muscle and (B) endothelial cells following 24 hours of stimulation 
with 20 ng/ml TNFα at 3 and 5 days after treatment removal. All treatments used a 
10 µM dose of MK2i, Data are mean ± SEM, n = 4. P values determined via one 
way ANOVA. From [2], reprinted with permission from AAAS. 
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Discussion 
Upon activation, MAPKAP Kinase II translocates from the nucleus to the cytoplasm  [37] and, as 
a result, an antagonist of activated MK2 such as the MK2i peptide used herein must be efficiently 
internalized and delivered into the cytosol in order to optimize bioactivity. However, when delivered in its 
free form the MK2i peptide becomes entrapped in late endosomes [8] and is restricted from accessing 
activated MK2 in the cytoplasm. Formulation of the positively charged, CPP-based MK2i peptide with the 
anionic, endosomolytic polymer PPAA was conceptualized as a method to enhance peptide 
endolysosomal escape and therapeutic potency. This approach was inspired by the convention for 
nonviral delivery of nucleic acids, which is based on electrostatic formation of polyplexes between anionic 
nucleic acids and positively charged CPP sequences, lipids, or polymeric transfection agents to enhance 
uptake and endosomal escape [45, 93, 94].  NP formulation yielded net negatively charged particle; 
serendipitously, the NP formulation significantly increased peptide uptake by VSMCs relative to the free, 
CPP-based MK2i peptide. Notably, the in vitro comparisons of MK2i-NPs and NE-MK2i-NPs suggest that 
the high level of MK2i-NP cell internalization was dependent on the specific composition of PPAA, rather 
than purely dictated by NP morphology and surface charge.  The α-alkyl substitution of the propyl moiety 
makes PPAA more lipophilic/hydrophobic relative to acrylic acid, suggesting that the observed differences 
in uptake may be the result of increased hydrophobic interactions of MK2i-NPs with the cell membrane. 
Hydrophobic interactions may nonspecifically trigger MK2i-NP cell internalization, or MK2i-NP 
internalization could be mediated through a more specific interaction, for example by VSMC scavenger 
receptors that are upregulated in settings of vascular stress and that internalize negatively 
charged/hydrophobic particles [95, 96]. 
Avoiding endolysosomal degradation and extracellular recycling is vital to optimizing potency and 
longevity of action of cytosolically-active peptides[7]. A sustained therapeutic effect is of particular 
importance for a peptide-based vein graft therapeutic where it is desirable for a single, intraoperative 
treatment to achieve prolonged bioactivity throughout the post-transplant inflammatory and healing 
phases. To this end, NP formulation improved the potency, intracellular retention and duration of 
bioactivity of the MK2i peptide in multiple vascular cell types through the pH-dependent membrane 
disruptive activity of PPAA, which is ideally tuned for directing endolysosomal escape. Furthermore, the 
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buffering capacity of the NPs may provide a means of cargo protection, since more acidic environments 
are typically more prone to degradation of biologic drugs. Once internalized, the duration of efficacy of the 
delivered peptide is dependent on rates of exocytosis, endo-lysosomal degradation, and cytoplasmic 
degradation. It is well established that free peptides in the cytosol are short-lived and rapidly broken down 
by intracellular proteolytic complexes (e.g. the ATP-dependent 26 S proteasome) [97]; the presented 
intracellular retention and duration of bioactivity data suggest that complexation with the PPAA polymer 
may not only facilitate endosomal escape but may also cytosolically stabilize the MK2i peptide and help 
sustain its bioactivity. 
The data presented herein firmly establish the anti-migratory and anti-inflammatory mechanisms 
of action of MK2i-NPs in VSMCs in vitro and confirm the utility of targeting the p38-MK2 pathway to inhibit 
multiple factors underlying IH pathogenesis. Although VSMCs are considered the primary target cell for 
therapeutically blocking IH, vascular endothelial cells also efficiently internalized the MK2i-NPs. 
Considering focal disruption of the endothelium occurs during vein graft harvest even under optimal 
conditions [98], one potential concern is that MK2i-NP inhibition of endothelial migration may have 
deleterious effects on vein graft re-endothelialization. However, evidence suggests that ECs responsible 
for vein graft re-endothelialization are predominantly derived from the surrounding artery [99]. This 
concern does, however, further justify the use of an ex vivo topical treatment scheme that will avoid non-
specific effects on cells outside the graft. Although not assessed here, the p38 MAPK pathway has also 
recently been implicated in TGF-β–mediated endothelial-to-mesenchymal transdifferentiation [32], which 
is believed to be a key mechanism underlying IH [100]. Recent studies have also demonstrated that MK2 
deficiency promotes endothelial healing and prevents endothelial recruitment of inflammatory cells in an 
arterial injury model [80]. Although the role of endothelial MK2 inhibition in IH remains unclear, our data 
support that MK2 inhibition decreases endothelial production of inflammatory cytokines. These findings 
motivate further investigation into the role of endothelial MK2 inhibition in IH. 
 
Conclusion 
 In vitro uptake, retention, and endosomal colocalization studies established that formulation into 
NPs drastically increases both cellular uptake and intracellular retention in both endothelial and vascular 
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smooth muscle cells. MK2i-NPs were found to facilitate endosomal escape and cytosolic delivery of a 
fluorescently labeled MK2i peptide. In vitro analysis of vascular smooth muscle and endothelial cell 
migration and inflammatory cytokine production revealed that MK2i-NPs significantly increased both the 
anti-migratory and anti-inflammatory potency and duration of therapeutic efficacy of the MK2i peptide. 
These results correlate well with the observed increase in uptake, intracellular retention, and endosomal 
escape facilitated by NP formulation with a pH-responsive, endosomolytic polymer. 
It is hypothesized that when the MK2i-NP nanotechnology presented here is translated in vivo, 
that the enhanced uptake and intracellular half-life demonstrated in vitro will results in optimized peptide 
delivery that minimizes the therapeutic dose required and will prolong the duration of efficacy of the 
treatment. However, further ex vivo studies will be necessary to elucidate the underlying molecular 
mechanisms responsible for the observed bioactivity and to verify that the preliminary in vitro results 
presented will hold true in the more complex, 3-dimensional architecture of human vascular tissue. 
Ultimately, in vivo studies in a relevant animal model will be required to verify that MK2i-NPs can inhibit 
multiple processes underyling IH pathogenesis in a clinically relevant, dynamic flow environment. These 
studies will provide further insight into the role that MK2 plays in the transdifferentiation of vascular 
smooth muscle cells from a contractile (i.e., healthy) to a synthetic (i.e., pathological) phenotype and 
establish the clinical translatability of this approach as a platform technology for intracellular peptide 
delivery. 
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CHAPTER IV 
 
MK2I-NPS AS A THERAPEUTIC FOR INTIMAL HYPERPLASIA 
 
Introduction 
Ex vivo, intraoperative treatment of grafts with MK2i-NPs is an ideal therapeutic strategy to 
enhance delivery to the target tissue and avoid potential for off-target effects or systemic toxicity.  MK2 
may represent an ideal target because of its involvement in inflammation, cell migration, and phenotypic 
modulation. A recent study on mouse vein grafts showed that while the free MK2i peptide prevented early 
intimal thickening, the rate of intimal thickening during weeks 1-4 post-transplant was similar between the 
treated and untreated control grafts [56]. Thus, there is a clinical need for both a therapeutic that 
comprehensively addresses the processes involved in IH and a delivery method that achieves potent and 
sustained therapeutic efficacy following a single treatment. In vitro bioactivity assays revealed that MK2i-
NPs sustained potent inhibition of multiple factors underlying IH: migration and inflammation. However, 
many promising drug delivery technologies lack in vitro to in vivo translatability [101], as the highly 
dynamic and highly complex 3-dimensional in vivo environment presents new delivery barriers that alter 
therapeutic pharmacokinetics. In order to elucidate if the increases in uptake seen in vitro will translate to 
increased uptake in human vascular tissue, fluorescently labeled MK2i will be utilized to visualize ex vivo 
uptake and vessel penetration in viable human saphenous vein (HSV) explants. Counterstaining with 
endothelial and vascular smooth muscle cell markers will be utilized to assess uptake in different vascular 
cell populations.  
To provide insight into the underlying molecular changes in p38-MAPK/MK2 signaling responsible 
for the anti-migratory and anti-inflammatory effects demonstrated in vitro, western blot analysis of the 
phosphorylation state of known MK2 substrates (i.e., hnRNP A0, CREB, and HSP27, see fig. 1.2) will be 
investigated ex vivo in viable HSV. Moreover, an ex vivo organ culture model of IH in will be utilized in 
conjunction with vessel morphometrical analysisto assess the ability of MK2i-NPs versus free MK2i to 
inhibit neointimal thickening. In addition to assessing tissue following organ culture, immunohistochemical 
analysis of treated HSV explants will be used to assess differences in vascular smooth muscle cell 
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phenotype.  Tissue viability will be assessed in HSV to ensure that ex vivo results are not affected by 
tissue toxicity due to NP formulation. 
Finally, to assess the clinical translatability of this NP approach to peptide delivery an in vivo 
rabbit model of bilateral jugular vein graft interposition into the common carotid artery that employs a 
polymeric cuff method to induce turbulent blood flow and accelerate graft IH will be undertaken (fig. 4.1). 
In this model, jugular vein grafts will be treated or given vehicle control for 30 minutes ex vivo, which is 
representative of the amount of time that grafts are explanted during human revascularization 
procedures. Grafts will be harvested 28 days post-operatively and histological sections prepared to 
measure intimal thickening. In addition,  immunohistochemical analysis of intimal cellular proliferation, 
macrophage recruitment/persistence, and contractile versus synthetic vascular smooth muscle cell 
phenotypic markers will also be used to provide further insight into treatment effects on various aspects of 
IH pathogenesis. 
 
 
 
 
Figure 4.1 – Anastomotic cuff technique for bilateral jugular vein grafting into the carotid artery. (A) 
Schematic of the anastomotic cuff technique for vein graft interposition: a) The vein graft is pulled through the 
cuff and then b) everted, c) fixed, and d) inserted into the artery and secured around the cuff. Reproduced from 
[3]. (B) A vein graft with ends everted around polymeric cuffs. (C) Interpositioned vein graft with reconstituted 
blood flow. 
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Methods 
Study design 
For ex vivo studies, HSV histology samples were blinded to the treatment group for all analyses. 
For in vivo studies, an a prior power analysis based upon pilot data determined a sample size of 4 rabbits 
(8 grafts) per treatment group to provide 95% power to detect significant difference in our primary 
endpoints with α=0.05. Endpoints and peptide dosage were selected based upon existing precedents for 
the evaluation of IH. Failed grafts (i.e., due to partial or complete thrombosis) and grafts in which the 
contralateral graft failed were excluded due to the compensatory changes in blood flow following 
contralateral graft occlusion. Contralateral treatments in each rabbit were randomized and samples were 
blinded prior to histological analyses. One rabbit was euthanized at day 14 due to thrombosis of both 
grafts. The incidence of graft failure was: NT - 10 grafts harvested, 2 failed due to thromboses, 1 
excluded due to contralateral failure, 7 patent; MK2i – 16 grafts harvested, 8 grafts failed due to 
thromboses, 0 excluded due to contralateral thrombosis, 8 patent; MK2i-NP – 14 grafts harvested, 2 
failed due to thrombosis, 3 excluded due to contralateral thrombosis, 9 patent. Altogether, n ≥ 7 patent 
grafts without contralateral occlusion per treatment group were included in the reported data. 
 
Human saphenous vein 
Upon approval by Vanderbilt Medical Center’s institutional Review Board, de-identified, discarded 
segments of HSV were collected from consented patients undergoing coronary or peripheral vascular 
bypass surgeries. Following surgical resection, HSV segments were stored in saline solution until the end 
of the surgical procedure, at which time they were placed in cold transplant harvest buffer (100 mM 
potassium lactobionate, 25 mM KH2PO4, 5 mM MgSO4, 30 mM raffinose, 5 mM adenosine, 3 mM 
glutathione, 1 mM allopurinol, 50 g/L hydroxyethyl starch, pH 7.4). All HSV segments were used within 24 
hours of harvest. Utilizing sterile technique, HSV segments were transferred to a 60 mm Petri dish. The 
end of each segment (0.5 mm) was removed with a blade, and excess adventitial and adipose tissue was 
removed with minimal manipulation. HSV segments were cut into consecutive rings with an approximate 
width of 1.0 mm to be utilized in organ culture experiments. Two rings from each segment were 
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immediately fixed in 10% formalin at 37°C for 30 min to obtain pre-culture intimal thickness 
measurements. 
Prior to organ culture experiments, HSV viability was confirmed. HSV rings were weighed and 
their lengths recorded. HSV rings were then suspended in a muscle bath containing a bicarbonate buffer 
(120mM NaCl, 4.7 mM KCl, 1.0 mM MgSO4, 1.0 mM NaH2PO4, 10 mM glucose, 1.5 mM CaCl2, and 25 
mM Na2HCO3, pH 7.4) equilibrated with 95% O2 and 5% CO2 at 37 °C. The rings were stretched and the 
length progressively adjusted until maximal tension was obtained.  Normalized reactivity was obtained by 
determining the passive length–tension relationship for each vessel segment. Rings were maintained at a 
resting tension of 1 g, which produces maximal responses to contractile agonists, as previously 
determined, and equilibrated for 2 h in buffer. Force measurements were obtained using a Radnoti Glass 
Technology force transducer (159901A) interfaced with a Powerlab data acquisition system and Chart 
software. HSV rings were initially contracted with 110 mM KCl (with equimolar replacement of NaCl in 
bicarbonate buffer) and the force generated was measured. 110 mM KCl causes membrane 
depolarization, leading to contraction of vessels containing functionally viable smooth muscle. 
 
Microscopic Analysis of MK2i delivery to HSV 
An Alexa-568 labeled MK2i peptide was prepared as stated in section 4.9. After verifying viability, 
HSV rings were treated with 100 µM labeled MK2i peptide, MK2i-NPs, or NE-MK2i-NPs for 30 minutes 
while suspended in a muscle bath, washed 2x in PBS -/-, and immediately embedded in OCT compound 
and frozen over dry ice. 5 µm cryosections were cut from the middle of each treated vessel and mounted 
on microscope slides. Immunofluorescence staining was then carried out with CD31 and α-SMA primary 
antibodies and a FAM labeled secondary antibody.  Microscopy images were obtained using a Nikon 
Eclipse Ti inverted fluorescence microscope. Gain settings were kept constant for all images acquired for 
all samples. 
 
HSV organ culture and assay for ex vivo IH 
After vessel viability was verified with multiple KCl challenges, additional rings were cut and 
placed in a 24 well plate and maintained in RPMI 1640 medium supplemented with 30% FBS, 1% L-
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glutamine and 1% penicillin/streptomycin for 14 days at 37 °C in an atmosphere of 5% CO2 in air. The 
rings were treated with MK2i-NPs, NE-MK2i-NPs, MK2i peptide, or buffer alone for 2 hours, washed, and 
given fresh media. The culture medium without treatments was replaced every 2 days for 14 days. 
 
HSV viability 
To ensure that treatments did not impact tissue viability, an MTT assay was performed on HSV 
rings at 1 and 14 days post-treatment (supplementary fig. 15). HSV rings were prepared and treated as 
noted above, and following 1 or 14 days of organ culture, HSV rings were weighed and then placed in 
250 µL of 0.01% methyl tetrazolium dissolved in DPBS for 1 hour. The reaction was stopped by placing 
the rings into distilled water.  The rings were then placed into 1 mL of CelloSolve and incubated at 37°C 
overnight. Following incubation, rings were mixed in solution, and the CelloSolve was extracted and 
placed into a cuvette where the optical density at 570 nm was determined. Relative viability calculations 
were based on the optical density normalized to the wet weight of the ring. 
 
Vessel morphometry and  immunohistochemical analyses 
After 14 days of organ culture, vein segments were fixed in 0.5 ml of 10% formalin at 37 °C for 30 
min and embedded in paraffin for sectioning. Beginning at the midportion of each ring, 5 transverse 
sections, spaced 5 μm apart, were cut from each specimen. Histological sections were prepared and 
separate sections were stained with Verhoeff–van Gieson (VVG, elastin fibers), Ki67 (cellular 
proliferation), caspase 3 (apoptosis), α-smooth muscle acting (α-SMA, contractile vascular smmoth 
muscle cell phenotypic marker), or vimentin (synthetic vascular smooth muscle cell phenotypic marker). 
Histology sections were imaged using a Nikon Eclipse Ti inverted fluorescence microscope, and 6 radially 
parallel measurements of intimal and medial thickness were randomly taken from each section using NIS 
Elements imaging software (total of 6–12 measurements per ring, n≥3 rings per treatment group from 
separate donors) to quantify intimal thickness. Intima was defined as tissue on the luminal side of the 
internal elastic lamina or the chaotic organization of the cells contained within it, whereas the medial layer 
was contained between the intimal layer and the external elastic lamina. Ki67-, caspase 3-, α-SMA–, and 
vimentin-positive staining in the intima was quantified by free form selecting the intima in imageJ and 
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using a color deconvolution method as previously described [102] and normalized to the number of 
intimal cell nuclei. 8 histological images from grafts from 2 different donors were analyzed for each 
treatment group. 
 
Western blot analysis of protein phosphorylation in HSV 
Following 2 hours of treatment, a portion of the treated HSV rings were snap-frozen with liquid 
nitrogen, pulverized, and homogenized using urea-DTT-CHAPS buffer. For analysis of hnRNP A0 
phosphorylation treated HSV rings were maintained in organ culture in fresh media for 24 hours prior to 
homogenization. For analysis of CREB and HSP27 phosphorylation HSV rings were frozen immediately 
after treatment removal. Lysates were centrifuged (6000 g, 20 minutes), and the supernatant was 
collected for each sample for evaluation of HnRNP A0, CREB, and HSP27 phosphorylation. Equal 
amounts of protein (20 µg per lane) were loaded on 15, 10, or 4–20% SDS–PAGE gels; proteins were 
electrophoretically separated and then transferred to Immobilon membranes. For hnRNP A0 
phosphorylation, membranes were probed overnight at 4°C with primary antibodies for phospho-hnRNP 
A0 (Millipore) and unphosphorylated hnRNP A0 (Santa Cruz). For CREB phosphorylation, membranes 
were probed overnight at 4°C with primary antibodies for phospho-CREB (abcam) and unphosphorylated 
CREB (abcam). For HSP27 phsophorylation membranes were probed overnight at 4°C with primary 
antibodies for phospho-HSP27 (Epitomics) and unphosphorylated HSP27 (Santa Cruz). After washing, 
the membranes were incubated with appropriate secondary antibodies (Li-Cor) for 1 hour at room 
temperature. The secondary antibody was imaged using the Odyssey direct infrared fluorescence 
imaging system and densitometrically quantified with LiCor Odyssey software v2.1 at 800 and 680 nm 
wavelengths. 
 
Rabbit bilateral jugular vein graft interposition model 
This study was approved by the Vanderbilt Institutional Animal Care and Use Committee and 
conforms to the Guide for the Care and Use of Laboratory Animals. Male New Zealand White rabbits 
(3.0–3.5 kg; n = 24) were anesthetized through an intramuscular injection with ketamine hydrochloride 
(1.4 mg/kg) and xylazine (0.2 mg/kg). Anesthesia was maintained with endotracheal intubation and 
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inhaled isoflurane (2.0–5.0%). A high-dose IV heparin bolus (250 U/kg) was administered immediately 
prior to carotid cross clamp. The operative procedure was performed with aseptic technique under 2.5x 
optical magnification. 
Vein bypass grafts were constructed with an anastomotic cuff technique as previously 
described[103]. Briefly, polymer cuffs consisting of a 2.0-mm body loop were fashioned from a 4-Fr 
introducer sheath. Following ligation of smaller tributary vessels, the external jugular veins were 
harvested (3.0-4.0 cm in length) for creation of an interposition graft into the common carotid artery. 
Jugular vein ends were passed through a cuff, everted, and fixed with 6-0 silk. Vein grafts were 
subsequently treated for 30 minutes in 2 mL of either 30 μM MK2i-NP, 30 μM MK2i peptide, or PBS (no 
treatment). Following treatment, the carotid artery lumen was exposed with a 2.0-cm arteriotomy, and the 
cuffed, reversed vein ends were inserted. A 3-0 silk was used to secure the artery around the cuff. Finally, 
1.0 cm of carotid artery back wall was cut away between the cuffs to permit vein graft extension. 
Rabbits were euthanized at 28 days post-operatively, and vein grafts were perfusion fixed in situ 
with 10% neutral buffered formalin under ~50 mm Hg pressure with a roller pump. Vein grafts were 
subsequently excised and sectioned into four segments avoiding the tissue overlying the cuff in order to 
allow for evaluation of morphological variation along the length of the graft. Histological sections were 
prepared and separate sections were stained with Verhoeff-van Gieson (VVG) , PCNA (abcam), α-SMA 
(abcam), vimentin (abcam), or RAM-11 (Dako). Intimal and medial thicknesses were quantified by taking 
3 measurements from each quadrant of each VVG stained vessel section (12 measurements/segment = 
48 measurements/graft). PCNA, α-SMA, vimentin, and RAM-11  positive staining in the intima was 
quantified by free form selecting the intima in imageJ and using a color deconvolution method as 
previously described[102] and normalized to the number of intimal cell nuclei. 16 histological images from 
4 different graft sections were analyzed for each treatment group. 
 
Results 
MK2i-NP delivery of peptide into intact human saphenous vein (HSV) was assessed revealing 
that uptake occurs in both endothelial and smooth muscle cells. As expected, MK2i-NPs, MK2i, and NE-
MK2i-NPs all showed more concentrated uptake at the luminal and adventitial surfaces that act as 
53 
diffusion barriers (fig. 4.2); Although MK2i was colocalized with the endothelial marker CD31 on the 
luminal surface of the vessel (fig. 4.2 B), MK2i penetration into the intimal and medial layers was verified 
by MK2i distribution through tissue layers that stained positively for the smooth muscle marker α-SMA 
(fig. 4.2 A). Furthermore, in accordance with in vitro results, MK2i-NPs increased the overall peptide 
uptake within the vessel wall (fig. 4.2 C). 
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Figure 4.2 - MK2i-NP formulation increases peptide delivery to human vein. (A) Immunofluorescence 
microscopy images and zoomed insets of human saphenous vein cross sections treated with Alexa-568 
labeled MK2i, MK2i-NPs, or NE-MK2i-NPs (red) and stained for the vascular smooth muscle cell marker 
α-smooth muscle actin (green) and the nuclear marker DAPI (blue). (B) Immunofluorescence microscopy 
images and zoomed insets of human saphenous vein cross sections treated with Alexa-568 labeled MK2i, 
MK2i-NPs, or NE-MK2i-NPs (red) and stained for the endothelial marker CD31 (green) and the nuclear 
marker DAPI (blue). (C) Pixel intensity distribution derived from the red fluorescent channel of entire (un-
zoomed) cross sectional images in A and B. From [1], reprinted with permission from AAAS. 
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Delivery of MK2i-NPs to intact HSV ex vivo modulated phosphorylation of several MK2 substrates 
relevant to graft IH (fig. 1.2).  The post-transcriptional gene regulator hnRNP A0 is among  these relevant 
downstream MK2 effectors and effectively stabilizes the mRNA of inflammatory cytokines thereby 
increasing their translation [35, 104, 105]. MK2i-NP treatment significantly reduced phosphorylation of 
hnRNP A0 in HSV at all concentrations whereas the free MK2i peptide only produced significant effects at 
100 µM (fig. 4.3). These results indicate that NP formulation enhances MK2i mediated inhibition of 
hnRNP A0 in human vein and agrees with in vitro data demonstrating equivalent MK2i-NP bioactivity at 
an order of magnitude lower dose than the free peptide. 
 
 
 
Figure 4.3 – Western blot analysis of hnRNP A0 phosphorylation in treated HSV. 
Representative western blots and quantification of western blot analysis showing the phosphorylation 
of MK2 substrate hnRNP A0 with and without treatment. Data are mean ± SEM (n ≥ 3 separate 
biological replicates from 3 separate donors). P values determined via one way ANOVA. From [1], 
reprinted with permission from AAAS. 
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In addition to hnRNP A0, activated MK2 phosphorylates the transcription factor CREB which 
binds to cAMP-responsive elements to promote expression of genes that induce smooth muscle cell 
migration [106, 107], proliferation [39, 108], and production of the inflammatory cytokines such as IL-6 [8]. 
Similar to hnRNP A0 phosphorylation results, MK2i-NPs were found to significantly enhance Mk2i-
mediated inhibition of CREB phosphorylation (fig. 4.4). Moreover, a 10 µM dose of MK2i-NPs were 
significantly more effective than an equivalent dose of free peptide, again demonstrating equivalent 
bioactivity at a 10-fold lower dose of peptide (i.e., 10 µM MK2i-NP vs. 100 µM MK2i). 
 
 
 
 
 
Figure 4.4 – Western blot analysis of CREB phosphorylation in treated HSV. Representative 
western blots and quantification of western blot analysis showing the phosphorylation of MK2 
substrate CREB with and without treatment. Data are mean ± SEM (n ≥ 3 separate biological 
replicates from 3 separate donors). P values determined via one way ANOVA. From [1], reprinted 
with permission from AAAS. 
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It was also confirmed that MK2i-NPs, as well as MK2i, significantly decreased phosphorylation of 
the MK2 substrate HSP-27 (fig. 4.5), which along with CREB, is believed to promote pathological 
vascular smooth muscle cell migration characteristic of IH [38, 42, 109].  
 
 
 
 
 
 
Figure 4.5 – Western blot analysis of HSP27 phosphorylation in treated HSV. 
Representative western blots and quantification of western blot analysis showing the 
phosphorylation of MK2 substrate HSP27 with and without treatment. Data are mean ± SEM (n 
≥ 3 separate biological replicates from 3 separate donors). P values determined via one way 
ANOVA. From [1], reprinted with permission from AAAS. 
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To investigate if the inhibited activity of these MK2 substrates would translate into a multipronged 
therapeutic approach to prevent vein graft failure, an ex vivo organ culture model of IH was carried out in 
HSV over a two week period.  This study revealed that MK2i-NPs significantly inhibited neointima 
formation in a dose-dependent fashion and at an order of magnitude lower peptide dose than free MK2i 
(fig. 4.6). Furthermore, MK2i-NP therapy at 100 µM MK2i was the only treatment that fully abrogated IH, 
yielding intimal thickness statistically equivalent to control tissues prepared for histology immediately after 
harvest (p=0.49).  
 
 
 
 
 
Figure 4.6 - Ex vivo treatment with MK2-NPs reduces neointima formation in human saphenous vein. (A) 
Neointima were visualized using Verhoeff Van Gieson staining of human saphenous vein samples that were 
treated for 2 hours and maintained in organ culture for 14 days. Red bars demarcate intimal thickness (scale 
bars, 100 µm). (B) Intimal thickness in human saphenous vein samples quantified after 14 days in organ culture. 
Data are mean ± SEM (n ≥ 3 separate biological replicates from 3 separate donors). *p ≤ 0.01 compared to no 
treatment control(NT), **p ≤ 0.001 compared to NT, 
Ɨ
 p ≤ 0.05. P values determined via one way ANOVA. From 
[1], reprinted with permission from AAAS. 
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 To ensure that treatments did not inhibit neointima formation due to tissue toxicity, an MTT assay 
was performed on HSV rings at 1 and 14 days post-treatment revealing that none of the treatments had 
any significant effect on HSV viability (fig. 4.7). 
  
 
 
 
To assess ex vivo cell-based mechanisms underlying MK2i-NP mediated inhibition of neointima 
formation in human saphenous vein, ki67 stained histological sections of treated HSV were used to 
analyze intimal/medial cellular proliferation. Ki67 is a nuclear protein that is associated with cellular 
proliferation and ribosomal RNA transcription and, thus, is a protein marker of proliferating cells. 
Analaysis of stained sections revealed that cellular proliferation markedly increased in untreated HSV 
over the 14 day organ culture period (fig. 4.8). However, treatment with MK2i-NPs as well as the free 
MK2i peptide was found to reduce cellular proliferation to baseline levels evinced by HSV samples prior 
to organ culture (i.e., preculture).  
Figure 4.7 - Human saphenous vein viability. Quantification of tissue viability in human 
saphenous vein rings treated for 2 hours and subsequently maintained in organ culture for 1 or 
14 days as assessed through an MTT assay. Data are mean ± SEM, n = 3 biological replicates 
from 3 separate donors. No statistically significant differences were observed. P values 
determined via one way ANOVA.  
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Figure 4.8 - Ex vivo treatment with MK2i-NPs reduces cellular proliferation in human saphenous vein. 
Representative images of ki67 stained histological sections of treated HSV. Ki67 positive staining was quantified 
by normalizing positive pixel staining to the number of nuclei as shown at the top of the figure. Data are 
represented as mean ± SEM (n = 8 separate histological images). P values determined by one way ANOVA. 
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In addition to assessing cellular proliferation, Caspase 3 stained histological sections of treated 
HSV were used to analyze apoptosis of intimal cells. Caspase 3 is a protein that interacts with other 
caspase proteins, where sequential activation of caspases plays a key role in effecting cellular apoptosis. 
Cellular apoptosis was significantly increased in all treated HSV samples relative to preculture samples 
(fig. 4.9). In agreement with ex vivo intimal thickening results, MK2i-NP treated HSV evinced significantly 
more intimal apoptosis than MK2i or NE-MK2i-NP treated HSV. 
62 
 
 
 
 
 
Figure 4.9 - Ex vivo treatment with MK2i-NPs increases intimal apoptosis in human saphenous vein. 
Representative images of Caspase 3 stained histological sections of treated HSV. Caspase 3 positive staining 
was quantified by normalizing positive pixel staining in the intima to the number of nuclei as shown at the top of 
the figure. Data are represented as mean ± SEM (n = 8 separate histological images). P values determined by 
one way ANOVA. 
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In order to evaluate MK2i-NP effects on vascular smooth muscle cell phenotype, α-smooth 
muscle actin (α-SMA) stained histological sections of treated HSV were analyzed. α-SMA is a 
multifunctional protein that forms microfilaments  that vascular smooth muscle cells utilize to generate 
contractile force, and expression of α-SMA is correlated with a healthy, contractile vascular smooth 
muscle cell phenotype [106, 110]. As expected, intimal expression of α-SMA significantly decreased 
during two weeks of organ culture indicating vascular smooth muscle cell transdifferentiation into a 
pathological, synthetic phenotype (fig. 4.10). Analysis of treated samples revealed that treatment with 
MK2i-NPs maintained significantly more α-SMA expression compared to untreated samples, whereas the 
free MK2i peptide did not. 
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Figure 4.10 - Ex vivo treatment with MK2i-NPs maintains a contractile vascular smooth muscle cell 
phenotype in human saphenous vein. Representative images of α-SMA stained histological sections of treated 
HSV. α-SMA positive staining was quantified by normalizing positive pixel staining I the intima to the number of 
nuclei as shown at the top of the figure. Data are represented as mean ± SEM (n = 8 separate histological 
images). P values determined by one way ANOVA. 
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In contrast to assessing vascular smooth muscle cell expression of contractile phenotypic 
markers, vimentin stained histological sections of treated HSV were prepared to analyze the intimal 
presence of synthetic vascular smooth muscle cell phenotypic markers. Vimentin is a type II intermediate 
filament protein that is expressed in mesenchymal cells and is one of the most common markers of a 
synthetic smooth muscle cell phenotype [110]. Considering that organ culture resulted in a loss of 
expression of the contractile marker α-SMA, it is hypothesized that a concomitant gain in synthetic 
phenotypic marker expression would occur. Indeed, untreated HSV subjected to two weeks in high serum 
organ culture demonstrated a significant increase in intimal vimentin expression (fig. 4.11). Treatment 
with MK2i-NPs, NE-MK2i-NPs, and free MK2i were all found to significantly reduce vimentin expression to 
levels less than or equal to preculture samples. Moreover, treatment with MK2i-NPs was not only found to 
significantly decrease vimentin expression compared to HSV treated with NE-MK2i-NPs or free MK2i, but 
also compared to preculture samples. 
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Figure 4.11 - Ex vivo treatment with MK2i-NPs inhibits vascular smooth muscle cell transdifferentiation 
into a synthetic phenotype in human saphenous vein. Representative images of vimentin stained histological 
sections of treated HSV. Vimentin positive staining was quantified by normalizing positive pixel staining I the 
intima to the number of nuclei as shown at the top of the figure. Data are represented as mean ± SEM (n = 8 
separate histological images). P values determined by one way ANOVA. 
 
 
67 
The therapeutic benefit of MK2i-NPs in vivo was assessed in a rabbit bilateral jugular vein graft 
interpositional transplant model that employs a polymeric cuff method to induce turbulent blood flow and 
accelerate graft IH [111]. In this model, jugular vein grafts were treated or given vehicle control for 30 
minutes ex vivo prior to transplant.  Grafts were harvested 28 days post-operatively, and Verhoeff Van-
Gieson (VVG) stained histological sections were used to quantify intimal thickness (fig. 4.12 A). 
Treatment with 30 µM MK2i-NPs significantly inhibited neointima formation compared to both untreated 
controls and the free MK2i peptide, which did not produce any significant change in neointima formation 
fig. 4.12 B).  
  
 
 
 
 
 
Figure 4.12 - Intraoperative treatment with MK2i-NPs reduces neointima formation in vivo in transplanted 
rabbit vein grafts. Rabbits vein graft transplants were treated for 30 minutes with MK2i or MK2i-NP (30 µM) in 
Heparin Plasma-Lyte. No treatment grafts were incubated in Heparin Plasma-Lyte alone. Tissue sections were 
evaluated 28 days later. (A) Neointima were visualized using Verhoeff Van Gieson staining of vein grafts. Red 
bars demarcate intimal thickness (scale bars, 100 µm). (B) Intimal thickness in perfusion fixed jugular vein 
interposition grafts was quantified 28 days post-treatement. Data are represented as mean ± SEM (n ≥ 7 grafts 
per treatment group). P values determined by one way ANOVA. From [1], reprinted with permission from AAAS. 
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To assess in vivo cell-based mechanisms underlying MK2i-NP mediated inhibition of neointimal 
thickening, proliferating cell nuclear antigen (PCNA), α-smooth muscle actin (α-SMA), and vimentin 
stained histological sections were used to analyze cellular proliferation and vascular smooth muscle cell 
phenotype. Intimal PCNA staining was significantly decreased by ~17-fold in grafts treated with MK2i-
NPs, whereas treatment with the free MK2i were similar to untreated grafts (fig. 4.13).  
  
 
 
MK2i-NP treated grafts also demonstrated increased staining intensity for α-SMA, which is a 
marker for contractile SMC phenotype[112], relative to untreated grafts or grafts treated with free MK2i 
(fig. 4.14 B). Images of α-SMA immunostained sections revealed that untreated and free MK2i treatment 
groups showed sparse intimal staining (fig. 4.14 A), indicating loss of the contractile VSMC phenotype 
and/or excess production of extracellular matrix proteins, both of which are implicated in vein graft IH. 
Figure 4.13 - Intraoperative treatment with MK2i-NPs reduces cellular proliferation of intimal cells in vivo 
in transplanted rabbit vein grafts. (A) Proliferation of intimal cells as shown using PCNA 
immunohistochemistry. (B) Quantification of PCNA positive nuclear staining in jugular vein graft sections 
normalized to intimal nuclei number. Data are represented as mean ± SEM (n ≥ 7 grafts per treatment group). P 
values determined by one way ANOVA. From [1], reprinted with permission from AAAS. 
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 In agreement with and conversely to increased contractile marker expression, intimal expression 
of the synthetic VSMC marker vimentin was also decreased in MK2i-NP treated grafts but not in grafts 
treated with free MK2i peptide (fig. 4.15). 
Figure 4.14 - Intraoperative treatment with MK2i-NPs promotes a contractile smooth muscle cell 
phenotype in vivo in transplanted rabbit vein grafts. (A) Intimal expression of the contractile marker α-
smooth muscle actin (SMA). (B) Quantification of α-SMA–positive staining in jugular vein graft sections were 
normalized to intimal nuclei number. Data are represented as mean ± SEM (n ≥ 7 grafts per treatment group). P 
values determined by one way ANOVA. From [1], reprinted with permission from AAAS. 
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The number of residual macrophages present in the intima of the vein grafts was also assessed 
in tissue sections using a rabbit macrophage specific antibody, RAM-11 (fig. 4.16 A and B). Fewer  
intimal macrophages were detected in MK2i-NP treated grafts, suggesting that MK2i-NPs blunted local 
macrophage recruitment and/or persistence (fig. 4.16 C). This mechanism is potentially mediated through 
decreased secretion of macrophage inflammatory protein 2 (MIP-2, also known as CXCL2) and/or MCP-1 
[56], both of which attract inflammatory cells and are upregulated either directly or indirectly through 
hnRNP A0 [35, 113, 114].  This mechanism is supported by our in vitro study results showing that MK2i-
NPs inhibited MCP-1 production in both smooth muscle and endothelial cells. Though the inflammatory 
response was predominately resolved in all samples at 28-days, macrophage persistence in untreated 
Figure 4.15 - Intraoperative treatment with MK2i-NPs inhibits vascular smooth muscle cell 
transdifferentiation to a syntehtic phenotype in vivo in transplanted rabbit vein grafts. (A) Intimal 
expression of the synthetic vascular smooth muscle phenotypic marker vimentin. (B) Quantification of intimal 
vimentin-positive staining in jugular vein graft sections were normalized to intimal nuclei number. Data are 
represented as mean ± SEM (n ≥ 7 grafts per treatment group). P values determined by one way ANOVA. From 
[1], reprinted with permission from AAAS. 
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samples agrees with previous observations that MCP-1 can be elevated even at 8 weeks after vein 
grafting, resulting in local recruitment of monocytes and pathogenesis of IH [92].   
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Figure 4.16 - Intraoperative treatment with MK2i-NPs reduces macrophage persistence in vivo in 
transplanted rabbit vein grafts. (A) Representative RAM-11 staining of rabbit jugular vein graft explant 
histological sections for each treatment group. Arrows demarcate positively stained cells. Left column scale bar = 
100 µm, right column zoomed view scale bar = 50 µm. (B) Example images from the color deconvolution method 
utilized to quantify positive RAM-11 staining in the intima of rabbit jugular vein explants. (C) Quantification of RAM-
11 positive macrophage staining in jugular vein graft sections normalized to intimal nuclei number. Data are 
represented as mean ± SEM (n ≥ 7 grafts per treatment group). P values determined by one way ANOVA. From 
[1], reprinted with permission from AAAS. 
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Discussion 
Previous studies have characterized the time course of IH pathogenesis in rabbit and canine 
models.  The investigators detected an initial burst in cellular proliferation during the first week, followed 
by continued graft adaptation that reaches steady state by week 12 [91, 115]. Here, it was hypothesized 
that enhanced endosomal escape would extend intracellular peptide half-life and that this would improve 
long-term graft patency following a single intraoperative treatment by more potently inhibiting IH-relevant 
signaling pathways and accelerating resolution of inflammation and the time required to reach steady-
state conditions. Indeed, avoiding endosomal entrapment was associated with increased longevity of 
intracellular peptide retention (Τ1/2 was increased 14-fold by incorporation into MK2i-NPs: MK2i-NP Τ1/2 = 
57.8 days vs. MK2i Τ1/2 = 4.1 days) and prolonged bioactivity in vitro. The latter was demonstrated by the 
sustained inhibition of migration and sustained inhibition of inflammatory cytokine production  5 days post-
treatment in both vascular smooth muscle and endothelial cells. A sustained effect was also seen in intact 
HSV, and treatment with 100 μM MK2i-NPs completely abrogated neointimal growth over 2 weeks in an 
ex-vivo organ culture model of IH; in this study, the shorter-lived, free MK2i peptide delivered at 
equivalent dose had an intermediate effect. Furthermore, there was also a long-term (28-day) therapeutic 
effect in treated grafts that were transplanted in vivo.  
At the cellular level, the long-term therapeutic benefit of MK2i-NP treatment in the rabbit vein graft 
model was associated with significantly decreased intimal cell proliferation, neointimal thickening, and 
number of macrophages. MK2i-NP treatment was also found to modulate vascular smooth muscle cell 
phenotype in vivo. It is well established that intimal hyperplasia is characterized by vascular smooth 
muscle cell transdifferentiation from a contractile phenotype to a ‘synthetic’ phenotype. A normal, 
contractile vascular smooth muscle cell phenotype is defined by high expression of contractile proteins 
such as α-SMA, low rough endoplasmic reticulum content, a low proliferative index, and fusiform, spindle-
shaped morphology. In contrast, a pathological, synthetic vascular smooth muscle cell phenotype is 
defined by low expression of contractile proteins, extensive extracellular matrix synthesis, high rough 
endoplasmic reticulum content, a high proliferative index, and a less elongated cobblestone morphology 
that is commonly referred to as epitheloid or rhomboid [110, 112]. In the context of modulating these 
phenotypic characteristics, MK2i-NP treatment increased neointimal expression of the contractile 
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phenotypic marker α-SMA and decreased expression of the synthetic phenotypic marker vimentin both ex 
vivo in human vein and in vivo in rabbit jugular vein grafts. In contrast, cell proliferation and expression of 
contractile vs. synthetic smooth muscle cell phenotypic markers were similar between in vivo grafts 
treated with the free MK2i peptide versus untreated control grafts. These data suggest that any cell-level 
therapeutic benefit from free MK2i treatment had been exhausted prior to the 28 day terminal time point.  
Although the mechanism through which MK2 modulates vascular smooth muscle cell phenotype is 
unclear, these results are the first to our knowledge that suggest that MK2 is a key factor in VSMC 
phenotypic modulation in vein graft remodeling. Phosphorylation of the CREB transcription factor 
contributes to cellular proliferation and the pathological, synthetic VSMC phenotype characteristic of IH 
[108, 116] which is a potential link since MK2i-NPs were found to reduce CREB phosphorylation in HSV. 
These combined data suggest that MK2i-NP graft treatment may have a unique capability to decrease the 
level of acute inflammation and/or accelerate the resolution of inflammation, block VSMC phenotypic 
modulation, and decrease the time post-transplant that it takes the graft to reach a steady state. These 
possibilities motivate future studies to better understand the role of MK2 in VSMC phenotype and to 
elucidate the in vivo pharmacokinetics and pharmacodynamics of MK2i-NPs in transplanted grafts in a 
larger animal model and over a broader timescale.  
The current studies validate the broad anti-inflammatory and anti-migratory mechanism of action 
of MK2i-NPs and confirm the utility of targeting the p38-MK2 pathway to inhibit multiple factors underlying 
IH pathogenesis. MK2i-NPs were shown to modulate pro-inflammatory mediators activated downstream 
of MK2 such as hnRNP A0 [35, 104, 105] and CREB[8]. MK2i-NP decreased hnRNP A0 phosphorylation 
in human tissue, which correlated to a decrease in production of the pro-inflammatory cytokines TNF-α, 
IL-6, and MCP-1 in vitro and reduced inflammatory cell recruitment/persistence in vivo at 28 days post-
transplant. MK2i-NPs were also shown to modulate migration-related pathways in human tissue, as 
demonstrated by reduced phosphorylation of HSP27, which triggers VSMC transition to a migratory and 
fibrotic myofibroblast phenotype [34, 38] and causes vein graft vasoconstriction [34, 35, 117]. The effects 
of HSP27 are mediated through regulation of cytoskeleton dynamics, which impacts migration towards 
pathologically relevant stimuli such as angiotensin II and PDGF [37, 38, 53, 118]. MK2i-NPs also 
decreased phosphorylation of the CREB transcription factor, which is also known to contribute to VSMC 
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migration [8, 106, 107]. Inhibition of both HSP27 and CREB activation correlated to reduced VSMC 
migration in vitro. To my knowledge, these results are the first to establish the relationship between MK2 
and the downstream pro-inflammatory and pro-migratory factors hnRNP A0, CREB, and HSP27 in intact, 
human vascular tissue. However, one major shortcoming of performing protein expression analysis in the 
whole organ setting is that the contribution of distinct cell populations (i.e. medial vascular smooth muscle 
cells vs. endothelial cells vs, adventitial cells) remains unclear. To this end, novel techniques such as 
laser capture microdissection (LCM) have been developed that allow for selective isolation of endothelial 
and smooth muscle cells from vein graft tissue [108]. The advent of this type of technology not only  
motivates more in-depth studies focused on the contribution of specific vascular cell populations to vein 
graft IH but also on the influence that these cell populations have on each other through juxtacrine and 
paracrine signaling.   
 
Conclusion 
A simple, translational approach was developed for formulation of nanoparticles that enhance 
cellular uptake and retention of a highly specific therapeutic peptide inhibitor of MK2. NP formulation 
enhanced the potency and longevity of action of the MK2i peptide, and the clinical translatability of this 
delivery technology was demonstrated in human tissue ex vivo and in a pre-clinical in vivo model.  These 
results also validate and provide mechanistic insight into the key role of MK2 in VSMC 
behavior/phenotype and vascular graft IH.  
The collective anti-inflammatory, anti-migratory, and phenotype-modulating actions of MK2i-NPs 
emphasize the utility of this therapy against a multifactorial process like IH, which involves a complex 
interplay of cell proliferation, migration, inflammation, and matrix synthesis.  Because this translationally-
relevant MK2i-NP formulation (formed by simple mixing; no complex syntheses, conjugations, or 
purifications required) comprehensively targets multiple factors involved in IH, it has potential to overcome 
the shortfalls of prior therapeutic candidates with more narrow mechanisms of action. This work further 
elucidates the molecular mechanisms underlying the initiation and progression of intimal hyperplasia and 
highlight key therapeutic targets to improve vein graft patency. MK2i-NPs showed significant clinical 
potential as an IH prophylactic therapy to be applied during vascular graft transplantation, and these 
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findings firmly establish the potential use of nanotechnology to enhance cell and tissue delivery, 
bioactivity, and intracellular pharmacokinetics of therapeutic peptides such as MK2i.  
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CHAPTER V 
 
NANO-POLYPLEXES AS A PLATFORM TECHNOLOGY 
 
Introduction 
Preliminary data demonstrates that formulation of the cationic MK2i peptide into an optimized NP 
formulation significantly increases cellular uptake and retention and facilitates endosomal escape. These 
attributes resulted in a significant enhancement in bioactivity in vitro, ex vivo, and in vivo. A multitude of 
cationic, cell penetrating peptide modified therapeutics have been developed that show potential for 
treatment of human disease [5, 13, 52, 54, 119-126]. Considering the potential of these cell penetrating 
peptide containing therapeutics in the context of the therapeutic enhancement seen with MK2i-NPs begs 
the question of whether or not this nano-polyplex approach can serve as a platform technology. 
In order to test if the nano-polyplex approach can be generalized to other therapeutic cell 
penetrating peptides, 2 different vasoactive peptides will be used in the formulation of NP libraries for 
characterization and optimization for further biological studies in vitro and ex vivo (Table 3).  
Peptide Sequence MW Function 
MK2i (MMI-0100) YARAAARQARAKALARQLGVAA 2283.67 
MAPKAP Kinase II 
inhibitor 
p-HSP20 (AZX-100) YARAAARQARAWLRRAsAPLPGLK 2690.06 HSP20 mimetic 
 
 
 
Peptides will be made through solid phase peptide synthesis with standard Fmoc chemistry. To determine 
an optimal nanoparticle formulation, a library of nano-polyplexes (NPs) will be prepared at a range of 
charge ratios (CR = ([NH3
+
]MK2i/[COO
-
]PPAA) from 10:1 to 1:10 for each peptide and characterized. 
Following filtration through 0.45 µm, MK2iNP size and surface charge based on ζ-potential will be 
analyzed through dynamic light scattering (DLS) analysis. Optimized MK2i--NP, p-HSP20-NP, RN22-NP 
and BH3-NP formulations size and morphology will be further characterized through TEM analysis of 
Table 5.1. Nano-polyplex peptide library. The vasoactive peptides MK2i and p-HSP20 that will be further studied 
in vitro and ex vivo. Red amino acid abbreviations indicate the presence of polar amino groups in the amino acid 
side chain that potentiate electrostatic interaction with PPAA:  R (arginine), K (lysine) - primary amines (strong 
base); N (asparagine), Q (glutamine) - amides (weak bases). 
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uranyl-acetate counterstained samples. The MK2i and p-HSP20 peptides will be fluorescently labeled 
with an amine-reactive Alexa-488 or Alexa-568 succinimidyl ester for the formulation of fluorescent NPs 
for in vitro uptake, retention, and endosomal escape studies.  Biocompatibility of MK2i-NPs and p-HSP20-
NPs will be assessed through an LDH cytotoxicity assay performed 24 hours after treatment. 
As discussed in chapter 1, a significant unmet clinical need exists for more specific therapeutic 
interventions for pathological vasoconstriction especially in the context of symptomatic vasospasm 
following subarachnoid hemorrhage. The mortality associated with subarachnoid hemorrhages is high 
(40%), largely due to delayed cerebral ischemia secondary to vasospasm.  The cost to society of SAH is 
greater than that of ischemic stroke due to the younger average age of those affected.  Current rescue 
therapies, nimodipine and endovascular coiling of the aneurysm are only marginally effective.  Thus, 
neuroischemic events due to SAH which result in permanent neurological, cognitive, or functional deficits 
represent a large unmet need. Both the MK2i and p-HSP20 peptides have shown promise to selectively 
target vasospastic vessels: both peptides inhibit vasoconstriction without having systemic vasodilatory 
effects by modulating actin dynamics in vascular smooth muscle cells as shown in figure 1.3. However, 
sequestration and accumulation of these vasoactive peptides in the endolysosomal trafficking pathway 
remains a key barrier to achieving optimal bioactivity on the actin regulatory machinery in the cytoplasm 
of vascular smooth muscle cells. Thus, the ability of optimized, fluorescently labeled MK2i-NP and p-
HSP20-NP formulations to facilitate cytoplasmic peptide delivery will be assessed through a modified 
subcellular fractionation procedure that enables effective separation of cytosolic and endosomal cellular 
content through selective semi-permeabilization of the outer membrane of vascular smooth muscle cells. 
This procedure will be optimized by monitoring release of the cytoplasmic enzyme lactate dehydrogenase 
under a range of semi-permeabilization conditions. Fluorescent MK2i- and p-HSP20-NP formulations will 
also be utilized to assess MK2i and p-HSP20 uptake and retention in vascular smooth muscle cells. Since 
each peptide is hypothesized to modulated actin dynamics, an actin stress fiber assay will be performed 
in angiotensin II stimulated vascular smooth muscle cells to assess peptide mediated inhibition of F-actin 
(i.e., filamentous actin) stress fiber formation.  
 To further assess MK2i- and p-HSP20-NP mediated vasorelaxation of smooth muscle, human 
saphenous vein (HSV) explants will be obtained from consenting patients, sectioned into 1mm rings, and 
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suspended in a muscle bath outfitted with a force transducer. After verifying HSV viability through KCL 
contractions, rings will be treated with NPs or free peptide and subsequently contracted with 
phenylephrine (10
-6
 - 10
-7
 M) to determine % inhibition of contraction and relaxed with cumulative log 
doses of sodium nitroprusside to determine % relaxation vs. pretreatment. Underlying mechanisms for 
results obtained through physiology studies will be assessed qualitatively through the visualization of F-
actin stress fiber formation in treated HSV explants that have been stimulated with angiotensin II. 
 
Methods 
MAPKAP Kinase II inhibitor (MK2i) peptide and phosphorylated heat shock protein 20 (p-HSP20) mimetic 
peptide syntheses. 
A cell permeant MK2 inhibitory peptide (MK2i) with the sequence YARAAARQARA-
KALARQLGVAA and a cell permeant phosphorylated heat shock protein 20 mimetic peptide (p-HSP20) 
with the sequence YARAAARQARA-WLRRAsAPLPGLK (where s denotes a phosphorylated serine 
residue corresponding to serine 16 in HSP20 that is activated by cyclic nucleotide signaling) were 
synthesized on a PS3 peptide synthesizer (Protein Technologies, Inc. Tucson, AZ) utilizing standard 
Fmoc Chemistry. N-methylpyrrolidone (NMP, Fischer Scientific) was utilized as a solvent in all peptide 
syntheses. HCTU was used as an activator (Chempep, Wellington, FL) in the presence of N-
methylmorpholine. All amino acids were double coupled in order to maximize yield and purity. Peptides 
were cleaved/deprotected in TFA/Phenol/H2O/triisopropylsilane (88/5/5/2).  The peptide was then further 
purified by reverse phase HPLC on a Waters 1525 binary HPLC pump outfitted with an extended flow kit, 
a Waters 2489 UV/Visible detector, and a phenomenex Luna C18(2) AXIA packed column (100A, 250 x 
21.2  mm, 5 micron). A) HPLC grade water with 0.05% formic acid and B) HPLC grade acetonitrile were 
used as the mobile phase, and the peptide was purified utilizing a 90% A to 90% B gradient over 25 mins 
(16 mL/min). Acetonitrile was removed from purified fractions with a rotary evaporator, and the purified 
fractions were then lyophilized.  Peptide purity was verified through electrospray ionization mass 
spectrometry (ESI-MS) on a Waters Synapt ESI-MS. 
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Monomer and polymer synthesis  
All reagents were purchased from Sigma and were of analytical grade unless otherwise stated. 2-
propylacrylic acid was synthesized according to the procedure outlined by Ferrito et al.[127] utilizing 
diethyl propylmalonate (Alfa Aesar) as a precursor. The 4-cyano-4-(ethylsulfanylthiocarbonyl) 
sulfanylvpentanoic acid (ECT) chain transfer agent (CTA) was synthesized as previously described[128]. 
RAFT polymerization of the poly(propylacrylic acid) (PPAA) was carried out in bulk under a nitrogen 
atmosphere at 70°C for 48 hours using 2,2’-azo-bis-isobutyrylnitrile (AIBN) as the free radical initiator. 
The reaction mix was put through three freeze-vacuum-thaw cycles and purged with nitrogen for thirty 
minutes prior to polymerization. The molar ratio of CTA to AIBN was 1 to 1, and the monomer to CTA 
ratio was set so that a degree of polymerization of 190 would be achieved at 100% conversion. Following 
polymerization, the resultant polymer was dissolved in DMF and precipitated into ether 5 times before 
drying overnight in vacuo. Gel permeation chromatography (GPC, Agilent) was used to determine 
molecular weight and polydispersity (Mw/Mn, PDI) of the PPAA homopolymer using HPLC-grade DMF 
containing 0.1% LiBr at 60°C as the mobile phase. Molecular weight calculations were performed with 
ASTRA V software (Wyatt Technology) and were based on experimentally-determined dn/dc values 
determined through offline injections of serial dilutions of the polymer through a refractive index detector 
(calculated PPAA dn/dc = 0.087 mL/g). Polymer purity and molecular weight were then verified through 
NMR spectroscopy. Samples were dissolved in D6MSO and analyzed using a Bruker 400 MHz NMR 
spectrometer equipped with a 9.4 Tesla Oxford magnet controlled by a Bruker VA-400 console. NMR 
spectra were subsequently analyzed using Bruker Topspin 3.0 software. 
 
MK2i nano-polyplex (MK2i-NP), phospho-HSP20 nano-polyplex (p-HSP20-NP) library syntheses and 
characterization 
PPAA was dissolved in 1 M NaOH and diluted into a phosphate buffer (pH 8) to obtain a stock 
solution. Purified MK2i peptide or p-HSP20 peptide was dissolved in phosphate buffer (pH 8). The MK2i 
or p-HSP20 peptide were then mixed with the PPAA polymer at a range of CRs from [NH3
+
]:[COO
-
] = 10:1 
to 1:10 to form MK2i-NPs or p-HSP20-NPs, respectively. The resulting nano-polyplexes were syringe 
filtered through a 0.45 µm PTFE filter, and the hydrodynamic diameter and ζ-potential were characterized 
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on a Malvern Zetasizer Nano-ZS with a reusable dip cell kit (Malvern Instruments Ltd., Worcestershire, 
U.K.). 
A CR of 1:3 was chosen as the lead MK2i-NP formulation whereas a charge ratio of 3:1 was 
chosen as the lead p-HSP20-NP formulation. The optimized MK2i-NP and p-HSP20-NP formulations 
were used in subsequent in vitro and ex vivo experiments. In order to verify the sizes indicated by DLS 
analysis, NP formulations were visualized through transmission electron microscopy (TEM) imaging. TEM 
samples were prepared by inverting carbon film-backed copper grids (Ted Pella) onto a 20 µL droplet of 
aqueous polyplex suspensions (1 mg/mL) and blotted dry. All samples were then inverted onto a 20 µL 
droplet of 3% Uranyl Acetate and stained for 30 seconds. Samples were then desiccated in vacuo for 2 h 
prior to imaging on a FEI Tecnai Osiris system. 
 
Cell culture 
Primary human coronary artery vascular smooth muscle cells (HCAVSMCs) were obtained from 
Lonza; HCAVSMCs were cultured in complete growth medium [vascular cell basal medium (ATCC) 
supplemented with 5% FBS, human basic fibroblast growth factor (bFGF, 5 ng/mL), human insulin 
(5µg/mL), ascorbic acid (50 µg/mL), L-glutamine (10 mM), human epidermal growth factor (EGF, 5 
ng/mL), 1% penicillin-streptomycin and 50 ug/mL plasmocin (Invivogen)] in a sterile incubator maintained 
at 37°C with a humidified, 5% CO2 atmosphere. 
 All cultures were maintained in 75cm
2
 polystyrene tissue culture flasks (BD Falcon) in a 37°C and 
5% CO2 environment with cell culture media refreshed every other day. Cells were grown to 80-90% 
confluence prior to being harvested and passaged. All cells were seeded at a density of 20,000-30,000 
cells/cm
2
, as required for each specific experiment.  Only cells from early passages (numbers 3-8) were 
used in experiments. 
 
 Cytotoxicity assay 
200 µL of cell suspension (at 10,000 cells/well) were seeded onto 96-well plates to yield an 
approximate 70% confluence per well. Cells were allowed to adhere to the plate overnight. Cells were 
then treated with 10, 50, 100, and 500 μM doses of MK2i-NPs, p-HSP20-NPs, MK2i peptide, p-HSP20 
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peptide, or PBS as a control treatment for 2 hours in Opti-MEM medium supplemented with 1% penicillin-
streptomycin. Treatments were subsequently removed and the cells were cultured in fresh complete 
growth medium for 24 hours. Cells were then washed 2x with PBS +/+ and cell viability was then 
determined by a CytoTox-ONE Homogenous Membrane Integrity assay (Promega) according to the 
manufacturer’s protocol. Briefly, 100 μL of Ambion KDalert Lysis Buffer was added to each well, and then 
100 μL of freshly prepared CytoTox-ONE reagent was added to each well. After 10 minutes of incubation, 
50 μL of stop solution was added, and the fluorescence of each well (λex = 560 nm, λem = 590 nm) was 
determined with a TECAN Infinite M1000 Pro plate reader. 
 
Flow cytometric quantification of peptide uptake and retention in HCAVSMCs 
An amine-reactive Alexa-488 succinimidyl ester (Life Technologies) was dissolved in DMSO and 
mixed at a 1 to 3 molar ratio with the MK2i or p-HSP20 peptide in 100 mM sodium bicarbonate buffer (pH 
= 8.3) and allowed to react for 3 hours. Unreacted fluorophore and organic solvent were removed using a 
PD-10 miditrap G-10 desalting column, and the fluorescently labeled MK2i and p-HSP20 peptides were 
lyophilized. PPAA polymer was mixed with fluorescently labeled MK2i peptide at a CR of [NH3
+
]/[COO
-
] = 
1:3 and syringe filtered through a 0.45 µm PTFE filter to form fluorescent MK2i-NPs. Similarly, PPAA was 
mixed with fluorescently labeled p-HSP20 at a CR of [NH3
+
]/[COO
-
] = 1:3 and syringe filtered through a 
0.45 µm PTFE filter to form fluorescent HSP20-NPs. HCAVSMCs were grown to 80-90% confluence, 
harvested, and seeded at 20,000 cells/well in a 24 well plate and allowed to adhere overnight. 
HCAVSMCs were treated with fluorescent MK2i peptide, MK2i-NPs, p-HSP20 peptide, p-HSP20-NPs, or 
PBS as a control at a concentration of 10 µM peptide in Opti-MEM medium supplemented with 1% 
penicillin-streptomycin for 30 minutes. Following treatment, cells were washed 2x in PBS, and either 
immediately harvested or incubated in complete growth media for an additional 72 hours. Cells were 
harvested with 0.05% trypsin-EDTA, centrifuged, and suspended in 0.1% Trypan blue in PBS (-/-) for 
analysis on a FACSCalibur flow cytometer (Becton Dickinson) with BD CellQuest
TM
 Pro software (V 5.2). 
Data was exported and analyzed with FlowJo software (V 7.6.4). All samples were run in triplicate. 
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 F-Actin stress fiber assay 
HCAVSMCs were seeded in Lab-Tek II 8-well chambered coverglass (Thermo Scientific Nunc) at 
15,000 cells/well and allowed to adhere overnight. Cells were then treated in low serum media (Optimem, 
1% FBS, and 1% P/S) with MK2i-NPs, p-HSP20-NPs, MK2i peptide, p-HSP20 peptide, or at 
concentrations of 10, 25, and 50 μM (PBS -/- as a control) for 1 hour. Following treatment, cells were 
washed 2x with PBS -/- and subsequently treated with 1 μM Angiotensin II (Sigma Aldrich) or PBS -/- 
(negative control) for 2 hours. After ANG-II stimulation cells were washed 2x with PBS, fixed in 4% 
paraformaldehyde for 5 minutes, permeabilized with 0.4% Triton-X 100 for 10 minutes, and blocked with 
1% BSA in PBS -/- for 15 minutes. Cells were then stained with Hoechst solution (1/5000 dilution in PBS -
/-) for 10 minutes followed by staining with Alexa-488-Phallodin (Life Technologies) for 30 minutes 
according to the manufacturer’s instructions. Stained coverslips were then inverted onto glass cover 
slides with ProLong Gold Antifade mounting medium (Invitrogen). Slides were allowed to dry for 24 hours 
prior to sealing and imaging. Treated cells were imaged using a Nikon Eclipse Ti inverted fluorescence 
microscope (Nikon Instruments Inc, Melville, NY) with NIS Elements imaging software. Gain settings and 
exposure times were kept constant for all images taken. The number of stress fibers per cell was 
quantified as previously described[129]. Briefly, in the NIS elements software, 3 separate intensity profiles 
were generated across the axis of stained cells perpendicular to the cell’s polarity. Prior to image 
analysis, the background noise from each image was removed using a rolling ball background subtraction 
filter with a radius of 70 pixels. A fluorescence level of 2000 RFU was set as the threshold for positive F-
actin fiber staining as the background fluorescence outside of the stained cells was never greater than 
this value. The stress fibers per cell were then quantified from the average of 3 intensity profiles from n ≥ 
6 cells from 2 separate experiments for each treatment group. Relative quantification of cellular F-actin 
content was further quantified using imageJ software to free hand select individual cells and to calculate 
the relative fluorescence intensity of n ≥ 6 cells from 2 separate experiments for each treatment group.  
 
Quantification of cytosolic vs. organelle bound peptide through semi-permeabilization 
In order to quantify the cytosolic bioavailability of the MK2i and HSP20 peptides a method to 
separate cytosolic and organelle bound (i.e. endosomal, lysosomal, golgi, etc.) peptide was adapted from 
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the methods developed by Liu et al [130]. The procedure was optimized for this experiment based upon 
LDH release from HCAVSMCs treated with varying concentrations of digitonin (Calbiochem) in buffer 
(150 mM NaCl, 0.2 mM EDTA, 20 mM HEPES-NaOH (pH 7.4), 2 mM DTT and 2 mM MgCL2) on ice for 
10 mins on a rotary shaker operating at 100 RPM. A concentration of 25 µg/mL was then chosen as the 
optimal digitonin concentration for selective semi-permeabilization of the HCAVSMC membrane and 
subsequently used for the analysis of intracellular peptide distribution. 
To quantify intracellular distribution of the MK2i and p-HSP20 peptides, HCAVSMCs were seeded 
into a 96 well plate at a density of 20,000 cells/cm
2
 and allowed to adhere overnight in complete growth 
medium. Cells were then treated with Alexa-488 labeled MK2i peptide, MK2i-NPs, p-HSP20 peptide, p-
HSP20-NPs at a concentration of 10 µM peptide (or PBS -/- as a control) in Opti-MEM medium 
supplemented with 1% penicillin-streptomycin for 30 minutes. Treatments were removed and cells were 
incubated in fresh medium for 6 hours. Each well was then washed 1x with ice cold PBS +/+ and then 
subsequently incubated with 20 uL of 25 μg/mL digitonin solution at 0°C (on ice) on a rotary shaker 
operating at 100 RPM for 10 minutes. The supernatant from each well was then transferred to a new 96 
well plate, and each well was washed with 80 μL ice cold PBS +/+ which was then transferred to the 96 
well plate containing the digitonin (cytosolic) fractions. 100 uL of 1% triton X-100 in PBS -/- was then 
added to each well to obtain a 96 well plate containing all non-cytosolic (i.e. organelle bound) cellular 
components, and the fluorescence of each well (λex = 495 nm, λem = 519 nm) was determined with a 
TECAN Infinite M1000 Pro plate reader. Readings were normalized to cell number and cytosolic content 
as determined by a CytoTox-ONE Homogenous Membrane Integrity assay (Promega) according to the 
manufacturer’s protocol (section 4.5). 
 
Western blot verification of cytosolic separation from intracellular organelles 
To further verify separation of the cytosol from intracellular organelles such as endosomes and 
lysosomes, western blot analysis of the cytosolic and organelle fractions from the digitonin semi-
permeabilization procedure was performed.  Briefly, cytosolic and organelle fractions were concentrated 
on a centrifuge using Vivacon 500 DNA concentrators (2000 MWCO). Equal amounts of protein (20 µg 
per lane) were loaded on 4–20% SDS–PAGE gels; proteins were electrophoretically separated and then 
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transferred to Immobilon membranes. The membranes were then probed overnight at 4°C with primary 
antibodies for the cytosolic proteins mitogen-activated protein kinase kinase 1/2 (MEK1/2) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and the endo-lysosomal markers early endosomal 
antigen 1 (EEA1) and lysosomal-assocaited protein 1 (LAMP1). All antibodies were obtained from Cell 
Signaling Technologies. After washing, the membranes were incubated with appropriate secondary 
antibodies (Li-Cor) for 1 hour at room temperature. The secondary antibody was imaged using the 
Odyssey direct infrared fluorescence imaging system and densitometrically quantified with LiCor Odyssey 
software v2.1 at 800 and 680 nm wavelengths. 
 
Human saphenous vein 
Upon approval by Vanderbilt Medical Center’s Institutional Review Board, de-identified, discarded 
segments of human saphenous vein (HSV) were collected from consented patients undergoing coronary 
or peripheral vascular bypass surgeries. Following surgical resection, HSV segments were stored in 
buffered salt solution until the end of the surgical procedure, at which time they were placed in cold 
transplant harvest buffer (100 mM potassium lactobionate, 25 mM KH2PO4, 5 mM MgSO4, 30 mM 
raffinose, 5 mM adenosine, 3 mM glutathione, 1 mM allopurinol, 50 g/L hydroxyethyl starch, pH 7.4). All 
HSV segments were used within 24 hours of harvest. Utilizing sterile technique in a sterile culture hood, 
HSV segments were transferred to a 60 mm Petri dish. The end of each segment (0.5 mm) was removed 
with a blade, and excess adventitial and adipose tissue was removed with minimal manipulation. HSV 
segments were cut into consecutive rings with an approximate width of 1.0 mm.  
Prior to experiments, HSV viability was confirmed. HSV rings were weighed and their lengths 
recorded. HSV rings were then suspended in a muscle bath containing a bicarbonate buffer (120mM 
NaCl, 4.7 mM KCl, 1.0 mM MgSO4, 1.0 mM NaH2PO4, 10 mM glucose, 1.5 mM CaCl2, and 25 mM 
Na2HCO3, pH 7.4) equilibrated with 95% O2 and 5% CO2 at 37 °C. The rings were stretched and the 
length progressively adjusted until maximal tension was obtained[131].  Normalized reactivity was 
obtained by determining the passive length–tension relationship for each vessel segment. Rings were 
maintained at a resting tension of 1 g, which produces maximal responses to contractile agonists, as 
previously determined, and equilibrated for 2 h in buffer. Force measurements were obtained using a 
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Radnoti Glass Technology (Monrovia, CA) force transducer (159901A) interfaced with a Powerlab data 
acquisition system and LabChart software (AD Instruments, Colorado Springs, CO). 
HSV rings were initially isometrically contracted with 110 mM KCl (with equimolar replacement of 
NaCl in bicarbonate buffer), and the generated force was measured. 110 mM KCl causes membrane 
depolarization, leading to contraction of vessels containing functionally viable smooth muscle. After 
vessel viability was verified with multiple KCl challenges, additional rings were cut to be utilized in smooth 
muscle physiology experiments and for F-actin staining. 
 
HSV Smooth Muscle Physiology Studies 
Inhibition of HSV Contraction 
Viable HSV rings were washed, allowed to equilibrate in bicarbonate solution for 30 min, and then 
contracted with phenylephrine (PE, 1 µM). All rings were washed and equilibrated in fresh buffer and 
allowed to relax until baseline contraction was achieved. Rings were then incubated with either MK2i 
peptide, MK2i-NPs, p-HSP20 peptide, p-HSP20-NPs, or buffer alone for 2 h. Treated HSV rings were 
then contracted with the same doses of PE, and the forces generated were again recorded (see fig. 7A). 
Measured force was normalized for ring weight and length and percent inhibition of contraction was 
calculated by dividing the post-treatment contractile force with the pre-treatment contractile force; pre-
treatment force generated with 1 µM PE was set as 100% contraction. Data was obtained in HSV from n 
≥ 3 separate patients. 
 
Enhanced HSV vasorelaxation 
Viable HSV rings were washed and allowed to equilibrate in bicarbonate solution for 30 min, and 
then contracted with phenylephrine (PE, 1 µM). Rings were relaxed with a cumulative log dose of sodium 
nitroprusside (SNP, 0.1-10 µM), a nitric oxide donor, and the resulting decrease in contractile force was 
recorded over time (see fig. 7D). All rings were again washed and equilibrated in buffer for 15 min. Rings 
were then incubated with either MK2i peptide, MK2i-NPs, p-HSP20, p-HSP20-NPs, or buffer alone for 2 
h, followed by treatment with the same doses of PE and SNP. The forces generated were again recorded, 
and measured force was normalized for ring weight and length and percent relaxation was calculated; 
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force generated with 100 µM PE was set as 0% relaxation. Data was obtained in HSV from n ≥ 3 
separate patients. 
 
Actin staining of Angiotensin II stimulated HSV 
Viable HSV rings were placed in a 24 well plate in RPMI medium supplemented with 10% FBS 
and 1% penicillin-streptomycin and allowed to equilibrate in an incubator at 37°C and 5% CO2 for several 
hours. HSV rings were then treated with 100 μM MK2i peptide, 100 μM MK2i-NPs, 500 μM p-HSP20, or 
500 μM p-HSP20-NPs or PBS -/- as a negative control for 30 minutes in Opti-MEM medium 
supplemented with 1% penicillin-streptomycin and then washed 2x in PBS -/-. Subsequently, treated HSV 
rings were stimulated with 10 µM angiotensin II for 2 hours and then washed 2x in PBS -/-. HSV rings 
were then immediately fixed in 4% paraformaldehyde for 4 hours at 37°C. HSV rings were then incubated 
overnight in 30% sucrose in 1x PBS -/-. HSV rings were washed 2x in PBS -/-, embedded in OCT and 
frozen. 10 micron cryosections were cut from the midportion of each HSV rings and placed onto 
SuperFrost Plus microscope slides (Fisher Scientific). The slides were then stained and imaged according 
to the procedure stated in the F-actin stress fiber assay section above. Full HSV sections were compiled 
through the image stitching capability in the NIS Elements software. 
 
Statistics 
Statistical analysis was performed with one-way ANOVA followed by Tukey’s post-hoc test to 
compare experimental groups. Analyses were done with OriginPro 8 software (Originlab, Northampton, 
MA) or Minitab 16 software (State College, PA). Statistical significance was accepted within a 95% 
confidence limit. Results are presented as arithmetic mean ± SEM graphically and p-values are included 
within figures or in the figure legends.  
 
Results 
The MK2i peptide with the sequence YARAAARQARA-KALARQLGVAA and the p-HSP20 
peptide with the sequence YARAAARQARA-WLRRAsAPLPGLK were synthesized via solid phase 
synthesis, and purity was verified through electrospray-ionization mass spectrometry (fig. 5.1).  
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Reversible addition fragmentation chain transfer (RAFT) polymerization was utilized to synthesize 
poly(propylacrylic acid) (PPAA) [DP = 193 (GPC), DP = 190 (H
1
 NMR), PDI = 1.47 (GPC)]. NPs were 
formed by simple mixing of the PPAA homopolymer with the MK2i or p-HSP20 peptides in PBS at pH 8.0, 
which is between the pKa values of the primary amines present on the peptides (pKa~9-12 depending on 
the amino acid residue) and the carboxylic acid moieties in the PPAA polymer (pKa~6.7); this ensures 
optimal solubility and net charge on both molecules to facilitate electrostatic complexation.  
Figure 5.1 – MK2i and p-HSP20 peptide characterization. Electrospray-ionization mass spectrometry (ESI-
MS) mass spectra for the HPLC-purified A) MK2i peptide (sequence: YARAAARQARA-KALARQLGVAA, MW = 
2283.67 g/mol) and B) p-HSP20 peptide (sequence: YARAAARQARA-WLRRAsAPLPGLK, MW = 2731 g/mol). 
The mass spectra show three major peaks each corresponding to the fragmentation of the full peptide 
sequence. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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To determine optimal nanoparticle formulation conditions, a series of MK2i-NPs and p-HSP20-
NPs were prepared at a range of charge ratios [i.e. CR = ([NH3
+
]MK2i / p-HSP20:[COO
-
]PPAA)], and the size 
distribution and particle surface charge were characterized through dynamic light scattering (DLS) and ζ-
potential analysis, respectively. As expected, MK2i-NP and p-HSP20-NP ζ-potential was directly 
proportional to the CR (figs. 5.2 A and 5.3 A). The CR also significantly affected NP size, with a narrow 
range of CRs yielding a unimodal size distribution (i.e. CR = 1:2 and 1:3 for MK2i-NPs, table 5.2, and CR 
= 3:1 for p-HSP20-NPs, table 5.3). A CR of 1:3 was utilized in subsequent studies for the MK2i-NP 
formulation, and a CR of 3:1 was utilized for the p-HSP20-NP formulation; these charge ratios 
consistently yielded a unimodal size distribution with minimal particle size and polydispersity (MK2i-NP 
dh=119 ± 28 nm, ζ = -11.9 ± 3.2 mV, fig. 5.2 B; p-HSP20-NP dh=141 ± 6 nm, ζ = -7.5 ± 2.8 mV, fig. 5.3 
B).  MK2i-NPs and p-HSP20-NPs prepared at optimal CRs were also characterized through TEM imaging 
(figs. 5.2 C and 5.3 C), which confirmed the presence of nano-structures with size distributions in 
accordance with DLS results. For subsequent in vitro and ex vivo studies, optimized NP formulations 
(figs. 5.2 D and 5.3 D) were compared to the corresponding free peptide. These optimized NP 
formulations are intentionally designed to respond to the decreased pH encountered in the endo-
lysosomal trafficking pathway to facilitate cytosolic peptide delivery, as the PPAA polymer has well-
defined pH-dependent endosomolytic activity[21, 77] and has previously demonstrated biocompatibility in 
animal models[78]. 
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Figure 5.2 - MK2i-NP formulation. A) Z-average diameter (bars) and zeta potential (circles) of MK2i-NPs 
prepared at a different charge ratios (CR = [NH
3
+
]
MK2i 
: [COO
-
]
PPAA
). Asterisks (*) denote a unimodal size 
distribution and the white bar represents the optimal MK2i-NP formulation that yielded a unimodal size 
distribution with minimal size and polydispersity. B) Representative DLS trace of optimal MK2i-NP formulation 
(CR = 1:3). C) Representative TEM image of uranyl acetate stained MK2i-NPs, scale bar = 200 nm. D) Synthesis 
and characterization summary for optimal MK2i-NP formulation. CR = charge ratio, D
h
= hydrodynamic diameter, 
ζ = zeta potential. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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Figure 5.3 - p-HSP20-NP formulation. A) Z-average diameter (bars) and zeta potential (circles) of p-HSP20-
NPs prepared at a different charge ratios (CR = [NH
3
+
]
p-HSP20 
: [COO
-
]
PPAA
). Asterisks (*) denote a unimodal size 
distribution, and the white bar represents the p-HSP20-NP formulation that yielded a unimodal size distribution 
with minimal size and polydispersity. B) Representative DLS trace of optimal p-HSP20-NP formulation (CR = 
3:1). C) Representative TEM image of uranyl acetate stained p-HSP20-NPs, scale bar = 200 nm. D) Synthesis 
and characterization summary for optimal p-HSP20-NP formulation. CR = charge ratio, D
h
= hydrodynamic 
diameter, ζ = zeta potential. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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NH
3
 
+
:COO 
-
 Z-ave diameter (nm) PDI 
10:1 10.32 ± 2.63* 0.314 
2:1 52.1 ± 46.86* 0.297 
1:1 970.6 ± 662.4* 0.41 
1:1.5 465.1 ± 138.4* 0.5465 
1:2 474.2 ± 32.59 0.239 
1:3 118.8 ± 26.76 0.271 
1:4 607.4 ± 285.2* 0.662 
1:5 213.0 ± 67.95* 0.407 
1:10 21.57 ± 9.89* 0.355 
 
 
 
 
 
NH
3
 
+
:COO 
-
 Z-ave diameter (nm) PDI 
10:1 659.4 ± 293.7* 0.594 
5:1 238.3 ± 38.13* 0.574 
4:1 169.1 ± 2.501* 0.591 
3:1 141.0 ± 5.783 0.207 
2:1 369.3 ± 69.83* 0.554 
1:1 1018 ± 786.6* 0.903 
1:2 1321 ± 1430* 0.662 
1:3 1369 ± 255.9* 0.750 
1:4 1772 ± 513* 0.470 
1:5 1496 ± 602.9* 0.429 
1:10 4246 ± 4428 0.741 
 
 
 
 
Table 5.2 - MK2i nano-polyplex library characterization. Size 
summary of MK2i-NPs prepared at different charge ratios 
([NH
3
+
]/[COO
-
]) as determined by DLS analysis. Asterisks (*) indicate 
multimodal size distributions (multiple peaks present). A CR of 1:3 was 
chosen as the optimal MK2i-NP formulation (red). Reprinted with 
permission from [1]. Copyright 2015 American Chemical Society. 
Table 5.3 - p-HSP20 nano-polyplex library characterization. Size 
summary of p-HSP20-NPs prepared at different charge ratios 
([NH
3
+
]/[COO
-
]) as determined by DLS analysis. Asterisks (*) indicate 
multimodal size distributions (multiple peaks present). A CR of 3:1 was 
chosen as the optimal p-HSP20-NP formulation (red). Reprinted with 
permission from [1]. Copyright 2015 American Chemical Society. 
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The biocompatibility of the lead candidate MK2i-NP and HSP20-NP formulations was compared 
to the corresponding free peptide at range of doses (10 – 500 μM peptide) in human coronary artery 
vascular smooth muscle cells (HCAVSMCs) in vitro. HCAVSMCs were treated for 2 hours and then 
incubated in fresh medium for 24 hours prior to running the cytotoxicity assay. No significant cytotoxicity 
was evident for MK2i-NPs at all concentrations tested, whereas the free MK2i peptide demonstrated mild 
toxicity at the highest dose tested (76% cell viability at 500 μM, fig. 5.4). HSP20-NPs and the HSP20 
peptide were found to be biocompatible with the exception of mild cytotoxicity detected at 500 μM (60% 
and 77% viability for p-HSP20-NPs and the free p-HSP20 peptide, respectively). 
 
 
 
Quantity of MK2i-NP and p-HSP20-NP uptake and intracellular retention over time were 
assessed through flow cytometric analysis of HCAVSMCs treated for 30 minutes, washed, and 
maintained in fresh medium for 0 or 3 days. More than an order of magnitude increase in uptake (~70-fold 
Figure 5.4. - NP cytocompatibility. The cytotoxicity of MK2i-NPs and p-HSP20-NPs was compared to the 
corresponding dose of free peptide in HCAVSMCs. Cells were treated for 2 hours and then allowed to incubate in 
fresh medium for 24 hours prior to running the cytotoxicity assay. *p<0.05 vs. NT, n=4 mean ± SEM. Reprinted 
with permission from [1]. Copyright 2015 American Chemical Society. 
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increase in MK2i uptake and ~35-fold increase in p-HSP20 uptake) was detected for both peptides when 
incorporated into NPs (fig. 5.5). Furthermore, HCAVSMCs treated with MK2i-NPs or p-HSP20-NPs 
demonstrated increased intracellular peptide retention 3 days after treatment removal compared to the 
free MK2i or p-HSP20 peptide (82% vs. 54% of initial uptake remaining for MK2i-NPs vs. free MK2i, fig. 
5.5 A and E; 70% vs. 35% retention of p-HSP20-NPs vs. free p-HSP20, fig. 5.5 B and F). Intracellular 
retention can be improved by reducing exocytosis of the intact peptide and/or degradation of the peptide 
in the endo-lysosomal pathway [87]. Considering that endo-lysosomes are preferentially exycotosed in 
nonsecretory smooth muscle cells[132], escape from endo-lysosomal trafficking would result in a 
decreased rate of exocytosis suggesting that peptide formulation in NPs facilitates endo-lysosomal 
escape. 
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Figure 5.5 - NP uptake and retention. Flow cytometric quantification of peptide uptake and retention of A) MK2i-
NPs vs. MK2i and B) p-HSP20-NPs vs. HSP20 at a 10 μM dose of peptide after 30 minutes of treatment. MK2i-
NPs achieved ~70 fold increase in peptide uptake at the same concentration whereas p-HSP20-NPs achieved a 
~35 fold increase in uptake.  C,D) Representative flow histograms of HCAVSMCs immediately after treatment and 
E,F) representative flow histograms demonstrating that formulation into NPs  increased peptide cellular retention 
after 3 days of culture in fresh medium post-treatment. The percentages overwritten on A-B represent the % 
retention at 3 days relative to 0-days post-treatment. Reprinted with permission from [1]. Copyright 2015 
American Chemical Society. 
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To investigate this potential connection between increased peptide intracellular retention and 
endosomal escape of peptides delivered via the NP formulation, a digitonin-based, semi-permeabilization 
technique[130] was adapted and optimized for measuring the relative quantity of cytosolic and vesicle-
bound peptide for NP and free peptide treated HCAVSMCs (fig. 5.6 A). Digitonin is a non-ionic detergent 
that under optimized conditions results in the selective semi-permeabilization of the cell membrane while 
leaving intracellular organelles (e.g., endosomes and lysosomes) intact. An optimized semi-
permeabilization procedure was determined by measuring the LDH (which is known to be localized to the 
cytosol) quantity in the “cytosolic” and “organelle” fractions from HCAVSMCs incubated with a range of 
concentrations of digitonin for 10 minutes on ice. (fig. 5.7). Western blot analysis of the cytosolic and 
organelle fractions collected using the optimized semi-permeabilization protocol verified effective 
separation of the cytosolic proteins mitogen-activated protein kinase kinase 1/2 (MEK1/2) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the endo-lysosomal markers early 
endosomal antigen 1 (EEA1) and lysosomal-assocaited protein 1 (LAMP1, fig. 5.6 B). Utilizing 
fluorescently labeled MK2i and p-HSP20 peptides allowed for quantification of the intracellular distribution 
of both peptides following delivery in their free form versus via NP formulations. This analysis revealed 
that formulation into NPs not only increased peptide uptake but also significantly increased the fraction of 
internalized peptide in the cytosol; the net effect was an approximately 8-fold increase in cytosolic MK2i 
delivery and ~29-fold increase in p-HSP20 delivery (fig. 5.6 C and D). These data suggest that the known 
pH-dependent membrane disruptive activity of PPAA enables the peptide-NP formulations to escape 
endo-lysosomal vesicles.  
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Figure 5.6 - NP Endosomal Escape and Cytosolic Peptide Delivery. A) Experimental design for separation of 
treated vascular smooth muscle cell cytosol and intracellular organelles using digitonin semi-permeabilization. 
Conditions for semi-permeabilization were optimized as shown in supplementary figure 3. B) Western blot 
validation of the optimized digitonin semi-permeabilization procedure confirmed separation of the cytosolic 
proteins mitogen-activated protein kinase kinase 1/2 (MEK1/2) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) from the endo-lysosomal markers early endosomal antigen 1 (EEA1) and lysosomal-associated protein 
1 (LAMP1). Comparison of the intracellular distribution of C) MK2i and D) p-HSP20 peptides when delivered alone 
or formulated into NPs demonstrates that increased cytosolic delivery is achieved with the NP formulations. 
Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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Subsequently, the efficacy of MK2i-NP and p-HSP20-NP mediated inhibition of F-actin stress 
fiber formation was quantified in Angiotensin-II (ANG II) stimulated HCAVSMCs. Both NP formulations 
enhanced peptide functional bioactivity as measured by a significant decrease in the average number of 
stress fibers per cell (fig. 5.8 A). Qualitatively, HCAVSMCs treated with the NP formulations yielded cell 
morphology and staining consistent with unstimulated control cells whereas HCAVSMCs treated with the 
free peptide still demonstrated stress fiber formation similar to stimulated control cells (fig. 5.8 B).  
 
 
 
 
Figure 5.7 - Digitonin semi-permeabilization optimization. The conditions for the digitonin semi-
permeabilization procedure to separate cytosolic components from intracellular organelles (i.e., endo-
lysosomal compartments) were optimized based upon LDH release following 10 minutes of incubation with 
various concentrations of digitonin at 0°C on rotary shaker operating at 100 RPM. 25 ug/mL digitonin was 
chosen as the optimal condition as no significant increase in release of cytosolic LDH was seen at higher 
concentrations. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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Figure 5.8 - Inhibition of F-actin stress fiber formation in vascular smooth muscle cells. A) F-actin stress 
fiber quantification in HCAVSMCs pre-treated with p-HSP20-NPs, free p-HSP20 peptide, MK2i-NPs or free 
MK2i for 1 hour and then stimulated with ANG II for 2 hours. The number of stress fibers per cell was calculated 
from three intensity profiles taken from the axis transverse to the cellular polarity from at least 6 different cells 
for each treatment group, *p<0.05, **p<0.01 , ***p<0.001 vs. NT + ANG II; Ɨp<0.1, ƗƗp<0.01, ƗƗƗp<0.001 vs. the 
free peptide at the same concentration. B) Representative fluorescence microscopy images of F-actin stress 
fiber formation in ANG II-stimulated HCAVSMCs and the corresponding intensity profile derived from the line 
shown in the image. The asterisk denotes the left side of the intensity profile shown. Gain settings were kept 
constant for all images obtained. Reprinted with permission from [1]. Copyright 2015 American Chemical 
Society. 
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The total amount of F-actin per cell was also quantified using Alexa-488 phalloidin, a stain that 
selectively binds to filamentous but not globular, actin (figs. 5.9 and 5.10). This analysis revealed a dose 
dependent inhibition of F-actin stress fiber formation by both peptide-NP formulations. Consistent with the 
average number of stress fibers per cell, the NP formulations of both peptides also demonstrated 
significantly enhanced inhibitory activity compared to the corresponding free peptide. Furthermore, a 50 
μM dose of MK2i-NPs or p-HSP20-NPs yielded actin staining similar to unstimulated control cells; in 
comparison, cells treated with 50 μM of each free peptide demonstrated robust stress fiber formation 
upon stimulation with ANG II.  
 
 
 
 
 
 
 
 
Figure 5.9 - Inhibition of F-actin stress fiber formation by MK2i-NPs.. A) F-actin stress fiber quantification 
in HCAVSMCs pre-treated with MK2i-NPs or free MK2i for 1 hour and then stimulated with ANG II for 2 hours. 
Data represents n ≥ 6 cells from 2 separate experiments: *p<0.05 vs. NT + ANG II **p<0.001 vs. NT + ANG II, 
Ɨp<0.05 vs. MK2i at same concentration. B) Representative fluorescence microscopy images of F-actin stress 
fiber formation in ANG II-stimulated HCAVSMCs after 1 hour treatment with free MK2i or MK2i-NPs. 
Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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The effect of the MK2i-NP and p-HSP20-NP formulations on smooth muscle physiology in human 
vascular tissue was assessed in order to evaluate them as potential treatments for vasospasm. For these 
studies, human saphenous vein (HSV) was collected from consented patients undergoing bypass grafting 
surgery and sectioned into rings. After verifying viability through KCL challenge in a muscle bath, the 
ability of each NP formulation to inhibit phenylephrine (PE) induced vasoconstriction was measured in 
HSV rings using an organ bath system outfitted with a force transducer with an experimental design 
where vessels were contracted, relaxed, treated, and then contracted again (fig. 5.11). 
Figure 5.10 - Inhibition of F-actin stress fiber formation by p-HSP20-NPs. A) F-actin stress fiber 
quantification in HCAVSMCs pre-treated with p-HSP20-NPs or free p-HSP20 for 1 hour and then stimulated with 
ANG II for 2 hours. Data represents n ≥ 6 cells from 2 separate experiments: *p<0.05, **p<0.01, ***p<0.001 vs. 
NT + ANG II, Ɨp<0.05, ƗƗp<0.001 vs p-HSP20 at same concentration. B) Representative fluorescence microscopy 
images of F-actin stress fiber formation in ANG II-stimulated HCAVSMCs after 1 hour treatment with free p-
HSP20 or p-HSP-20-NPs. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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Untreated control HSV rings displayed no changes in the second round of PE induced contraction 
relative to the initial contraction.  However, intermediate treatment with the MK2i or p-HSP20 peptides 
significantly inhibited the second PE-induced HSV contraction (figs. 5.12 and 5.13). Consistent with in 
vitro F-actin stress fiber results, equivalent doses of peptide delivered via NP formulations demonstrated 
significantly enhanced peptide-mediated inhibition of contraction compared to the free peptide. Notably, 
treatment with a dose of free PPAA polymer equivalent to the highest NP dose administered showed 
negligible effects on PE-induced HSV contraction (fig. 5.12) indicating that the enhanced inhibitory 
activity is mediated through enhanced peptide bioactivity and is not a non-specific effect of the 
endosomolytic polymer. This enhanced ability to inhibit vasoconstriction demonstrates the translational 
Figure 5.11 – Experimental design for inhibition of contraction studies. HSV rings 
are initially contracted with PE and then relaxed. After 2 hours of treatment with NPs, free 
peptide, or control, post treatment contraction is measured. Reprinted with permission 
from [1]. Copyright 2015 American Chemical Society. 
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potential of these NP formulations as a prophylactic approach to prevent vasospasm in applications such 
as coronary or peripheral bypass grafting. 
 
 
 
Figure 5.12 - MK2i-NP treatment inhibits vasoconstriction in human saphenous vein. Quantification of 
MK2i and MK2i-NP mediated inhibition of contraction. PPAA polymer equivalent to the highest dose of MK2i-
NPs was included as a vehicle control. Ɨp < 0.05; *p < 0.05, **p<0.01, ***p<0.01 vs. NT, n ≥ 3 separate donors. 
Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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 In addition to testing the efficacy of these NP formulations as a prophylactic therapy, the ability of 
the MK2i- and p-HSP20-NPs to enhance sodium nitroprusside (SNP) induced vasorelaxation was 
evaluated as a potential salutary therapeutic intervention (e.g., to treat SAH induced vasospasm) in viable 
HSV explants (fig. 5.14).  
Figure 5.13 - p-HSP20-NP treatment inhibits vasoconstriction in human saphenous vein. Quantification of 
p-HSP20 and p-HSP20-NP mediated inhibition of contraction. Ɨp < 0.05; *p < 0.05, **p<0.01, ***p<0.01 vs. NT, n 
≥ 3 separate donors. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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Again, both NP formulations demonstrated an enhanced ability to promote SNP-induced 
vasorelaxation at all concentrations tested (figs. 5.15 and 5.16) whereas untreated HSV or HSV treated 
with the PPAA polymer alone showed negligible differences in vasorelaxation (fig. 5.15). This enhanced 
ability to enhance vasorelaxation demonstrates the translational potential of these NP formulations as a 
salutary intervention to treat vasospasm in applications such as symptomatic vasospasm following 
subarachnoid hemorrhage.  
Figure 5.14 – Experimental design for inhibition of contraction studies. 
Experimental design for enhanced vasorelaxation studies: HSV rings are initially 
contracted with PE and subsequently relaxed with SNP. HSV rings are then treated for 
two hours with NPs, free peptide, or control and then contracted and relaxed under the 
same conditions to compare post-treatment to pre-treatment relaxation. Reprinted with 
permission from [1]. Copyright 2015 American Chemical Society. 
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Figure 5.15 - MK2i-NP treatment enhances vasorelaxation in human saphenous vein. Quantification of 
MK2i and MK2i-NP enhanced vasorelaxation. PPAA polymer equivalent to the highest dose of MK2i-NPs was 
included as a vehicle control. Ɨp < 0.05; *p < 0.05, **p<0.01, ***p<0.01 vs. NT, n ≥ 3 separate donors. Reprinted 
with permission from [1]. Copyright 2015 American Chemical Society. 
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In order to qualitatively assess the correlation of F-actin stress fiber formation with the smooth 
muscle physiology results in human tissue, HSV rings were pretreated with free peptide or the NP 
formulations and then subsequently stimulated with ANG II prior to F-actin staining with Alexa-488 
phalloidin (fig. 5.17). In concordance with the smooth muscle physiology results, HSV rings treated with 
NP formulations showed diminished phalloidin staining compared to HSV treated with the free peptide. 
Altogether, these results indicate that MK2i- and p-HSP20-NPs significantly enhance the ability of the 
MK2i and p-HSP20 peptide to inhibit vasoconstriction and promote vasorelaxation by modulating actin 
dynamics in human smooth muscle tissue. 
 
Figure 5.16 – p-HSP20-NP treatment enhances vasorelaxation in human saphenous vein. Quantification of 
p-HSP20 and p-HSP20-NP enhanced vasorelaxation. Ɨp < 0.05; *p < 0.05, **p<0.01, ***p<0.01 vs. NT, n ≥ 3 
separate donors. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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Discussion 
Biomacromolecular therapeutics, specifically therapeutic CPPs, show great promise for improving 
upon the lack of specificity, potency, and biocompatibility that characterize small molecule drugs. 
However, a number of delivery barriers exist that undermine the feasibility of their clinically translation. 
Thus, a significant unmet need exists to address the delivery barriers that therapeutic CPPs face. There 
are a large number of intracellular targets that can be effectively modulated with biomacromolecular 
therapeutics such as peptides, yet the barriers of uptake and endosomal entrapment have essentially 
rendered these targets ‘undruggable.’  As a result, this simple approach to increasing peptide uptake and 
facilitating endosomal escape opens a previously unexplored therapeutic space that harbors significant 
potential to improve treatment options for a broad spectrum of pathologies. Furthermore, the global 
pharmaceutical industry has faced prohibitive costs in the development new molecular entities; thus, the 
nano-polyplex technology presented herein befits the major transition that is occurring to shift focus onto 
the development of drug delivery systems that can improve extant therapeutics [133].  
In addition to establishing a modular platform for cytosolic delivery of biomacromolecular 
therapeutics, these studies provide key insight into the role that MK2 and HSP20 play in regulating 
vascular tone by modulating cytoskeletal dynamics. The data presented herein verify the feasibility of this 
method and demonstrate a novel approach to the treatment, both prophylactic and salutary, of 
vasospasm. These results motivate further studies in animal models of vasospasm, for instance in an 
established rat model of subarachnoid hemorrhage induced symptomatic vasospasm [134] in which 
Figure 5.17 - MK2i-NP & p-HSP20-NP treatment inhibit stress fiber formation in human saphenous 
vein. F-actin visualization in Alexa-488 phalloidin stained cryosections of human saphenous vein explants 
pretreated and subsequently stimulated with ANG-II demonstrating decreased F-actin in samples treated with 
the NP formulations. Reprinted with permission from [1]. Copyright 2015 American Chemical Society. 
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MK2i-NPs or p-HSP20-NPs are used as preventative or interventional treatments with real time 
monitoring of cerebral perfusion using quantitative imaging methods. However, the use of this technology 
in intravascular applications raises the question of whether or not these NPs are hemocompatible and 
amenable to intravenous (IV) administration, as recent studies have shown that analogous polyplexes are 
not compatible with IV dosing due to aggregation and poor biodistribution [135]. Thus, future studies 
evaluating NP hemocompatibility and the investigation of alternative approaches to impart 
hemocompatibility to the NP formulations are required to expand the applicability of this platform 
technology to systemic delivery applications. Furthermore, considering that the MK2i and p-HSP20 
peptides were modified with the same CPP sequence (i.e., YARAAARQARA) which begs the question of 
whether this approach is equally effective with other commonly used CPPs such as TAT, penetratin, 
oligoarginines, etc. Similarly, are other biomacromolecules such as nucleic acid based or protein/enzyme 
based therapeutics that are modified with cationic CPP sequences also amenable to this NP approach in 
addition to peptide based therapeutics? These questions motivate additional investigation of this 
approach to define the limitations of this platform technology in its current form and to guide future 
technology development and optimization. 
 
Conclusion 
A platform technology was developed for formulation of electrostatically-complexed nanoparticles 
that facilitate intracellular delivery and concomitantly increase the bioactivity of therapeutic peptides. 
Specifically, this platform was applied to deliver vasoactive peptides that modulate vascular tone by 
affecting actin dynamics in vascular smooth muscle cells. NP formulation enhanced the potency of both a 
MK2 inhibitory peptide and a phosphorylated HSP20 mimetic peptide, and the translatability of this 
delivery technology was demonstrated in human vascular tissue ex vivo.  These results also validate and 
provide mechanistic insight into the role of actin dynamics in vascular smooth muscle physiology and 
highlight promising therapeutic targets for prevention of pathological vasoconstriction and enhancement 
of salutary vasorelaxation. 
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CHAPTER VI 
 
CONCLUSION & FUTURE DIRECTIONS 
 
Summation of presented work 
The therapeutic potential of peptides has continually increased as a result of an ever expanding 
interest in biologically derived medical interventions: a simple search for literature relevant to the phrase 
‘therapeutic peptide’ in the PubMed biomedical literature archive at the beginning of 2015 yields over 
29,000 results.  Peptides are especially attractive due to their increased specificity, biocompatibility, and 
solubility in contrast to small molecule drugs that dominate the current pharmaceutical market. Despite 
these advantages, there is a lack of effective delivery technologies that can circumvent the numerous 
anatomical and metabolic barriers present in vivo that limit intracellular delivery of peptides; peptides 
generally have short half-lives, suffer from proteolytic degradation, lack the ability to translocate the cell 
membrane, and have poor intracellular bioavailability due to entrapment within the degradative/recycling 
vesicles of the endo-lysosomal trafficking pathways [5-8]. Approaches previously explored to overcome 
these barriers have included altering peptide chemistry to improve proteolytic resistance and in vivo half-
life [9-11] and use of electroporation or cell-penetrant/fusogenic peptides to increase cellular 
internalization [12-14]. The development of colloidal drug carriers such as liposomes, micelles, and 
nanoparticles for delivery of biomacromolecular therapeutics has also increased dramatically in the past 
decade [15-17]. Despite these advances, there are no examples of nanocarrier formulations for 
intracellular peptide delivery that have been simple, robust, and scalable enough to justify translation for 
clinical use. Thus, the goal of this work was to develop a simple, generalizable peptide drug delivery 
nano-formulation to enhance the cellular uptake, endosomal escape, intracellular retention, and 
bioactivity of therapeutic peptides. 
 The nano-polyplex platform technology that was developed for this purpose met all of 
these criteria and the translatability of this approach was demonstrated through the ability of an NP 
formulation containing an MK2 inhibitory peptide to inhibit the multifactorial pathogenesis of intimal 
hyperplasia in human tissue ex vivo and in vivo in a rabbit vein graft model. Furthermore, the modular 
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nature of this platform was demonstrated by the enhanced cytosolic delivery and therapeutic efficacy of 
two vasoactive peptides that were incorporated into optimized NP formulations targeted towards 
vasospasm. These results establish the feasibility and promise of this NP approach, but they also raise a 
plethora of questions that motivate further research: 
 What is the specific interaction responsible for increased uptake of NP formulations? How does 
NP formulation alter intracellular trafficking following internalization? 
 How does MK2 inhibition, specifically mediated through NP formulation of an MK2 inhibitory 
peptide, modulate vascular smooth muscle cell phenotype? What are the underlying molecular 
mechanisms and signaling pathways involved, and what are the temporal dynamics underlying 
these changes in the context of vein graft remodeling? How does MK2i formulation into NPs 
affect the entire transcriptome of VSMCs and are there off target effects? 
 How does MK2 inhibition and MK2i delivery in an NP formulation affect endothelial function in 
vein graft remodeling? How is intercellular signaling between distinct vascular populations 
affected in the context of MK2 inhibition? 
 How can treatment penetration into the vessel wall be improved when topically administering 
MK2i-NPs ex vivo? 
 What are the pharmacokinetics and pharmacodynamics of MK2i-NPs in vivo? 
 Are other CPP sequences and biomacromolecular drug such as DNA, siRNA, miRNA, proteins, 
and enzymes that are modified with cationic CPPs equally amenable to NP formulation and do 
they result in increases in uptake, retention, and bioactivity consistent with the data presented 
here? 
 Are NPs hemocompatible (i.e., IV administerable) and, if not, can we alter their structure and/or 
composition to impart hemocompatibility? 
 Can we further improve the biocompatibility of NPs by altering their structure and/or composition? 
 Can MK2i-NPs and/or p-HSP-20 NPs effective prevent/treat SAH induced symptomatic 
vasospasm in vivo? 
 Can we improve the synthesis of NPs and is their synthesis scalable? Can we alter their 
production to increase reproducibility, homogeneity, and yield? 
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Future Directions 
Elucidation of MK2i-NP uptake mechanisms and subsequent intracellular trafficking 
It is well established that facilitating endosomal escape of biomacromolecular therapeutics with 
intracellular targets enhances bioactivity by increasing cytoplasmic bioavailability and circumventing 
lysosomal degradation and/or exocytosis out of the cell [7, 58, 94, 136]. However, formulation of a CPP 
based therapeutic peptide into a nanoparticle can significantly alter cellular uptake kinetics and can alter 
the underlying mechanisms of uptake [84, 137-139]. The MK2i CPP chosen for this study is cationic in 
nature, whereas formulation into a NP results in a negative surface charge as shown by DLS results (ζ ~ -
12 mV for MK2i-NPs at a CR = 1:3). A number of studies have demonstrated that the surface charge 
significantly affects the uptake and trafficking of therapeutic nanoparticles [140, 141], and, as a result, 
formulation of cationic CPP-based peptides, such as MK2i, into an anionic nanoparticle formulation is 
anticipated to have a significant effect on cellular uptake and trafficking. A number of approaches can be 
utilized to investigate uptake mechanisms, including uptake inhibition studies (table 6.1) and 
ultrastructural analysis of cellular organelles during uptake through electron microscopy.  
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Tools to Investigate Cellular Internalization 
Name Use Mechanism  
Amiloride Inhibits macropinocytotsis Inhibits Na
+
/H
+
 ion transport [8] 
Chondroitin Sulfate A/B 
(CSA/CSB) 
Competitive binding to 
chondroitin sulfate 
Competitvely inhibitis binding to chondrotin 
sulfate on the cell surface[8] 
Colchicine 
Inhibit microtubule 
polymerization / 
destabilize microtubules 
Plant metabolite that binds to tubilin, 
preventing microtubule polymerization[8] 
Cytochalasin D  
Inhibit macro 
pinicytosis/phagocytosis 
Inhibits actin polymerization; clathrin- and 
caveolae-mediated pathways have recently 
been shown to require actin for formation 
and invagination of both coated pits and 
caveosomes[142] 
Dynasore 
Inhibit clathrin-mediated 
endocytosis 
Inhibits dynamin-GTPase [142] 
Genistein  
Inhibit caveolae-mediated 
endocytosis 
Inhibits natural isoflavone tyrosine kinase  
[142] 
Heparin 
Competitive binding to 
Heparin sulfate 
Competitvely inhibitis binding to Heparin 
sulfate on the cell surface[143] 
Ionomycin 
Macropinocytotic 
regurgitation 
Calcium ionophore that raises intracellular 
calcium levels[8] 
Methyl-beta-
cyclodextrin (MβCD) 
May inhibit both clathrin- 
and caveolae-mediated 
pathway 
Cyclic heptasaccharide that sequesters and 
alters cholesterol-rich domains within the 
plasma membrane[144] 
Dextran sulfate 
competes with modified 
LDL for scavenger 
receptor mediated uptake 
The negative charge associated with 
dextran sulfate causes uptake through 
scavenger receptors responsible for LDL 
internalization[145] 
polyinosine/polyinosinic 
acid 
Competitively binds to SR-
A  
Immunostimulant known to interact with toll 
like receptor 3[146] 
low density lipoprotein 
(LDL) 
Competitvely binds to SR-
B and CD36 scavenger 
receptors 
Lipoprotein known to be internalized by 
various scavenger receptors[147] 
 
 
To this end, preliminary uptake inhibition studies were performed in HCAVSMCs inhibited 
with either 50 µM amiloride (macropinocytosis inhibitor), 50 µM Dynasore (clathrin-mediated 
endocytosis inhibitor), or 5 mM methyl-β cyclodextrin (inhibitor of lipid raft mediated endocytosis, both 
clathrin- and caveolae-mediated). Every treatment group demonstrated inhibition of uptake for all 
inhibitors tested, indicating that multiple endocytic routes are involved in cellular uptake (fig. 6.1). 
However, only MK2i-NPs were significantly inhibited by pre-treatment with amiloride, indicating that 
macropincytosis plays a significant role in MK2i-NP uptake but not in NE-MK2i-NP or MK2i uptake. 
Both Dynasore and MβCD also significantly inhibited MK2i-NP uptake, and it has been shown that 
Dynasore can also inhibit macropinocytosis under certain circumstances [148]. 
Table 6.1 - Summary of various cellular uptake inhibitors and their function. 
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Furthermore, preliminary TEM analysis of HCAVSMCs treated for 10 minutes with MK2i-NPs or 
free MK2i peptide demonstrated vesicular morphologies consistent with those seen in fluorescence 
microscopy and in agreement with results from uptake inhibition studies, with MK2i-NP treated cells 
demonstrating large invaginations indicative of macropinocytosis (vesicles 250 nm- 1µm in diameter, fig. 
6.2 A-D), whereas HCAVSMCs treated with free peptide showed much smaller vesicles indicative of 
endocytosis (25-100 nm, fig. 6.2 D). 
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Figure 6.1 – MK2i-NP uptake inhibition. HCAVSMCs were either pre-treated for 30 minutes with either 50 µM  
Amiloride, 50 µM   Dynasore, or 5 mM MβCD and subsequently treated with MK2i-NPs, NE-MK2i-NPs, or MK2i 
peptide. *P<0.05, **p<0.01 vs. NT in the same treatment group. 
* 
** 
** 
Figure 6.2 – TEM analysis of MK2i-NP uptake. Representative TEM images of A-C) MK2i-NP and D) MK2i 
peptide uptake in HCAVSMCs.  
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 Future studies looking at a wider range of uptake inhibitors and the utilization of MK2i-labeling 
(e.g., with gold or some other contrast agent for electron microscopy) for electron microscopy mediated 
visualization of  MK2i localization in cellular organelles will provide further insight into the mechanism of 
MK2i-NP uptake. Furthermore, microscopic analysis of fluorescently labeled MK2i-NP uptake in 
conjunction with cells transfected with plasmids coding for protein markers of various trafficking pathways 
(e.g., markers of early endosomes, late endosomes, lysosomes, golgi, etc.) will further elucidate the 
changes in MK2i intracellular trafficking following internalization. 
 
Investigation of MK2i-NP mediated modulation of vascular smooth muscle cell phenotype 
MK2 is activated downstream of p38 MAPK and is implicated as a key effector of the pro-
inflammatory, migratory VSMC phenotype that characterizes IH. Phosphorylated MK2 translocates from 
the nucleus to the cytosol [37] where it activates a number of downstream effector and regulatory proteins 
that induce an inflammatory response, vasoconstriction, and pathological VSMC proliferation, migration, 
and excess ECM production [56, 124]. Vasoconstriction and migration are primarily mediated through 
MK2 phosphorylation of LIM-K and HSP 27: LIM-K phosphorylates and inactives members of the 
ADF/cofilin family of actin filament severing proteins resulting in stabilization of F-actin stress fibers [76, 
79], whereas phosphorylation of HSP27 results in relocalization from the tip of actin filaments to the cell 
surface, allowing for actin polymerization. Pro-inflammatory effects of MK2 are primarily a result of 
downstream phosphorylation of the post-transcriptional gene regulators heterogeneous nuclear 
ribonucleoprotein A0 (hnRNP A0) and tristetraprolin (TTP), which modulates their interactions with AU-
rich regions of mRNA, leads to stabilization and enhanced expression of inflammatory cytokine mRNAs 
such as MIP-2, TNF-α and IL-6 [149-151].As a result, inhibition of MK2 activation should significantly 
curtail the transition of VSMC to a pathological phenotype. In order to further understand how inhibition of 
MK2 modulates vascular smooth muscle cell phenotype, future studies looking at changes in expression 
levels of phenotypic markers in treated human vascular tissue over time, either through 
immunohistochemical or western blot analysis, will provide further insight into the temporal dynamics of 
phenotypic changes. Furthermore, investigation of the underlying signaling responsible for these changes 
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through analysis of the vascular smooth muscle cell transcriptome will further elucidate the molecular 
level regulation of vascular smooth muscle cell phenotype. 
 
Further investigation of MK2i-NPs as a prophylactic treatment to prevent vein graft failure 
In vivo data from a rabbit vein graft model demonstrate that MK2i-NP treatment significantly 
inhibits intimal hyperplasia. However, ex vivo uptake studies in viable human vascular tissue 
demonstrated uptake that was predominantly concentrated on the luminal and adventitial surfaces of the 
vessel indicating that endothelial cells also internalize a significant amount of MK2i-NPs. This 
heterogeneous uptake raises several issues: 1) What are the effects of MK2 inhibition on endothelial 
function during vein graft remodeling? 2) How does intercellular juxtacrine signaling between endothelial 
and vascular smooth muscle cells affect vein graft remodeling? 3) How can we increase penetration of 
the treatment into the vessel wall to provide a more homogenous treatment distribution through the target 
tissue? As mentioned in the conclusion of chapter 4, techniques such as laser capture microdissection 
could potentially be utilized to more specifically investigate the effects of MK2 inhibition on endothelial 
cells during vein graft remodeling. Furthermore, techniques such as pressure seeding the MK2i-NP 
treatment into the vessel wall using a multi-stage balloon catheter (e.g., using the Occlusion Perfusion 
Catheter developed by Advanced Catheter Therapeutics) could potentially increase treatment penetration 
into the vessel wall and further improve vascular graft patency. 
MK2i-NP treatment appeared to significantly extend the duration of therapeutic efficacy of the 
MK2i peptide which motivates further investigation of the in vivo pharmacokinetics and 
pharmacodynamics of MK2i-NP treatment. Studies utilizing radiolabeled MK2i can be utilized to elucidate 
in vivo pharmacokinetics and gene expression analysis of treated tissue over time can be used to further 
elucidate in vivo pharmacodynamics. These studies would provide valuable insight into the ability of NP 
formulation to extend the therapeutic half-life of peptide based therapeutics and would further bolster the 
feasibility and translatability of MK2i-NPs as a prophylactic treatment to prevent adverse vein graft 
remodeling and improve vein graft patency.  
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Applicability of NP formulation to other cell penetrating peptides and  biomacromolecular therapeutics 
 Considering that the studies using the MK2i- and p-HSP20-NP formulations utilized that peptides 
were modified with the same CPP sequence (i.e., YARAAARQARA) motivates investigation of the 
feasibility of this approach to other CPP sequences that are commonly conjugated to peptides and other 
biologic drugs to increase uptake. To this end, preliminary proof of concept studies using two proapoptotic 
peptides with potential for antineoplastic applications were undertaken (table 6.2) 
Peptide Sequence MW Function 
R3-RN22 RRRKFVRSRRPRTASCALAFVN 2648.17 
p19ARF tumor 
suppressor mimetic 
Penetratin-Bak-BH3 
RQIKIWFQNRRMKWKKMG 
QVGRQLAIIGDDINRRY 
4404.28 
Bak-derived Bcl-2 
homology 3 domain 
 
 
 
The Penetratin- (i.e., antennapedia) Bak-BH3 fusion peptide was purchased from Anaspec (As-62262) 
and the p19 ARF tumor suppressor mimetic peptide was kindly gifted by Dr. Stephen R. Hann’s cell and 
developmental biology laboratory at Vanderbilt University. Both oligoargnines and penetratin (which is 
derived from the homeodomain of the Drosophila transcription factor antennapedia) are commonly used 
CPP sequences to increase the uptake of biologics and nanoparticles. DLS analysis and TEM imaging 
studies were used to assess the size and zeta potential of RN22 nano-polyplexes (RN22-NPs, fig. 6.3) 
and Penetratin-Bak-BH3 nano-polyplexes (BH3-NPs, fig. 6.4). An optimal CR of 1:3 was chosen for each 
NP formulation and zeta potential was found to be directly proportional to CR in all cases. Interestingly, 
this charge ratio was identical to the optimal CR for the MK2i-NP formulation, possibly indicating that a 
CR of 1:3 may be an optimal CR for a wide array of NP formulations regardless of peptide and CPP 
identity. These results indicate that this NP approach is applicable to other CPP sequences and further 
supports that this modular technology can serve as a platform for intracellular peptide delivery. However, 
it has yet to be demonstrated whether these proapoptotic NP formulations increase peptide uptake, 
retention, and bioactivity which motivates further in vitro investigation of other NPs formulated with 
peptides for various applications. In addition, it has yet to be demonstrated that non peptide-based 
Table 6.2 - Pro-apoptotic peptides for NP formulation. The pro-apoptotic peptides R3-RN22 and Penetratin-Bak-
BH3 for proofs of concept for the nanopolyplex platform. Red amino acid abbreviations indicate the presence of 
polar amino groups in the amino acid side chain that potentiate electrostatic interaction with PPAA:  R (arginine), K 
(lysine) - primary amines (strong base); N (asparagine), Q (glutamine) - amides (weak bases). 
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biomacromolecular therapeutics such as nucleic acids and proteins or enzymes that are modified with 
cationic CPPs are also amenable to this NP approach. Future studies looking at NP formulations utilizing 
CPP modified DNA, RNA, PNA, proteins, and/or enzymes will provide further insight into the broad 
applicability and potential limitations of nano-polyplex formulation of biomacromolecular therapeutics. 
 
 
 
 
 
Figure 6.3 – RN22-NP formulation. A) Size summary of RN22-NP library. Asterisks (*) indicate multimodal 
size distributions (multiple peaks present). The red box indicates the optimized formulation chosen for further 
study. B) Zeta potential of RN22-NP formulations. C) Representative size distributions and TEM image of 
RN22-NPs. 
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Development of NPs for treatment of vasospasm  
 Preliminary results indicate that NP formulation incorporating the vasoactive peptides MK2i and 
p-HSP20 can effectively inhibit vasoconstriction and 
enhance NO-mediated vasorelaxation indicating that 
these formulations are a promising approach to treat 
vasospasm. Preliminary studies utilizing this approach 
in an established noncraniotomy  in vivo rat model of 
subarachnoid hemorrhage induced vasospasm [134] 
are currently underway. This model utilizes a suture to 
perforate the bifurcation of the internal and ascending 
carotid artery to induce a brain hemorrhage, and the 
resulting changes in blood flow can be visualized 
Figure 6.4 – BH3-NP formulation. A) Size summary of BH3-NP library. Asterisks (*) indicate multimodal 
size distributions (multiple peaks present). The red box indicates the optimized formulation chosen for 
further study. B) Zeta potential of BH3-NP formulations. C) Representative size distributions and TEM 
image of BH3-NPs. 
Figure 6.4 – LDPI image of cerebral perfusion in 
a rat. The bring portion on the right of the image 
corresponds to the section of the skull that was 
shaved down to facilitate vascular imaging. 
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through the use of laser doppler perfusion imaging (LDPI) applied to a shaved down section of the rat 
skull (fig. 6.4). Utilizing NP treatment in conjunction with this quantitative imaging technique will further 
elucidate the ability of MK2i- and p-HSP20-NP formulations to prevent and treat symptomatic vasospasm 
following subarachnoid hemorrhage. 
 
Approaches to improving NP hemocompatibility and biocompatibility 
 Considering that NP treatment for vasospasm applications would likely require intravascular 
administration, the hemocompatibility of these NP formulations becomes a key issue. Recent studies 
have shown that analogous polyplexes are not compatible with IV dosing due to aggregation and poor 
biodistribution [135]. Thus, approaches to alter NP structure and composition must be considered to 
improve hemocompatibility. One promising approach is altering the NP structure to be composed of 
polymeric nanogels (i.e., crosslinked nanoparticles). In contrast to electrostatically complexed linear 
polymers, this approach would significantly increase the colloidal stability of the NPs. Furthermore, by 
altering the composition to incorporate hydrophilic ‘stealth’ polymers that are resistant to opsonization, 
such as poly(ethylene glycol) or poly(hydroxypropyl methacrylate) the hemocompatibility and 
biocompatibility of the NP formulations can be further increased. However, altering the composition and 
structure of the NPs may have deleterious effects on uptake and bioactivity, so extensive in vitro 
characterization of these alternative NPs would be required to verify that they retain their desired 
functionality. 
 
Development of improved and scalable NP synthesis methods 
 Although mixing of a polymer and peptide for NP formulation provides a simple approach to NP 
formulation, improving upon the reproducibility and increasing the scale of NP synthesis would be 
required in order to translate this NP approach into clinical use. In the past decade the use of microfluidic 
mixing devices, or micro-mixers, has substantially increased a promising approach to improve 
nanoparticle synthesis [152-157]. To this end, a tangential spin micromixer that utilizing impinging vortex 
mixing streams has been developed to yield a reproducible method for the synthesis of monodisperse 
NPs through flash nano-complexation (fig. 6.5). 
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By modulating the flow rates of each solution being injected via syringe pump the resulting Reynolds 
number and mixing conditions can be fine-tuned to modulate the size and polydispersity of the resulting 
nano-polyplexes. In fact, preliminary data indicates that we can reduce NP size and increase the 
reproducibility of NP synthesis utilizing this method (fig. 6.6). Thus, the use of a micromixer system to 
facilitate flash nano-complexation represents a promising approach to improving the reproducibility and 
scalability of NP synthesis for clinical translation. Investigation of whether this method of NP synthesis 
can be adapted to a hand-held dual-syringe device with a mixing nozzle will further bolster the 
translatability of this platform technology to improve therapeutic biomacromolecular delivery. Moreover, 
the use of a spray dryer to formulated inhalable NP formulations would further broaden the applicability of 
this approach to include therapies targeted for pulmonary delivery, motivating investigation of NP 
synthesis methods in addition to flash nanocomplexation. 
 
Figure 6.5 – Tangential spin micro-mixer for flash nano-complexation of 
nano-polyplexes. The micromixer is designed so that individual solutions of the 
polymer and peptide are injected through a microfluidic mixing reactor that results in the 
mixing of impinging vortices of each solution rotating in opposite directions, thereby 
decreasing mixing time and improving nano-polyplex synthesis. 
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A 
B 
MK2i-NPs: Simple batch mixing by hand 
MK2i-NPs: Micro-mixer with Reynolds # = 500 
Figure 6.6 – Comparison of NP synthesis methods. (A) DLS size analysis of three separate 
batches of MK2i-NPs prepared by simple batch mixing with a benchtop pipette demonstrating inconsistent 
NP formation. (B) DLS size analysis of three separate batches of MK2i-NPs prepared by a tangential 
spin micromixer operating at a Reynolds number of 500 demonstrating improved reproducibility and 
decreased polydispersity. 
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The recent elucidation of molecular regulators of apoptosis and their roles in cellular oncogenesis 
has motivated the development of biomacromolecular anticancer therapeutics that can activate 
intracellular apoptotic signaling pathways. Pharmaceutical scientists have employed a variety of 
classes of biologics toward this goal, including antisense oligodeoxynucleotides, small interfering 
RNA, proteins, antibodies, and peptides. However, stability in the in vivo environment, tumor- 
specific biodistribution, cell internalization, and localization to the intracellular microenvironment 
where the targeted molecule is localized pose significant challenges that limit the ability to 
directly apply intracellular-acting, pro-apoptotic biologics for therapeutic use. Thus, approaches to 
improve the pharmaceutical properties of therapeutic biomacromolecules are of great significance 
and have included chemically modifying the bioactive molecule itself or formulation with 
auxiliary compounds. Recently, promising advances in delivery of pro-apoptotic 
biomacromolecular agents have been made using tools such as peptide “stapling”, cell penetrating 
peptides, fusogenic peptides, liposomes, nanoparticles, smart polymers, and synergistic 
combinations of these components. This review will discuss the molecular mediators of cellular 
apoptosis, the respective mechanisms by which these mediators are dysregulated in cellular 
oncogenesis, the history and development of both nucleic-acid and amino-acid based drugs, and 
techniques to achieve intracellular delivery of these biologics. Finally, recent applications where 
pro-apoptotic functionality has been achieved through delivery of intracellular-acting 
biomacromolecular drugs will be highlighted. 
 
 
biomacromolecular drug; apoptosis; intracellular delivery; RNA interference; siRNA; peptide 
drug; endosome escape; delivery barriers 
 
 
 
Traditionally, cancer treatments have utilized relatively crude techniques such as surgical 
resection, chemotherapy, and radiation. These approaches can suffer from multiple 
shortcomings including incomplete eradication of the cancer, emergence of treatment- 
resistant cell phenotypes, and undesirable side-effects on healthy tissues. One of the basic 
paradigms of tumorigenesis is that cells that become defective or damaged are able to 
survive and grow in an abnormal, uncontrolled manner rather than succumbing to built-in 
programmed death pathways. An improved understanding of the signaling pathways 
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responsible for tumor cell evasion of apoptosis combined with recent technological advances 
in the engineering of molecularly-targeted drugs will potentially revolutionize cancer 
therapies by enabling the rational design of specialized therapeutics that target cancer- 
specific phenomena. These advances could lead to cancer-specific, if not patient-specific, 
therapeutics tailored to directly combat the aberrant, tumorigenic molecules responsible for 
diverse neoplastic phenotypes. 
 
The ability to more rationally design pro-apoptotic therapeutics for cancer is strongly 
dependent upon robust knockdown or inhibition of targeted molecules with great affinity 
and specificity. Synthetic small molecule drugs are the traditional approach for 
pharmacological inhibition, but synthesis and screening of prospective compounds is a long 
and tedious process and often yields products with suboptimal target specificity and/or 
pharmacokinetic profiles. In the normal, healthy cell, numerous levels of negative feedback 
exist for regulating molecular activities, including contributors at both post-transcriptional 
and post-translational levels. It may be ideal to utilize or mimic these “natural” mechanisms 
in the cell through delivery of therapeutics made from the same biologic building blocks 
(nucleic and amino acids) as the regulatory molecules endogenously present. For example, if 
exogenous doublestranded RNA with an antisense strand complementary to a target mRNA 
is delivered, it can commandeer the evolutionarily-conserved intracellular machinery in the 
cell to achieve sequence-specific gene silencing [1]. Alternatively, naturally-occurring 
protein antagonists or abbreviated peptide fragments containing their active sequences can 
be exogenously delivered to bolster the bioactive, intracellular pool of the antagonist, which 
may be functionally depleted (i.e., not present or mutated) in certain cancers. 
 
Biomimetic, nucleic acid- or amino acid-based drugs clearly have the potential to be 
therapeutically applied to alter intracellular apoptotic signaling pathways. However, delivery 
can be a challenge, especially for intracellularacting macromolecules, because they are 
generally not able to cross cellular membranes. This delivery barrier can have negative 
effects both on cellular internalization and on escape from intracellular vesicles (i.e., 
endosomes) that inhibit access to the microenvironment (i.e., cytosol or mitochondria) 
where the molecular target is localized. For this reason, extracellular-acting molecules 
represent the largest sector of biologics currently used in the pharmaceutical industry. For 
example, biotechnological development of monoclonal antibody drugs is a strong and 
rapidly expanding field. Recent reviews indicate that there are at least 22 FDA-approved 
therapeutic monoclonal antibodies and hundreds more in the pipeline, with anticancer agents 
like Herceptin (trastuzumab), Rituxan (rituximab), and Avastin (bevacizumab) leading the 
way [2, 3]. This recent surge in biological drug development can be used as a precedent to 
indicate that establishing the basic infrastructure necessary for the manufacture of biologic 
drugs is feasible. Pro-apoptotic, RNA-based antisense drugs have also been extensively 
tested in clinical trials for multiple cancer types including melanomas, leukemias, 
lymphomas, gastroesophogeal carcinoma, and prostate cancer [4–9]. Although a distinct 
therapeutic advantage for use of antisense drugs has not been unequivocally proven at this 
point, the volume of trials in this area provide added optimism that intracellular-acting 
biologics can be feasibly developed for clinical use. 
 
Overall, the accrual of new knowledge by cancer biologists to elucidate the molecular 
underpinnings of cancers has outpaced the rate at which pharmaceutical scientists and 
engineers have developed technologies that capitalize on this information clinically. 
Broadly-applicable platform technologies that confer the ability to efficiently deliver protein 
and RNA-based drugs intracellularly may be the key link to opening up a fertile new world 
of druggable targets that enable better clinical translation of new findings in cancer biology. 
Herein, the current molecular understanding of both the intrinsic (mitochondrial) and 
extrinsic (death receptor) apoptosis pathways is reviewed. Subsequently, delivery barriers of 
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intracellular-acting biomacromolecular apoptotic agents and a survey of the current 
pharmaceutical and biomaterial technologies that can be employed to overcome these 
barriers is discussed. Finally, a survey of recent pro-apoptotic therapeutic applications 
employing intracellular-acting biologic drugs, including the delivery techniques used and the 
molecular targets pursued, is presented. 
 
 
Apoptosis is a normal physiological process that occurs both in the homeostatic maintenance 
of adult tissues and during embryonic development. Apoptotic cells undergo a characteristic 
set of prominent morphological changes including alteration in cellular shape, nuclear and 
cytoplasmic condensation, and cellular fragmentation [10]. Eventually, apoptotic fragments 
of these cells are removed by phagocytes, and cytoplasmic leakage (i.e., necrosis) is 
avoided. Apoptosis can be triggered through both extrinsic and intrinsic pathways, where the 
extrinsic pathway is mediated by transmembrane death receptors, and the intrinsic pathway 
is triggered by a variety of factors [11] including environmental stress (e.g. hypoxia and 
reactive oxygen species), growth factor withdrawal [12], chemotherapy [13], and radiation 
[14]. These pathways converge at the level of activation of caspases, which are intracellular 
proteases that serve as the “executioners” of apoptosis [15, 16]. Under normal 
circumstances, caspase activation is primarily controlled by the B cell lymphoma 2 (Bcl-2) 
family of proteins, which provides upstream regulation of mitochondrial membrane potential 
[17, 18]. Importantly, mutations that lead to cancerous apoptotic resistance typically leave 
the intrinsic machinery intact, allowing it to be harnessed therapeutically [19]. 
 
The extrinsic apoptotic pathway is regulated by members of the tumor necrosis factor (TNF) 
receptor superfamily known as death receptors (see Fig. 1). This group of transmembrane 
death receptors includes Fas (CD95/Apo-1) and the TNF-related apoptosis inducing ligand 
(TRAIL) receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) [20]. The Fas and TRAIL 
receptors are activated by the Fas ligand (FasL) and TRAIL, respectively, and these events 
result in the clustering of death receptors and the recruitment of the Fas-associated death 
domain (FADD) molecule [21]. In the case of TRAIL receptor activation, the recruited 
FADD molecule contains an effector region that catalyzes the caspase cascade by binding 
and activating caspase-8 and caspase-10 (known as the death-inducing signaling complex, or 
DISC). The activated Fas death receptor, on the other hand, recruits the death-associated 
protein (Daxx), which promotes apoptosis through activation of the apoptosis signal- 
regulating kinase-1 (ASK-1) and c-Jun N-terminal kinase (JNK) pathway [22]. Extracellular 
Inhibitors of the extrinsic pathway include membrane-bound decoy receptors 1–3 (DcR1, 
DcR2, DcR3), soluble Fas receptors (sFas), and soluble osteoprotegerin (OPG). 
Downstream from TRAIL receptor ligation, activation of caspase-8 is inhibited 
intracellularly by phosphoprotein enriched in astrocytes 15 (PEA-15) and cellular FLICE 
inhibitory protein (c-FLIP) [23–25]. Examples of potential therapeutic targets within the 
extrinsic pathway include activation of Fas and TRAIL death receptors as well as decreasing 
the expression of inhibitory molecules such as c-FLIP [26–28]. 
 
A variety of cellular stresses activate the transcription factor p53, which is known as the 
tumor suppressor gene. p53 inhibits tumorigenesis by triggering apoptosis in stressed or 
damaged cells and operates through several proposed mechanisms including the 
transactivation of pro-apoptotic factors [29]. One of the important functions of p53 is its role 
in the Bcl-2 pathway. The members of the Bcl-2 family of proteins are key regulators of 
caspase activation and are considered to constitute the cell’s intrinsic “apoptotic switch” [17, 
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30]. There are two subsets of pro-apoptotic proteins in the Bcl-2 family and one subset of 
anti-apoptotic proteins, all of which contain one to four of the Bcl-2 homology (BH) 
domains. The first pro-apoptotic subset includes Bcl-2-associated X protein (Bax) and 
Bcl-2-antagonist/killer protein (Bak), both of which contain BH domains 1–3. Bax is 
normally free within the cytoplasm and translocates to the mitochondrial membrane 
following an apoptotic stimulus, whereas Bak permanently resides on the mitochondrial 
membrane [31]. Bak and Bax are generally considered to be redundant in function, and once 
activated, they each homo-oligomerize into multimers that insert into the mitochondrial 
membrane. These multimeric structures create “pores” that release cytochrome C, ATP, 
Smac, and Omi from the mitochondria to trigger a signaling cascade that results in caspase 
activation and apoptosis (see Fig. 1) [31, 32]. 
 
The other two subsets of Bcl-2 family members (Bcl-2-like and BH3-only proteins) are 
upstream mediators of apoptosis, and their interplay controls the activation of Bak and Bax. 
The Bcl-2-like subset includes members such as Bcl-2, Bcl-xL, and Mcl-1, and this group is 
anti-apoptotic in function. In general, these proteins contain all four BH domains, and the 
highly conserved BH1, BH2, and BH3 domains of Bcl-2-like proteins are thought to form a 
hydrophobic pocket that engages the BH3 domain of Bak/Bax [33, 34]. This interaction is 
the means by which the Bcl-2-like proteins neutralize the pro-apoptotic function of Bak/Bax. 
The ability of Bcl-2-like proteins to antagonize Bak/Bax and functionally inhibit apoptosis is 
believed to be determined by their relative activity compared to the third subset of the Bcl-2 
family, the BH3-only proteins. 
 
The members of the BH3-only subset, as the name implies, contain only the BH3 domain, 
and this group is represented by proteins such as Bim, Bid, Bad, Noxa, Puma, and several 
more. The BH3-only group promotes apoptosis by engaging the Bcl-2-like proteins in the 
same binding cleft that the Bcl-like proteins utilize to antagonistically bind to the BH3 
domain of Bak and Bax [11]. Essentially, the BH3-only proteins compete with the BH3 
domains of Bak/Bax for this binding pocket on the Bcl-2-like proteins, and by occupying 
this site, the BH3-only proteins inhibit Bcl-2-like inhibition of Bak/Bax and indirectly 
activate apoptosis [35, 36]. It is by this set of competing interactions that the relative balance 
of pro-apoptotic BH-3-only and pro-survival Bcl-2-like proteins is believed to control the 
apoptotic switch. 
 
The discussed model for apoptotic control is known as the indirect activation model (i.e., 
BH3-only proteins indirectly activate Bak/Bax). It is important to note that a direct 
activatioBak and are inhibiten model has also been proposed where BH3-only proteins Bid 
and Bim directly activate Bax and d by anti-apoptotic Bcl-2, Bcl-XL, Mcl-1, Bcl-w, and Bfl/ 
A1. Bad, Bik, Noxa, Hrk, Bmf, and Puma are considered to be sensitizers that compete for 
the binding site of anti-apoptotic molecules in this model [37]. However, more recent studies 
have shown compelling evidence in favor of the indirect activation model, and the 
discussion herein will assume its accuracy [38, 39]. It is also important to note that the 
descriptions of the models provided in this review are somewhat simplified in that all 
members within each of the three Bcl-2 family subclasses are not identical in function. For 
example, cytosolic Bad binds to Bcl-2 and Bcl-XL, which can indirectly activate Bak/Bax, 
enabling oligomerization, mitochondrial disruption, and apoptosis [40]. However, Bad 
interacts weakly with Mcl-1, and as a result, if Mcl-1 is predominantly present in the cell, 
apoptosis may still be resisted even in the presence of Bad [41]. In contrast, Noxa is known 
to bind only to Mcl-1 and A1 [38]. Although a discussion of the differences in the specific 
interactions mediated by each of the proteins within each of the Bcl-2 subsets is outside the 
scope of this review, these are important points to consider in drug design. For example, 
pro-apoptotic therapies that target specific Bcl-2 family members may not be effective if the 
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cells upregulate alternate Bcl-2-like members that are able to circumvent the drug activity 
and maintain pro-survival signaling. 
 
There is also a family known as inhibitors of apoptosis proteins (IAPs) that operates 
downstream of Bak/Bax and activation of initiator caspases to prevent activation of the 
executioner caspases (caspase-3,-7, and -9) [42]. The IAP family has eight members 
including cellular-IAP1 (cIAP1), cIAP2, X-linked IAP (XIAP), Survivin, Bruce, and Livin, 
all of which contain the baculovirus IAP repeat (BIR) domain [43]. Negative regulators of 
the IAP family members also exist and examples include the pro-apoptotic molecules Smac 
and Omi, which are released upon depolarization of the mitochondrial membrane by Bak 
and Bax [44]. A diversity of tumors overexpress IAPs, with survivin in neuroblastoma and 
c-IAP1/2 in epithelial malignancies being notable examples, and this dysregulation 
contributes to their apoptotic resistance [45]. Current therapeutic targets within the IAP 
family include XIAP and Survivin inhibition or delivery of Smac or Omi to enhance 
chemotherapeutic effects [11, 46]. 
 
“Oncogene” is a broad term for genes that are normally responsible for general cell 
maintenance and proliferation that have been mutated, resulting in tumorigenic phenotypes. 
Oncogenes can be derived from genes that normally encode a variety of proteins such as 
growth factors, growth factor receptors, transcription factors, and kinases. There are many 
examples of oncogenes, and this topic has been reviewed extensively elsewhere [47]. An 
important example of a cell survival pathway whose mutation is associated with oncogenesis 
is the epidermal growth factor receptor (EGFR) family of protein tyrosine kinases (PTKs). 
In humans, the EGFR family consists of the human epidermal receptors (HERs) and 
includes HER1, HER2, HER3, and HER4 [48, 49]. Activation of these protein tyrosine 
kinases results in downstream activation of pro-survival pathways such as the 
phosphatidylinositol 3-kinase/Akt (PI3K/Akt) and signal transducers and activators of 
transcription (STAT) pathways [50]. Akt can inhibit pro-apoptotic Bad, activate the pro- 
survival nuclear factor-κB (NF-κB), and also inhibit the pro-apoptotic transcription factor 
Forkhead [51]. NF-κβ activation induces the transcription of the key anti-apoptotic genes c- 
FLIP, Bcl-2, and Bcl-XL, whereas Forkhead induces the transcription of the pro-apoptotic 
genes FasL and Bim [52, 53]. PTKs can also activate STAT-3 and STAT-5, which results in 
their translocation to the nucleus and transactivation of the anti-apoptotic genes Bcl-XL, 
Mcl-1, and Survivin [54–56]. Cancer cells can become reliant on oncogenes for their 
sustained survival and growth, making oncongene inhibition an excellent target for 
induction of apoptosis. Current therapeutic strategies targeting the described oncogenic pro- 
survival pathway include using antibodies (e.g. cetuximab and panitumumab) or small 
molecule drugs (e.g. gefitinib and erlotinib) to inhibit EGFR binding [11], NF-κB activation 
(e.g. the proteasome inhibitor bortezomib) [57], or progression of the PI3K/Akt pathway 
[58]. The transcription factor c-myc represents another oncogene that is often dyregulated in 
cancerous cells [59], and therapeutic applications for the inhibition of this oncogene will 
also be discuess in more detail herein. 
 
 
Controlled manipulation of gene expression using RNA interference (RNAi) has been 
rigorously pursued for almost two decades now, and thorough elucidation of this mechanism 
combined with recent breakthroughs in RNA delivery technologies have RNAi poised to 
make a tremendous impact on pro-apoptotic therapies. RNAi is an especially promising 
therapeutic approach for inhibition of anti-apoptotic Bcl-2-like proteins, oncogenes, or other 
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relevant targets because it allows for optimal therapeutic specificity and breadth (i.e., in 
theory, any desired gene target can be efficiently silenced). The initial discovery of RNAi 
came in 1990 when Napoli et al. observed an unexpected reduction in expression when 
delivering RNA in an attempt to overexpress chalcone synthase in Petunias [60]. Others 
elucidated and applied this finding by delivering antisense oligodeoxynucleotides (ODN), 
complementary sequences of DNA, which yielded modest reduction in gene expression in 
C. elegans [61]. In 1998, Fire et al. showed that intracellular-acting double stranded RNA 
(dsRNA) was more effective than either the sense or anti-sense strand alone [1]. In fact, 
dsRNA has been shown to be 100 to 1000 times more effective than ODNs due to a longer 
half-life and greater potency [62]. Over the next few years, researchers proved that 
endogenous RNAi, known as microRNA (miRNA), exist and that it serves as a natural, post- 
transcriptional controller of gene expression where cellular machinery selectively degrades 
complementary mRNA in an enzymatic manner [63]. The elucidation of similar machinery 
for RNAi in mammalian cells further heightened the interest in therapeutically harnessing 
these pathways [64]. 
 
Since these early findings, the mechanisms of ODN and that of miRNA, dsRNA, siRNA, 
and short hairpin RNA (shRNA) have been more clearly elucidated (see Fig. 2). Single- 
stranded antisense ODN are thought to function by multiple mechanisms including 
translational arrest due to steric blockage of ribosomes by ODN-mRNA Watson-Crick base 
pairing and also through RNase-H-mediated cleavage of both the ODN and mRNA strands 
[65]. Endogenous RNAi molecules in the form of microRNA (miRNA) enter the cytoplasm 
after transcription, or alternatively, functionally-similar dsRNA can be exogenously 
delivered. shRNA that more closely mimic the structure of endogenous miRNA have also 
been exogenously delivered [66]. In each of these cases, the RNase III family enzyme Dicer 
cleaves the miRNA/dsRNA/shRNA to produce guide RNA, more commonly known as 
small interfering RNA (siRNA). siRNA are double-stranded RNA 19–21 base pairs in 
length with 3’ nucleotide overhangs [67], these molecules can assemble into the RNA 
induced silencing complex (RISC), a nuclease complex that degrades complementary 
mRNA in a sequence specific, enzymatic manner [63]. RNAi efficiency has been further 
improved by delivering siRNA that directly enters the RISC rather than upstream dsRNA/ 
shRNA that must be processed first by Dicer [68]. Because of the tremendous promise of 
siRNA to be used therapeutically (i.e., for silencing anti-apoptotic genes in cancer cells), 
most of the RNAi applications in this review will be focused on delivery of siRNA. 
However, to be used clinically, a number of significant delivery barriers must be overcome 
between initial application of the siRNA (i.e. intravenously or intratumorally) and its 
association with the RISC machinery in the cytoplasm of target cells. 
 
The relative abundance of Bcl-2-like proteins and the BH3-only proteins is a major 
determinant in Bak/Bax activity and therefore, cellular homeostasis [69]. The disruption of 
this homeostasis caused by abnormal, excessive Bcl-2-like protein activity is thought to be a 
primary cause of both tumorigenesis and the ability of established tumors to resist 
conventional cancer therapies [70–73]. For example, dysregulation of apoptosis was first 
linked to neoplasia by Vaux et. al upon the elucidation of the function of Bcl-2 as a potential 
oncogene [74]. Since that initial report, Bcl-2 overexpression has been found to be a 
common hallmark of many cancers, especially lymphomas, and it is linked to decreased 
likelihood of cancer patient survival [71–73, 75–77]. As a result of the remarkable efforts of 
scientists to elucidate the apoptosis signaling pathway and to define the molecular causes for 
cellular oncogenesis, pharmaceutical scientists have been able to rationally design pro- 
apoptotic peptides and other amino acid-based drugs that target tumorigenesis at its 
molecular foundations. One promising strategy is application of peptides derived from the 
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BH3 domains of Bcl-2 family members. For example, minimal 16 amino acid sequences 
contained in the BH3 domains of pro-apoptotic Bcl2 family members are capable of 
mimicking the activity of full-length BH3-only proteins by occupying the binding site of 
Bcl2-like proteins and blocking their ability to repress Bak/Bax [78]. Therefore, synthesis 
and delivery of these peptides presents a logical approach for negating overexpression of 
Bcl-2-like proteins and triggering apoptosis in cancer cells (see Fig. 3). However, like RNA 
drugs, peptide drugs face a robust set of delivery challenges related to maintenance of 
stability, biodistribution to the tumor, and intracellular delivery to the microenvironment 
containing the pertinent molecular target. 
 
 
Advances in the understanding of the molecular etiology of cellular oncogenesis have made 
it apparent that nucleic acids, peptides, and other biologics have great potential for specific 
manipulation of aberrant intracellular apoptosis signaling pathways to trigger death or 
chemosensitivity of cancer cells. However, the desired bioactivity of intracellular-acting 
pro-apoptotic biomacromolecular therapeutics can be limited by numerous delivery barriers 
including: proteolytic/nuclease degradation in the in vivo environment, opsonization leading 
to systemic clearance, inability to achieve specific targeting to the desired tissues/cells, non- 
specific binding and/or side-effects, inability to translocate the cellular membrane, inability 
to escape from the endo-lysosomal and exocytosis pathways, and lack of therapeutically- 
relevant concentrations of drug achieved within the intracellular microenvironment where 
the molecular target is located (Fig. 4) [79–82]. Stability of biologics is a primary concern 
considering the harsh environment encountered in vivo. The inherent intermediacy of RNA 
during gene expression predisposes it to having a relatively short half-life. For example, 
naked siRNA is degraded in minutes to one hour [83], and absorbance of serum proteins to 
drug carriers can opsonize them for removal from the body through the macrophages of the 
reticuloendothelial system (i.e., in the liver) [84, 85]. Furthermore, delivery to nontargeted, 
healthy tissues can lead to significant, non-specific cytotoxicity and negative side effects. 
Therefore, targeted delivery is often pursued to augment the effect of the drug and 
potentially avoid undesirable cell/tissue damage. The biologics discussed herein have 
therapeutic action in the cytoplasm, so cell membrane translocation is also essential. 
However, RNA- and amino acid-based drugs have relatively large molecular weight and 
hydrophilicity relative to small molecule drugs that can diffuse through lipid bilayer 
membranes. As a result, these drugs are internalized by endocytosis, which creates the added 
barrier of escaping from endo-lysosomal vesicles. Herein, currently available delivery 
technologies and recent pro-apoptotic applications are surveyed for both RNA- and amino 
acid-based therapeutics. 
 
 
Advances in pharmaceutical technology and an increased understanding of the 
pharmacokinetics of biomacromolecular drugs have led to the development of a variety of 
tools to address systemic and intracellular delivery barriers. Pharmaceutical techniques for 
efficient intracellular delivery of peptide/protein therapeutics and siRNA include 
electroporation, fusion with cell-penetrating peptides (CPPs) and/or fusogenic peptides, 
chemical modifications that convey pharmaceutical properties onto the bioactive molecule 
itself (i.e. peptide “stapling”), formulation into liposomes/nanoparticles, and conjugation to 
“smart” polymers, among others. The specific approach utilized is typically selected based 
upon the pathological application and class of drug being delivered. For example, while 
neither peptide nor siRNA therapeutics can traverse cell membranes by simple diffusion, 
there are additional RNA-specific properties that pose unique delivery challenges. One 
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distinguishing characteristic of RNA is that it is a polyanionic material due to the negative 
charges from the phosphate groups in the RNA backbone. Since anionic macromolecules are 
not very efficiently internalized by cells, approaches for shielding the neagative charges on 
nucleic acids (i.e. by loading into liposomes or formulation into cationic polyplexes) is an 
important consideration that is typically less relevant for peptide delivery. 
 
There are a variety of relatively simplistic techniques useful for in vitro transfection or for in 
vivo application to superficial pathologies where the primary goal is getting past the skin 
barrier. For example, electroporation is a technique where high voltage pulses are applied to 
the target tissue (usually skin) triggering a voltage drop across the cell membrane of locally 
affected cells. This stimulus disrupts the lipid structure and forms aqueous pathways in the 
membrane that allow biomacromolecules to diffuse across [86]. Despite the lack of a clear 
mechanistic understanding of the permeabilization process, it is widely accepted that electric 
fields above 200 mV form nanopores in the cell membrane [87–89]. Electroporation has 
been used to deliver siRNA, proteins, and antibodies to various cell types. For example, 
optimized electroporation of deoxycytidine kinase (dCK) siRNA into acute T-cell 
lymphoblastic CEM cells resulted in 70–80% suppression of dCK mRNA and its enzyme 
activity [90]. Similarly, novel electroporation microchips have been shown to achieve 
transfection of the GFP plasmid into HEK-293 cells with transfection efficiency as high as 
90% [91]. There are also numerous protein delivery applications that have been pursued. 
Electroporation of the enzyme β-galactosidase into murine melanoma cells has been 
achieved at efficiencies of 20% [87], and electroporation has also been used to deliver 
exogenous antigens into the cytoplasm of T-hybridoma cells in order to preferentially 
activate class I MHC processing [92]. In addition, it was found that electroporation delivered 
detectable levels of monoclonal antibodies against G1-specific cyclin D1into 80% of CV1 
and MCF7 cells, and intracellular delivery of the antibody successfully inhibited mitosis in 
these cells [93]. Although electroporation can potentially affect cell viability, optimized 
electroporation protocols have resulted in techniques that sufficiently permeabilize cell 
membranes (i.e. >90% of cells) for therapeutic translocation while maintaining 80–90% cell 
viability [94, 95]. 
 
Another technique similar to electroporation is iontophoresis, which involves application of 
a constant current to move charged proteins or siRNA (i.e., through the epidermis) [96, 97]. 
Due to the ion-driven nature of this approach, delivery efficiency correlates to the charge of 
the drug utilized, and example applications of this technique include transdermal delivery of 
the insulin protein [97–99] and siRNA delivery for ocular gene therapy [100]. Application 
of ultrasound has also been explored as a means of peptide delivery (i.e. low-frequency 
sonophoresis) [101]. Sonophoresis is thought to disrupt lipid structure in various tissues, and 
tissue-specificity is achievable by varying the frequency of ultrasound waves applied. This 
approach has primarily been studied for applications involving transdermal drug delivery. 
Although iontophoresis and sonophoresis can be used to effectively translate through the 
skin’s stratum corneum, they do not necessarily enable cellular internalization. Thus, 
electroporation is the most promising technique within this category based on potential for 
intracellular delivery. However, loss of cell viability and the inability to pursue in vivo 
applications where less superficial tissues are targeted represent key limitations of 
electroporation. 
 
Other techniques explored for biomacromolecular drug delivery include photochemical 
internalization and tissue permeation using laser irradiation. Photochemical internalization is 
a technique that relies on the localization of amphiphilic photosensitizing agents into the 
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endosomal membrane. Upon exposure to a light source, these agents generate highly- 
reactive singlet oxygen species that damage and permeabilize the endosome [102]. The use 
of photochemical internalization as a tool for intracellular delivery was originally proposed 
by Berg et. al. who utilized lysosomes as photochemical targets [103]. Subsequently, Berg 
and authors used photochemical internalization for the cytosolic delivery of the protein toxin 
gelonin, as well as for the site-specific, photochemically enhanced delivery of the anti- 
neoplastic glycopeptide bleomycin [104, 105]. Photochemical internalization has also been 
utilized for prolonging siRNA-mediated gene silencing [106]. Despite the intracellular 
biomacromolecular drug delivery potential of photochemical internalization, current 
applications are limited by the lack of supporting technologies (i.e., fiber-optic probes) that 
can be employed to activate photochemical agents in deeper tissues in vivo. 
 
Another technique with applicability for the delivery of pro-apoptotic peptides and siRNA is 
laser-irradiation induced tissue permeation, specifically with an erbium:YAG laser [107– 
109]. Use of laser irradiation has been found to increase antigen-induced antibody 
production following skin vaccination and enhanced transdermal delivery of a number of 
other therapeutic agents including vitamin C, 5-fluoruracil, and 5-aminolevulinic acid [107– 
109]. Additionally, skin pre-treatment with a low-fluence erbium:YAG laser has been shown 
to increase transdermal siRNA delivery up to 10-fold compared to untreated groups [110]. 
The mechanism underlying the laser irradiation delivery method is thought to involve the 
disruption of intercellular connections (i.e. gap junctions) allowing for enhanced drug 
permeation through the skin barrier [107]. However, like electroporation and iontophoresis, 
laser irradiation is used to enhance the transdermal transport of drugs, and it is limited by the 
inability to overcome intracellular delivery barriers. 
 
CPPs, also known as protein transduction domains (PTDs), were originally developed to 
mimic viruses that are able to translocate their own genetic material across cell and 
endosomal membranes. The 1988 discovery that the transactivating transcriptional factor 
(TAT) of HIV-1 can penetrate cell membranes [111, 112], followed by the discovery of 
antennapedia (a.k.a. penetratin) which is derived from Drosophila [113], rapidly stimulated 
the use of CPPs for intracellular biomacromolecular drug delivery. The finding that the 
antennapedia peptide was rich in positively charged arginine residues subsequently 
motivated the development of synthetic, arginine-rich CPPs (AR_CPPs, or oligoarginines) 
[114]. A multitude of other CPPs have since been discovered from naturally occurring 
sequences or synthetically designed, including transportan, VE-cadherin derived peptide 
(pVEC), the herpes simplex virus type I derived CPP VP22, diatos peptide vectors 
(Vectocell®), various oligoarginines, and many other novel sequences [88, 114–120]. A 
representative list of some of the most widely studied CPPs is given in Table 1. 
 
The mechanism of cellular internalization of CPPs is thought to vary depending on the 
peptide sequence, the architecture of the drug formulation, and the cargo being delivered 
[121]. Cell entry mechanisms are hypothesized to include membrane fusion via binding of 
CPPs to cell surface proteoglycans, the endocytosis pathway (caveolindependent, clathrin- 
dependent, or caveolin- and clathrin-dependent), and macropinocytosis [121–124]. If the 
CPP and its cargo are taken up through endocytosis or macropinocytosis and a mechanism 
to escape these intracellular vesicles (inherent or through modification) is not present, the 
drug may be either degraded in the lysosome, remain sequestered in the early or late 
endosome, or undergo trafficking for exocytosis [121, 125]. Thus, a combinatorial 
therapeutic approach is commonly employed where the cell-penetrating properties of a CPP 
are coupled with the endosomolytic properties of fusogenic proteins/peptides or pH– 
responsive “smart” polymers [125–129]. Additional consideration must also be given to 
ensure that the CPP does not result in non-specific side effects. For example, Ward and co- 
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authors reported unexpected effects of CPPs on kinase inhibition [130]. Furthermore, some 
CPPs have also been shown to have cytotoxic effects depending on the synthetic route and 
CPP formulation used (e.g. some retroinverso cell penetrating peptides have been shown to 
result in severe cytotoxicity mediated through nonspecific side effects) [131]. Other 
potential disadvantages of CPPs include poor serum and protease stability and their 
indiscriminate cell entry, which could be problematic for systemic delivery applications 
where specific cells (i.e., in a tumor) are targeted. Herein, CPP delivery of pro-apoptotic 
biomacromolecules will be the focus. However, CPP conjugation to small molecule 
chemotherapeutics (i.e., doxorubicin and camptothecin) has also been assessed and found to 
either meet or exceed current standards achievable through delivery of the “free” drug [132– 
134]. 
 
In order to avoid sequestration or degradation within the endo-lysosomal pathway, peptides 
with membrane fusogenic activity can be employed. These peptides are generally 
amphipathic in structure and transition into a more lipophilic state at slightly acidic pH (i.e., 
in the microenvironment of endo-lysosomes), allowing them to partition into and disrupt 
lipid bilayer membranes [135]. Initially, the understanding of the structure and function of 
fusogenic peptides depended upon studies on the viral and cellular fusion proteins found in 
nature. These fusion proteins are generally either glycoproteins contained in viral envelopes 
or proteins involved with fusion protein attachment receptors (i.e., soluble N- 
ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE)) [136]. In the 
case of the viral envelop, this interaction involves insertion of an α-helical peptide domain 
into the cell membrane catalyzing fusion of the viral envelope with the cellular or 
endosomal membrane. One of the most widely utilized fusogenic peptides is the N-terminal 
sequence of the Influenza hemagglutinin subunit HA-2 and its derivatives [137–140]. A 
multitude of other fusogenic proteins have also been discovered or created, including 
synthetic hemagglutinin derivatives, model amphipathic peptides (MAPs), β-amyloid trans- 
membrane protein derivatives, membrane-disruptive peptides found in various toxins and 
venoms, and a family of fusion-associated small transmembrane (FAST) proteins (i.e. the 
p10 avian reovirus, the p14 reptilian reovirus, and the p15 baboon reovirus) [121, 135–148]. 
A representative list of fusogenic peptides is given in Table 2. Note that penetratin, 
transportan, and TAT are classified as both fusogenic peptides as well as CPPs due to their 
fusion based mechanism of cell entry at physiological pH. In contrast, other fusogenic 
peptides listed typically rely on a stimulus, such as lowered pH, in order to catalyze 
membrane fusion, and, therefore, they are best used toward endo-lysosomal escape as 
opposed to cellular uptake. 
 
Colloidal systems, including liposomes, micelles, and nanoparticles, are widely used for 
drug delivery because they can carry large drug quantities, physically shield drug cargo from 
enzymatic activity, and provide simple routes for modification with other molecules that can 
be used to finely tune the pharmaceutical properties [149]. For example, multiple functional 
components can be incorporated through loading (i.e., drug) into the interior of the 
nanoparticle or surface modification with moieties such as cell-targeting molecules, CPPs, 
fusogenic peptides, pHresponsive polymers for endosomal escape, and hydrophilic polymers 
(i.e. PEGylation for increased stealth within the systemic environment). Modification with 
the CPP TAT has been one of the more widely utilized approaches, while other colloidal 
drug carrier modifications include alternate CPPs such as R8 and IRQ, fusogenic peptides 
such as GALA and penetratin, and a variety of molecules including nuclear localization 
signals (NLS) and extracellular receptor-targeting ligands such as folic acid [121, 126, 128, 
149–154]. Mitochondria-targeted vehicles are one especially promising, recent development 
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in colloidal drug carriers pertinent to the delivery of pro-apoptotic peptides. Since 
mitochondria are central to controlling cellular apoptosis, targeted drug delivery to these 
organelles may enable development of more potent pro-apoptotic therapies. One successful 
liposome-based approach to mitochondrial drug delivery incorporated the 
mitochondriotropic lipid triphenylphosphonium (TPP), mitochondrial targeting signal 
(MTS) peptides, CPPs, or synergistic combinations of these components [155]. However, 
significant challenges to mitochondrial drug delivery still exist, especially for applications 
that require control of intra mitochondrial trafficking. This combinatorial approach, 
however, provides a good example of the complex optimization possible through 
modulation of the composition and stoichiometric ratios of the different components of 
multifunctional particulate carriers. 
 
One of the most common methods for nucleic acid transfection is formulation with lipids 
[156–158]. Lipid agents can form vesicles with a lipid bilayer membrane surrounding an 
aqueous interior where hydrophilic drugs can be encapsulated, or cationic lipids can be used 
to form lipoplexes with anionic nucleic acids. Lipids can either fuse to the cell membrane or 
enter the cell by endocytosis, eventually releasing their cargo into the cytoplasm [159, 160]. 
Information on liposome preparation, physicochemical properties, and applications can be 
found in more detail in a review of liposomal drug delivery systems by Samad et al. [160]. 
Lipids are commonly combined with other components to incorporate added functionality. 
For example, Morrissey et al used a cationic and fusogenic lipid (SNALP) delivery vesicle 
coated with a PEG-lipid layer to provide a neutral, hydrophilic exterior [161]. As a result of 
the multi-functional potential of liposomes and nanoparticles, they have also become 
promising candidates for the treatment of drug resistant cancers. For example, Huang and 
authors have developed multifunctional liposomes with a removable PEG shield that are 
capable of highly efficient tumor biodistribution and intracellular co-delivery of siRNA and 
doxorubicin to combat tumor cells with multi-drug resistant (MDR) phenotypes [162, 163]. 
In another analogous design, a guanidinium-containing liposome incorporated multiple 
components including a P-glycoprotein drug efflux pump inhibitor to combat drug 
resistance, anisamide for cancer cell targeting, and doxorubicin as a chemotherapeutic agent. 
The guanidinium compounds have been shown to generate reactive oxygen species (ROS) 
such as hydroxyl free radicals (•OH) [164], and these ROS radicals are hypothesized to act 
as second messengers that reduce MDR phenotype through activation of c-Jun N-terminal 
kinase (JNK) and c-Jun [165, 166]. 
 
A variety of inorganic nanoparticles and polyplex- or micelle-forming polymers have also 
been pursued as biomacromolecular delivery vehicles. In some applications, especially with 
inorganic nanoparticles, technological advances have been pursued that combine both image 
contrast and therapeutic functionalities. For example, siRNA-loaded Au nanoparticles 
(AuNPs) coated with cationic polymers have been reported to increase RNA half-life 6-fold 
when compared to naked RNA in vitro [167]. Quantum dot nanoparticles, renowned for 
their optical properties, have also been functionalized to successfully deliver siRNA and 
have tremendous potential to serve as “theranostic” platforms [168, 169]. Several natural 
organic polymers have also been used to make polyplex nanoparticles for siRNA delivery 
including sugar containing polymers such as atelocollagen [170, 171] and chitosan [172]. 
One important consideration in fabrication of nanoparticles is control of particle size and 
polydispersity. For example, control of nanoparticle size and aggregation for polyplexes is 
typically controlled by adjusting the nitrogen to phosphate charge ratio (N/P ratio). Kong et 
al. showed that the hydrodynamic diameter of nanoparticles consisting of poly[2- 
(dimethylamino) ethyl methacrylate] PDMAEMA/siRNA binary polyplexes could be varied 
from 102 nm to 58 nm simply by increasing the N/P ratio from 1 to 3 [173]. However, for 
polyplexes, further consideration must be given to the possibility that siRNA bioactivity 
could be hindered by stable (nonreversible) complexation with a polycationic carrier. One 
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method to address this issue is to utilize bioreducible disulfide linkages to connect siRNA to 
their carriers rather than using electrostatic complexation, a technique that has demonstrated 
significant improvements in transfection efficiency with no apparent cytotoxic effects [174, 
175]. 
 
The ability to escape endo-lysosomal pathways in order to avoid degradation or exocytotic 
recycling out of the cell represents one of the most important carrier functionalities for 
biomacromolecular drug cytosolic delivery. “Smart”, pH-responsive synthetic polymers 
with membrane-disruptive behavior that mimics the functionality of fusogenic peptides have 
been intensely studied for this purpose. This class of delivery systems can take the form of 
soluble polymer-drug conjugates, polyplexes, and micelles, and, thus, it overlaps partially 
with the more general “nanoparticle” category. These polymer therapeutics are typically 
designed to be activated by the decreasing pH gradient experienced during trafficking from 
the extracellular environment (i.e. pH ~7.4) into the intracellular endolysosomal pathway 
(i.e., 6.8 > pH > 5). “Smart” polymers can be finely-tuned to respond in this 
physiologicallyrelevant pH range to trigger endo-lysosomal vesicle disruption, and this 
functionality can be harnessed to deliver therapeutic biomacromolecules to the cytosol. 
 
Two primary subclasses of synthetic, pH-responsive polymers exist (anionic and cationic), 
and they produce endo-lysosomal escape through very different mechanisms (see Fig. 5 for 
structures of representative anionic and cationic pH-responsive polymers). The anionic 
polymers, for example, become more hydrophobic in acidic environments, triggering 
adoption of a less solvated, compact globule conformation that partitions into and disrupts 
lipid bilayers [176–179]. Some of the most thoroughly studied pH-responsive polymers are 
poly(alkylacrylic acids), a family of anionic polymers that was primarily pioneered by the 
Tirrell laboratory’s work on poly(ethylacrylic acid) (PEAA) [176, 178]. Examples of other 
anionic, pH-sensitive polymers that have since been applied for intracellular delivery 
include poly(styrene-alt-maleic anhydride) (PSMA), poly(propylacrylic acid) (PPAA), and 
various copolymers containing PPAA and PSMA [127, 129, 180–183]. Murthy et. al. 
developed a related class of “encrypted” polymers that also have lipophilic activity that 
disrupts endo-lysosomal membranes. In the encrypted delivery system, PEG polymers 
attached via acid-labile acetal linkages “shield” a hydrophobic, endosomolytic polymer 
backbone until being shed upon exposure to acidic pH [183, 184]. We and others have 
successfully applied members of the anionic smart polymer subclass toward intracellular 
delivery of polymer-peptide and polymerprotein soluble conjugates as well as for siRNA 
delivery using particulate polyplex- and micelle-based formulations [125, 127, 185, 186]. 
 
A variety of cationic endosomolytic polymers have also been developed, and this alternate 
subclass of “smart” polymers employs a colloid osmotic mechanism described by Behr et. 
al. as the “proton sponge” effect [129, 176, 177, 180, 187]. Following internalization of 
extracellular cargo, early endosomal compartments are normally acidified by the action of 
an ATPase-driven proton pump in their membrane. The proton sponge effect is triggered by 
weakly basic cationic polymers that “absorb” the protons pumped into these vesicles, which 
buffers against the acidification of the endosomal microenvironment. This buffering triggers 
continued, abnormal import of protons and their counter-ions, establishing an osmotic 
imbalance that triggers water influx, vesicle swelling, and endosomal disruption [75]. 
Examples from this class of pH-responsive polymers include poly(L-lysine), linear and 
branched poly(ethylenimine) (PEI), poly(amidoamine) (PAMAM) dendrimers, poly(β- 
amino esters) (PBAE), and histidine and/or imidazole containing copolymers [188–194]. 
Due to the inherent electrostatic interaction between positive and negative macromolecules, 
it is logical to utilize cationic polymers to condense nucleic-acid based drugs. The 
electrostatic packaging approach also protects the nucleic acids by providing resistance to 
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nucleases present in vivo. However, the cationic nature of these polymers also predisposes 
them to indiscrimate cellular uptake, instability due to competing interactions with charged 
serum or extracellular matrix proteins, and cytotoxicity. All of these are significant barriers 
to clinical use of polycations, and as a result, recent developments have been aimed at 
overcoming these shortcomings. For example, for the “gold standard” polycation PEI, 
cytotoxicity and serum instability can both be improved simply by using lower molecular 
weight PEIs (5–48 kDa) [195–197]. Alternatively, partial modification of PEI amines with 
other molecules, such as poly(ethylene glycol), imidazole, peptides, or receptor-targeting 
moieties has also been shown to reduce nonspecific cellular uptake and cytotoxicity [198– 
202]. Polymer biodegradability can also be a significant advantage as exemplified by PBAE 
carriers, which decompose into cytocompatible, low molecular weight degradation products 
and are significantly less toxic than PEI and poly(L-lysine) [203, 204]. A representative list 
of cationic polymer-mediated siRNA delivery applications is given in Table 3. 
 
Drugs designed for intravenous delivery must be equipped to navigate a complex variety of 
potential interactions with erythrocytes, serum proteins in the blood, and extracellular matrix 
proteins in the target tissue prior to cell uptake. For example, opsonization with serum 
proteins can “mark” drug carriers for removal from the body through the reticuloendothelial 
system, and anionic matrix proteins such as glycosaminoglycans can destroy the integrity of 
electrostatic polyplexes [84, 85, 205]. PEGylation is the primary method used to increase 
longevity in the circulation and make drugs more inert in order to minimize nonspecific cell 
uptake, drug aggregation, immunogenicity, and toxicity [206–211]. PEGylation is well- 
accepted to increase in vivo blood circulation half-life [212], but it can also reduce 
therapeutic efficacy by interfering with cellular uptake and endosomal escape [209]. For 
example, Hatakeyama and coworkers found gene silencing achievable using a lipid-based 
nano-device carrying interfering RNA to vary from 70% to 5%, with level of knockdown 
activity being inversely proportional to amount of PEGylation [213]. This observation 
suggests that the degree of PEGylation and PEG chain lengths should be optimized to 
balance inhibition of undesirable drug interactions with maintenance of bioactivity. For 
example, Gao et al. tested a series of liposomes with varied degrees of PEGylation for 
siRNA delivery, and liposomes containing 2.5% PEG showed the best HER1 gene silencing 
activity [214]. Other studies have indicated that a degree of substitution in the range of 10 to 
30 using a PEG chain length of 2000 Da to be the most effective approach to stealth 
liposome formulation [202]. Wang and authors demonstrated PEGylated nanoparticles to 
reduce cytotoxicity relative to traditional formulations with PEI or cationic liposomes, 
although this was at the expense of significantly reduced cellular uptake. However, the loss 
of uptake could be compensated for by inclusion of the targeting peptide Bombesin, and this 
also enabled better cell-type specificity by limiting internalization of the carrier to 
receptormediated uptake [211]. In another study, Huang et al. recently found that the 
“shedability” of PEG from the surface of liposomes played an important role in improving 
tumor biodistribution and activity. In these studies, an unprecedented 70–80% of the 
injected drug dose accumulated within xenograft tumors, and effective silencing of 
oncogenes was achieved at impressively low (i.e., <1mg/kg) siRNA doses [208, 215, 216]. 
Finally, another means to minimize negative effects of PEGylation is to incorporate 
cleavable peptide linkages between the base carrier and the PEG chains such that the PEG 
layer is cleaved off by enzyme (i.e., matrix metalloproteinase (MMP)) activity present in the 
target tissue [213]. Ultimately, PEGylation provides a method to increase systemic half-life 
and avoid non-specific interactions with blood components, but targeting molecules 
enabling receptor-mediated uptake or removal of the PEG chains may be necessary for 
optimal therapeutic activity. 
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Ligands or antibodies specific to internalized extracellular receptors that are expressed 
specifically on targeted cell types can be used to achieve drug selectivity in the body. For 
example, the peptide (EPPT), which targets the tumor-specific, underglycosylated MUC-1 
(uMUC-1) antigen, has been used to deliver siRNA to HBV cells [161]. Other examples 
include anisamide, a ligand of sigma receptor that is overexpressed in many human 
malignant tumor cells [162] and folic acid (FA), a ligand whose receptor is highly expressed 
in many epithelial cancers [217–219]. Another common cancer cell target is the transferrin 
receptor (TrfR), a glycoprotein involved in iron homeostasis and cell growth that is 
overexpressed on numerous tumor cells [220]. In fact, the amount of transferrin receptors on 
malignant cells has been shown to be as much as 100-fold greater than on normal cells [221, 
222]. As a result, transferrin [223–225] and TrfR antibodies [226–228] have been used in a 
number of targeted drug delivery applications. These examples provide a sampling of the 
receptor-mediated targeting used to enhance drug uptake by cancer cells. 
 
Many of the characteristics of idealized siRNA 
sequences were initially identified by Elbashir and authors. For example they discovered that 
duplexes made of 21 base pairs with 3’ overhangs 2 nucleotides in length are optimal, and 
they also determined that mismatches between the antisense siRNA and mRNA in the 
middle of the siRNA can abolish activity, while the 3’ nucleotide has little effect on gene 
silencing [64, 68, 229]. Reynolds and co-authors more recently completed a 
systematic, mass screening of siRNA sequences for 2 genes and identified low Guanine/ 
Cytidine content, a low internal stability at the 3’ end of the sense strand, and lack of 
inverted repeats as desirable siRNA characteristics in addition to uncovering sense strand 
base preferences at specific sites in the sequence [230]. Since the primary focus here is on 
the carriers utilized for siRNA delivery, the reader is referred to reviews by Aigner for a 
more thorough discussion on siRNA sequence optimization [231, 232]. One common 
approach to silencing a new gene is to acquire several siRNA sequences that satisfy these 
design criteria and that target different loci on the mRNA. The sequences can be either 
pooled together or screened individually to identify an optimal sequence for further study. 
Off-target gene silencing and nonspecific immune responses mediated through toll-like 
receptors can also be triggered by suboptimal siRNA sequences, and instances have 
occurred where nonspecific effects have been misinterpreted as siRNA-driven phenotype 
modification resulting from silencing of a target gene [233]. However, siRNA therapeutic 
potential remains strong as chemical modifications and new rules for sequence identification 
are progressing in-step with the iterative improvements in delivery approaches. In 
preclinical studies, testing for immune activation and verifying phenotypes independently 
using different siRNA sequences against the gene of interest are desirable standards of 
practice [234]. 
 
Generally, peptides have poor in vivo stability, cellular uptake, 
and overall pharmacokinetics, but recent synthetic advances have led to the development of 
peptidic therapeutics endowed with these properties. With this approach, peptide 
intracellular delivery barriers can be overcome through the physicochemical properties of 
the peptide therapeutic itself as opposed to gaining these functionalities through conjugation 
to a peptide/polymer or loading into a liposome or nanoparticle. The modification of peptide 
therapeutics to improve stability and potency was initiated by the advent of retroinverso 
peptides, or peptides in which each naturally occurring L-amino acid is replaced with the D- 
enantiomer and the peptide bonds are reversed [235]. In addition to retroinverso peptides, 
chemical cross-linking has also been used to stabilize secondary structure of peptides, and 
this method of stabilizing peptides containing α-helices increases stability of the secondary 
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structure and peptide potency [236]. The crosslinking chemistry as well as the 
chemoselectivity of the reaction can significantly affect the pharmacological and structural 
properties of the peptide and continue to be optimized for various therapeutics [237]. 
Classical approaches to stabilization of α-helices make use of covalent bonding between the 
i and i+4 or i and i+7 side chain groups and are comprised of lactam, disulfide, or metal- 
mediated linkages [237–240]. 
 
Early peptide cross-linking approaches have since evolved into the development of stapled 
peptides, or peptides in which non-natural, olefin-conjugated amino acids are used to 
incorporate controllable cross-links. The link between olefin groups consists of an all 
hydrocarbon ‘staple’ between successive turns (i.e., i and i+4) of the α-helical structure and 
is formed through a ring-closing ruthenium-catalyzed olefin metathesis reaction [241–243]. 
Blackwell and Grubbs first described stapled peptides [244], and later, the Verdine 
laboratory further optimized the metathesis reaction and the overall stapled peptide design 
[243]. Use of an all hydrocarbon ‘staple’ can improve structural stability, potency, protease 
resistance, and even cell permeability [241]. The ability of stapled peptides to achieve 
cellular entry is hypothesized to be a consequence of their stabilized structure and has been 
shown to involve an energy-dependent endocytotic uptake mechanism [245]. Stapled 
peptides are evolving into an indispensable tool for the intracellular delivery of pro- 
apoptotic sequences, and significant clinical promise has been shown for the stapled 
peptides known as stabilized α-helix of BCL-2 domains, or SAHBs [241]. 
 
 
Cancer biologists have provided a relatively thorough understanding of the aberrantly 
expressed genes that grant cancerous cells their hallmark ability to evade apoptosis, possess 
self-sufficiency in growth signals, display high proliferative potential, promote 
angiogenesis, and metastatically invade other tissues [246]. RNAi has been pursued for a 
diversity of gene targets responsible for these traits, both those where silencing directly 
induces apoptosis and those that sensitize cells to secondary therapeutics. Initial RNAi 
applications in cancer therapy were primarily ODN approaches, and 21 example gene targets 
that have been pursued with antisense directed at inducing apoptosis in breast cancer were 
reviewed in a 2002 report [247]. However, due to the subsequent elucidation of the 
enzymatic mechanism and higher potency of double-stranded siRNA, the field has 
predominantly shifted from ODN toward siRNA approaches for cancer therapies [65]. The 
more recent approaches have utilized siRNA to manipulate targets in the Bcl-2 family and 
IAPs, in addition to other targets related to cell signaling, viral oncogenes, cell cycle, 
metabolism, and nutrient transport [248]. Robustly testing for therapeutic effects mediated 
by siRNA is contingent upon successful siRNA intracellular delivery and target gene 
silencing. Supplementary Materials Table 1 surveys a sampling of published siRNA delivery 
approaches and the relative level of gene knockdown that has been achieved using different 
transfection techniques. Herein, we specifically highlight siRNA applications in pro- 
apoptotic therapies, and because clinical utilization of siRNA is the ultimate goal, we 
attempt to differentiate between reports where apoptosis-related targets where tested in vitro 
(Table 4) versus the more translational studies done in vivo (Table 5). 
 
The most direct and aggressively pursued pro-apoptotic RNAi method has been silencing of 
Bcl-2-like proteins Bcl-2 and Bcl-xl [249]. Knockdown of these Bcl-2-like subfamily 
members allows the indirect activation and homo-oligomerization of Bax/Bak, the critical 
pro-apoptotic triggers of the mitochondrial apoptosis pathway (see Fig. 1). RNAi of Bcl-2 
has been proven to increase apoptosis and arrest growth of HeLa and several other cancer 
cell lines, and the apoptotic effect can be amplified with co-delivery of chemotherapeutics 
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[250, 251]. Poeck et al. introduced 5’-triphosphate modifications onto Bcl-2 siRNA, with 
the triphosphate chemistry being incorporated to activate Retinoic acid-inducible gene 1 
(RIG-1) in innate immune cells. This triggered interferon expression, creating an immune 
response that acted synergistically with Bcl-2 silencing, and the combined effects produced 
50% apoptosis of melanoma cells and a reduction in tumor size in mice [252]. Silencing of 
intracellular Bcl-2 has also been utilized to increase sensitivity to activators of the extrinsic 
apoptosis pathway (i.e., TRAIL) in melanomas, but Bcl-2 knockdown was found to be a less 
effective sensitizer relative to knockdown of the IAPs Survivin and XIAP [253]. 
 
 
 
Apoptotic resistance in various cancers can, in part, be attributed to the overexpression of 
specific IAPs. For example, Survivin and Livin are overexpressed in neuroblastoma, and c- 
IAP1 and c-IAP2 are overexpressed in epithelial malignancies [45, 254]. As a result, 
silencing of IAPs has also been pursued as a route to reduce cancer cell resistance to 
apoptosis [255]. Survivin is released from the mitochondria during apoptotic signaling to 
negatively regulate caspase activation [256], and its silencing in HeLa cells has been shown 
to induce apoptosis [257]. However, in other cell lines like human sarcoma, the apoptotic 
effect was limited to only 10% of the cells when no secondary treatment was applied [258]. 
In a more recent in vivo study, Survivin siRNA (4 mg/dose) complexed with DharmaFECT 
was injected intratumorally into mice twice per week over a 3 week period. This approach 
resulted in a 40% reduction in human lung adenocarcinoma tumor weights, and co-delivery 
of Survivin siRNA with cisplatin produced a stronger antitumor response than either drug 
alone [259]. Livin is a newly discovered IAP that inhibits caspases 3, 7, 9, and cytochrome 
c, making it a logical choice for pro-apoptotic RNAi therapy. Knockdown of Livin created 
an apoptotic effect in HeLa cells [257] but only limited response in other cell types. XIAP is 
another IAP that inhibits caspases 3, 7, and 9, and thus, it is also a viable target for RNAi- 
mediated apoptosis. Dan and co-authors found that approximately 80% apoptosis was 
induced when XIAP was inhibited in ovarian cancer cells [260]. Furthermore, in vivo 
transfection of XIAP siRNA using intratumoral injection and electrotransfection pulsing 
decreased tumor cell proliferation by 75% relative to control groups in a 50-day tumor study 
on MCF-7 breast cancer xenografts [261]. 
 
Normal cells regulate the transcription factor c-myc tightly, but in cancerous cells, mutations 
in c-myc deregulate its expression, triggering uncontrolled cellular proliferation [59]. In fact, 
mutation of c-myc is a hallmark of some cancers (i.e., Burkitt's lymphoma), and in some 
cases it is essential for cancer cell survival, making it a promising potential drug target 
[262]. For example, in vitro silencing of c-myc (80% knockdown) in MCF-7 cells has been 
found to reduce their growth rate both in vitro and in vivo (in cells transfected prior to their 
inoculation into the mouse), and a 40% induction of apoptosis was measured upon serum 
withdrawal in c-myc deficient cells versus only 6% in controls [263]. Systemic delivery of 
siRNA through electrostatic condensation onto protamine-functionalized targeting 
antibodies has been used for delivery of pooled siRNA sequences against c-myc, MDM2, 
and VEGF, which was shown to reduce the size of subcutaneous B16 melanoma tumors by 
more than 50% relative to control groups at a 9-day endpoint [264]. Huang and co-authors 
have thoroughly assessed c-myc knockdown in mouse models using lipid-based carriers, and 
they have found that c-myc silencing effectively induces apoptosis and reduces tumor 
growth [262, 265, 266]. 
 
Although c-myc has been a primary oncogene drug target, inhibition of other onconges has 
also been pursued therapeutically. HER2 is an example of an oncogene that is often 
dysregulated in many types of cancers and causes excessive cell growth. This oncogene is 
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particularly relevant in breast cancer, and siRNA targeting HER2 has been shown to arrest 
growth and trigger apoptosis in vitro in several cell types, including HER2-expressing 
MCF-7 breast cancer cells [267]. Polo-like kinase 1 (PLK-1) is another gene involved in 
regulation of cell cycle progression. Many cancer cells overexpress PLK-1, and it is 
hypothesized that this aberrant expression can cause excessive cell growth and inhibition of 
p53-induced activation of apoptosis [268]. PLK-1 overexpression promotes chromosome 
instability and overrides mitotic checkpoints leading to immature cell division [269]. 
Silencing the expression of PLK-1 in nasopharyngeal carcinoma (C666-1) cells with 
systemic delivery of siRNA has been found to result in significant apoptosis and decreased 
tumor growth [270]. In addition to nasopharyngeal carcinoma, dramatically increased 
apoptosis has been shown to result from PLK-1 siRNA silencing in breast cancer cells, 
HeLa cells, colon cancer cells, and lung cancer cells, with as high as 50% apoptotic 
induction reported in some cell lines [271]. Furthermore Benoit, Henry, and authors showed 
that an approximately 50% reduction of PLK-1 gene expression in NCI/ADR-RES and 
OVCAR8 ovarian cancer cells lines sensitized these cells to doxorubicin cytotoxicity [272]. 
This study, among others discussed below, achieved powerful, synergistic effects by co- 
delivering siRNA and small molecule chemotherapeutic drugs. 
 
Most of the studies discussed up to this point demonstrate the potential of siRNA to directly 
induce apoptosis through silencing of Bcl-2 proteins, IAPs, and oncogenes. However, many 
of these studies have indicated that application of siRNA alone is often not enough to create 
a robust pro-apoptotic effect, and, thus, multi-component approaches may be optimal. One 
common approach is to simultaneously deliver chemotherapeutics and RNAi agents 
designed to silence genes known to cause cancer chemoresistance [273]. This approach is 
especially relevant for cancer patients whose previously treated, residual tumors develop 
multidrug resistance (MDR). MDR is a genetic or acquired trait of cancer cells that exhibit 
resistance against multiple, structurally or mechanistically unrelated anticancer drugs. MDR 
cancer cells are characterized by poor uptake, increased excretion, and elevated metabolism 
of drugs (see Fig. 6). Drugs that are influenced by reduced uptake are mostly water soluble 
drugs that are internalized by routes similar to nutrients, and these include antifolate 
methotrexate, nucleotide analogues (5-fluorouracil and 8-azaguanine), and cisplatin [274, 
275]. Drug resistance caused by increased drug efflux from the cell affects drugs that are 
ejected through cell membrane transporters, and these drugs include anthracyclines 
(doxorubicin (Dox) and daunorubicin), vinca alkaloids (vinblastine and vincristine), RNA 
transcription inhibitor actinomycin-D, and the microtubule-stabilizing drug paclitaxel [276]. 
In many cases, MDR cells simultaneously acquire mechanisms that impede intracellular 
drug accumulation and also undergo oncogenic alterations that diminish their susceptibility 
to the drugs. 
 
The "classical" MDR phenotype results from decreased intracellular drug accumulation due 
to the drug efflux activity of the adenosine triphosphate binding cassette (ABC)-transporter 
MDR1/P-glycoprotein (MDR1/P-gp, ABCB1) encoded by the human MDR1 gene. 
Overexpression of P-gp frequently contributes to MDR phenotype because it transports a 
broad spectrum of drugs including Dox, vinblastine, and paclitaxel out of the cell. 
Development of P-gp inhibitors selectively targeting MDR cancer cells to decrease drug 
efflux may sensitize these cells to chemotherapy and improve patient outcomes [277]. To 
this end, more than a 10-fold decrease in the LC50 of amrubicinol was recently observed in 
an amrubicinol-resistant small-cell lung cancer cell line (PC-6/AMR-OH) treated with P-gp 
siRNA (~70% knockdown achieved) relative to controls with basal P-gp levels [278]. 
Another recent study tested P-gp silencing as an adjunct to Bortezomib, which is a selective 
inhibitor of the proteasomal pathway. Despite its potency in chemoresistant myeloma 
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patients, some patients become refractory to prolonged treatment [279, 280]. Rumpold et al. 
demonstrated that sensitivity to Bortezomib could be restored by knockdown of P-gp with 
siRNA [281]. In this study, siRNA silencing of P-gp was found to improve the EC50 of 
Bortezomib from 25 mg/mL to 4.5 mg/mL and the EC50 of MLN273 (another proteasomal 
inhibitor) from 253 ng/mL to 9.8 ng/mL in MDR myeloma cells. Minimizing the active 
dose, in addition to cell-specific targeting (if achievable), are of paramount importance in P- 
gp silencing approaches because P-gp serves as a vital cellular transport mechanism in 
normal cells, and its nonspecific inhibition can lead to negative side effects. 
 
Ral-interacting protein (RLIP76) is another multifunctional membrane transporter, involved 
in stress-defense and apoptosis resistance. RLIP76 transports glutathione-conjugate (GS-E) 
compounds, thus controlling the intracellular concentration of pro-apoptotic, oxidized lipid 
byproducts and also chemotherapeutic agents. Depletion or suppression of RLIP76 with 
antibodies or siRNA confers increased chemosensitivity (e.g., to 2–3 fold higher cell death 
from 4-hydroxynonenal in small cell lung cancer) [282–284]. Furthermore, recent studies 
have shown that inhibition or depletion of RLIP76 by antibodies, siRNA, or antisense can 
lead to drastic and sustained regression of lung, kidney, melanoma, colon, and prostate 
cancer xenografts with no observed recurrence of tumors and no evident toxicity [282, 285– 
289]. 
 
The oncogene c-Myc has also been proposed to contribute to MDR efflux pump expression 
[290, 291], and for this reason inhibition of c-Myc has been hypothesized to enhance tumor 
sensitivity to chemotherapeutics. Dox is known to be especially susceptible to MDR efflux 
pump activity [292], and Huang and authors have attempted to address this problem through 
co-delivery of Dox with siRNA against c-Myc. In this study, it was demonstrated that 
delivery of c-Myc siRNA to mice with MDR ovarian cancer xenografts down-regulated 
efflux pump expression and promoted nearly 2 times greater tumor uptake of Dox relative to 
controls not receiving c-Myc siRNA [162]. However, other evidence suggests that c-Myc 
knockdown and chemotherapy treatments may be more effective if done sequentially rather 
than simultaneously. For example, silencing of c-Myc in medulloblastoma cells was found 
to slow cell growth. However, c-Myc knockdown also decreased cell sensitivity to cisplatin, 
etoposide, and ionizing radiation and reduced apoptosis by 24–56%, presumably due to the 
key role c-Myc plays in apoptotic signaling in these cells [293]. 
 
Cyclin D1 proto-oncogene is another potentially relevant anticancer gene target because it is 
an important regulator of G1 to S-phase transition during cell division, and it also serves as a 
cofactor for several transcription factors. Cyclin D1 is overexpressed in many human 
pancreatic cancers, a cancer type with an especially poor patient prognosis due to 
shortcomings in early detection and the fact that pancreatic tumors are commonly resistant 
to chemotherapeutic agents [294, 295]. Thus, improvement of pancreatic cancer therapies is 
an area of significant clinical need, and siRNA knockdown of Cyclin D1 may have promise 
in this area. For example, siRNA silencing of Cyclin D1 in pancreatic tumor cells has been 
shown to enhance cisplatin- and fluoropyrimidine-mediated growth inhibition. In these 
studies, cisplatin- and fluoropyrimidine-mediated apoptosis was enhanced by approximately 
3-fold in Cyclin D1-overexpressing pancreatic tumor cells delivered Cyclin D1 siRNA 
relative to cells treated with a control siRNA [294]. Several studies have also demonstrated 
that the anti-apoptotic, tumorigenic activity of D-type cyclins (D1, D2, and D3) may be 
dependent on cooperative interaction with other growth promoting genes such as c-Myc and 
Ras [296, 297]. For example, co-expression of c-Myc and cyclin D3 promotes lymphoid cell 
resistance to dexamethasone-induced apoptosis, and overexpression of cyclin D1 inhibits 
drug-induced apoptosis in rat embryo fibroblasts ectopically expressing c-myc [298]. 
Furthermore, cyclin D1 positively correlates with high basal and cisplatin-induced activity 
of NF-κB, which contributes to chemoresistance and cell survival through inducing 
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expression of anti-apoptotic Bcl-2 family of proteins [299, 300]. Finally, a recent 
investigation by Biliran et al. revealed a relationship between c-Myc and cyclin D1 that 
affects cell apoptosis and drug sensitivity [301] (see Fig. 7). This exemplifies the complex 
interrelationships that occur between oncogenes during tumorigenesis and provides a 
number of viable gene targets whose silencing may act synergistically with other cancer 
therapies. 
 
In addition to serving as an adjunct to small molecule drugs, gene silencing has also been 
utilized to sensitize cancer cells to radiation therapy. For example, DNA-dependent protein 
kinase (DNA-PK) is hypothesized to make cells resistant to radiation therapy, and An and 
co-authors tested the effect of DNA-PK silencing in HeLa cells. The authors demonstrated a 
7-fold decrease in cancer cell number 6 days after a 2 Gy dose of irradiation in HeLa cells 
delivered siRNA targeting the catalytic motif of DNA-PK relative to control cells receiving 
irradiation only. Interestingly, the hypothesized mechanism for this effect was a concomitant 
repression (~80% decrease) of c-Myc expression in cells where DNA-PK was silenced 
[302]. Thus, the DNA-PK gene could be an attractive anticancer gene target for sensitization 
of cancer cells to radiation therapy whose inhibition may lead to co-repression of other 
harmful oncogenes. 
 
 
The intracellular delivery of peptides that mimic BH3-only protein activity is one of the 
most extensively studied amino acid-based pro-apoptotic strategies [125, 241, 242, 245, 
303–306]. Peptide therapeutics occupy a small but promising niche among other classes of 
pro-apoptotic anticancer drugs such as therapeutic antibodies and small molecule Bcl-2 
antagonists [307–309]. Among the pro-apoptotic peptide sequences derived from BH3 
domains, stapled BH3 peptides (SAHBs) may have the most ideal pharmacological 
properties because of their improved stability of the α-helical structure, protease resistance, 
cell permeability, and increased affinity to the multi-domain, BH3 binding “pockets” on 
Bcl-2-like proteins [245]. However, BH3 peptide mimics continue to be developed and 
screened in new formulations in an effort to optimize their therapeutic potential. The 
utilization of BH3 peptides has also stimulated the discovery of small molecule drugs, 
including ABT-737 and ABT-263, which have similar functionality to BH3-only peptides 
[303, 306, 310]. Peptide mimics of BH3-only proteins have been derived from several of the 
BH3-only proteins (i.e. Bim, Bid, Bad, Noxa, Puma, etc.) and also from the BH3 domains of 
Bak and Bax. Peptides derived from BH3 domains of different parent proteins have different 
specificities, and, clinically, this may be important for the design of cancer- or patient- 
specific therapeutic regimes. For example, Shangary and co-authors demonstrated that 
agents based on the Bax BH3 domain may be best aimed at cancers overexpressing Bcl-2, 
while peptides derived from the BH3 domain of Bad may be more useful for tumors 
overexpressing Bcl-xL [311]. Generally, BH3 peptides have shown promise as pro-apoptotic 
agents, and herein we will survey the results of tests where they have been delivered using 
electroporation, CPPs, stapled peptides, liposomes/nanoparticles, and pH-responsive smart 
polymers. 
 
Pro-apoptotic peptides derived from the BH3 domains of Bak and Bax have been tested with 
electroporation, and it was found that at 48 hours after peptide delivery, cell viability was 
reduced by 40% in prostate tumor cells [312]. BH3 peptides have also been conjugated with 
CPPs to improve intracellular delivery. For example, peptides derived from the Bak BH3 
domain have been fused with the CPP penetratin, and this approach resulted in ~80% 
decrease in HeLa cell viability relative to the unmodified BH3 peptide control [304]. 
Likewise, a truncated Bax-derived BH3 peptide fused with TAT (i.e. pTAT-p3Bax) 
chemosensitized NRP-154 prostate epithelial cells and enhanced induction of apoptosis by 
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thapsigargin (a non-competitive inhibitor of sarco-endoplasmic reticulum Ca2+ ATPase) 
[313]. 
 
In addition to the use of CPPs to enhance intracellular delivery of pro-apoptotic therapeutics, 
cell-specific targeting peptides/ligands can be utilized to achieve tumor selectivity. For 
example, Minko and authors delivered apoptotic BH3 peptide drugs targeted with the 
Luteinizing-hormone-releasing hormone (LHRH) peptide, a molecule whose receptor is 
overexpressed on numerous cancer cell types. In this study, the LHRH-BH3 peptide 
produced a significant loss in cell viability (peptide IC50 3.97 ± 0.33 ng/mL) in A2780 
human ovarian carcinoma cells, while no significant toxicity was caused by the BH3 peptide 
without the LHRH sequence [314]. CPP-conjugates have also been created that incorporate 
mechanisms for tissue-targeted delivery. In one example of this approach, the antineoplastic 
agent chlorambucil was conjugated to a chimeric peptide containing the cyclic, breast-tumor 
targeting peptide cCPGPEGAGC (PEGA) the CPP pVEC. In breast cancer MCF-7 cells, the 
IC50 for chlorambucil was 128 µM, while chlorambucil conjugated to the PEGA-pVEC had 
an approximately 4-fold lower IC50 of 30 µM [133]. In a prostate cancer application, Li et 
al. developed a novel fusion peptide (BSD352) that consisted of the CPP TAT, a sequence 
from the BH3-only protein Puma (TAT-BH3Puma), an anti-vascular endothelial growth 
factor peptide (SP5.2), and an anti-basic fibroblast growth factor peptide (DG2). It was 
found that the components of the fusion peptide acted synergistically to inhibit the growth of 
androgen-sensitive human prostate adenocarcinoma (LNCaP) xenograft tumors in a mouse 
model, and tumor volume was decreased from ~1500 mm3 to ~300 mm3 in treated mice 
relative to PBS controls. Mechanistically, the fusion peptide was found to elevate levels of 
Bax, enhance cytochrome c release, and induce caspase-9 cleavage to induce tumor cell 
apoptosis while simultaneously inhibiting angiogenesis and endothelial cell proliferation 
[315]. However, despite observing a dose-dependent, synergistic apoptotic effect in LNCaP 
cells, minimal levels of apoptosis were observed in PC3 and RWPE-1 cell lines. Finally, 
tissue specific delivery has also been sought using photochemical internalization. In this 
realm, Shamay et al. have tested a light-activated, caged CPP fused with a pro-apoptotic 
peptide (D)(KLAKLAK)2, a peptide that was designed by Ellerby and coworkers [316]. It 
was found that upon 10 minutes of light exposure, 80% of the therapeutic was internalized, 
producing a 90% loss of viability in PC3 prostate cancer cells [317]. 
 
Stapled peptides have also been used in several pro-apoptotic peptide delivery applications 
and have shown potential as potent in vivo therapeutics. Walensky et al. tested a BH3 
stapled peptide, or SAHB, derived from the BH3 domain of the BID protein in a murine 
RS4;11 leukemia xenograft model. Their results demonstrated that daily treatment with the 
stapled peptide significantly prolonged survival and, by day 5, regression of leukemia cells 
from the spleen and kidney was detectable, while leukemic expansion was apparent at these 
sites in the control group [245]. In another leukemia model, Moellering and authors used a 
stapled peptide termed SAHM1 to inhibit the NOTCH transcription factor in a murine model 
of T-cell acute lymphoblastic leukemia (T-ALL). It was found that daily treatment with the 
SAHM1 therapeutic resulted in dose-dependent tumor regression and a 5-fold increase in 
caspase 3/7 activities in treated cells [318]. Other preliminary studies that have not yet 
reached in vivo testing are exploring new SAHBs, and in one recent application, Stewart and 
authors reported promising in vitro results from a Mcl-1-derived SAHB Mcl-1 inhibitor 
[319]. 
 
Liposomes have also been employed as pro-apoptotic delivery vehicles with promising 
results in animal tumor models. Ko et al. reported that cationic liposomes loaded with pro- 
apoptotic peptide (D)(KLAKLAK)2 and Bcl-2 antisense oligodeoxynucleotide G3139 
inhibited B16(F10) melanoma tumor growth in a mouse model by over 50% (reduction in 
tumor size from ~1000 mm3 to <500 mm3) and that the inhibitory effects correlated with 
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increased caspase activity [154]. Additionally, Xu and authors studied the therapeutic 
efficacy of a liposomal carrier loaded with caspase-6 and anti-human epidermal growth 
factor receptor (HER2) antibody in both HER2 positive (i.e. SK-BR-3 human breast cancer 
and SKOV-3 human ovarian cancer) and HER2 negative (i.e HeLa human utero-cervical 
carcinoma and BT325 human glioma) cancer cell lines [307, 308]. Time-dependent cell 
death was observed in HER2 positive cells, whereas no significant effect was observed in 
HER2 negative cells. In a murine SK-BR-3 tumor xenograft model, liposomes loaded with 
the anti-HER2 antibody resulted in a >50% decrease in tumor growth and prolonged 
survival when compared to the liposome alone. In a parallel study, Wang and authors 
utilized the same antibody-loaded liposome approach to prolong survival and significantly 
inhibit tumor metastasis in a murine model of human osteosarcoma [308]. 
 
“Smart” pH-responsive polymers have also been investigated for the intracellular delivery of 
pro-apoptotic amino acid-based biologic drugs. For example, we have developed a 
multifunctional, endosomolytic polymer that enhanced delivery and pro-apoptotic effects of 
a CPP-BH3 peptide [79]. This delivery system is based on poly(N-(2- 
hydroxypropylmethacrylamide))-b-poly(propylacrylic acid-co-butyl methacrylate-co- 
dimethylaminoethyl methacrylate) (pHPMA-b-p(PAA-co-BMA-co-DMAEMA) containing 
a pyridyl disulfide polymer chain end functionality incorporated through a reversible 
addition fragmentation chain transfer (RAFT)-based synthetic procedure. This reversible 
pyridyl disulfide conjugation site was utilized so that the peptide could be released from its 
carrier in the reducing environment of the cytoplasm. The pHPMA block was designed to 
confer long circulation times, and the propylacrylic acid-containing pH-responsive 
terpolymer block was incorporated to mediate pH-activated endosomal escape. Peptide 
conjugates with pHPMA-b-p(PAA-co-BMA-co-DMAEMA increased HeLa cervical 
carcinoma cell apoptotic activity over free peptide and resulted in 50% tumor cell death in 
cultures after 6 h of treatment [79]. More recently, we have also utilized pH-responsive 
homopolymers of propylacrylic acid to deliver protein antigens for anticancer vaccines. In 
these studies, ovalbumin was incorporated as a model protein antigen to test the ability of 
these polymer-based vaccines to stimulate class I MHC presentation and antigen-specific 
cytotoxic T-cell activation. These activities require cytosolic delivery and processing of the 
antigen, which was augmented in this case using the endosomolytic polymer carrier. In an in 
vivo study using the EG.7-OVA mouse tumor protection model, PPAA ovalbumin 
conjugates produced a functionally significant prophylactic effect. PPAA-based protein 
vaccine delivery facilitated an 8-fold increase in antigen-specific CTL production and an 
approximately 3.5-fold increase in the length of tumor-free survival relative to mice 
delivered vehicle controls [185]. 
 
 
The discovery of new pro-apoptotic drug targets, the development of new delivery 
techniques for intracellularacting biologics, and the identification of novel cell-targeting 
strategies are providing researchers with the tools needed to produce more effective anti- 
cancer therapies. As demonstrated through numerous in vivo preclinical tests, delivery of 
pro-apoptotic siRNA, proteins, peptides, and antibodies is being optimized through 
continually evolving approaches to overcome delivery barriers. Among these approaches, 
stapled peptides and stealth liposomes have great potential, especially with respect to the 
improved stability and specificity of stapled peptides and the capability of recent liposome 
formulations to deliver as much as 80% of systemically injected payloads into a tumor. 
These promising technologies enable scientists to unlock a new universe of intracellular 
targets that are druggable by biomacromolecules. The optimal targets for these drugs tend to 
be dependent on the type of cancer, and future treatments may be tailored to patient-specific 
cancer phenotypes. While these approaches will potentially be utilized to develop new 
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stand-alone therapeutics, the most promise to this point has been demonstrated through 
synergistic combinations of biomacromolecular drugs and currently available 
chemotherapeutics. Thus, future trends may include further development and optimization 
of technologies that can successfully navigate the array of both extra- and intracellular 
barriers to achieve co-delivery of biologic and small molecule drugs. Rapid progress in both 
the fundamental understanding of apoptosis and in the engineering of improved delivery 
systems suggests that clinical successes utilizing intracellular-acting pro-apoptotic 
biomacromolecular drugs are forthcoming. 
 
 
Refer to Web version on PubMed Central for supplementary material. 
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STAT Signal tranducers and activators of transcription 
 
RNAi RNA interference 
shRNA Short-hairpin RNA 
siRNA Small interfering RNA 
uMUC-1 Underglycosylated MUC-1 
 
FA Folic acid 
 
TrfR Transferrin receptor 
 
CPP Cell penetrating peptides 
MAP Mitogen-activated protein 
MAPK14 p38 MAP kinase 
PCD Cystamine bisacrylamide-diaminohexane 
 
PCM Primary cardiomyocyte 
 
MEND Multifunctional envelope type nano device comprised of lipid/protein 
transduction domain peptide 
 
TUNEL TdT dUTP nick end labeling 
 
Dox Doxorubicin 
 
CDP Cyclodextrin-containing polycations 
 
AuNPs Au nanoparticles 
 
PAMAM Poly(amidoamine) 
 
EHCO N-(1-aminoethyl)iminobis[N-(oleicyl-cysteinyl-Histinyl-1-aminoethyl)propio 
namide 
 
PBAE Poly(B-amino esters) 
 
RGD Arg-Gly-Asp 
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MDR Multi drug resistance 
ROS Reactive oxygen species 
JNK c-Jun N-terminal kinase 
BN Bombesin 
StA Stearic acid 
 
RIG-1 Retinoic acid-inducible gene 1 
 
plk-1 Polo-like kinase 1 
 
RRM2 Ribonucletodide reductase 
 
ABC ATP-binding cassette 
 
DNA-PK DNA-dependent protein kinase 
 
RLIP76              RaI-interacting protein 
GS-E                  Glutathione-conjugate 
P-gp                    P-glycoprotein 
AMR Amrubicinol 
 
FDA Food and Drug Administration 
 
PTDs Protein transduction domains 
 
TAT Trans-activating transcriptional factor 
 
pVEC VE-cadherin derived peptide 
 
FAST Fusion-associated small transmembrane 
 
MAPs Model amphipathic peptides 
NLS Nuclear localization signal 
TPP Triphenylphosphonium 
MTS Mitochondrial targeting signal 
PSMA Poly(styrene-alt-maleic anhydride 
PPAA Poly(propylacryic acid) 
PEI Polyethylenimine 
 
PAMAM Poly(amidoamine 
 
SAHBs Stabilized α-helix of BCL-2 domains 
Bim Bcl-2-interacting mediator of cell death 
Bid BH3-interacting-domain death agonist 
Bad Bcl-2-associated death promoter 
Bmf Bcl-2-modifying factor 
 
Puma P53-upregulated modulator of apoptosis 
 
Bik Bcl-2-interacting killer 
 
Hrk Harakiri 
 
LHRH Leutinizing-hormone-releasing hormone 
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Figure 1. Schematic summarizing the cellular intrinsic and extrinsic apoptosis pathways The 
extrinsic pathway is activated by receptors such as Fas, DR4, and DR5 that, when bound 
by their ligands, associate with cytosolic adapter death domains, i.e., FADD and Daxx. The 
FADD complex eventually activates executioner caspases (−3 and −7) while (Fas-specific) 
Daxx leads to caspase-independent apoptosis mediated downstream through JNK. 
Osteoprotegerin, sFas, DcR1, DcR2, and DcR3 inhibit the ligation of apoptotic death 
receptors, and PEA-15 and c-FLIP are relevant inhibitors of caspase-8 activation via the 
FADD pathway. The activation of the intrinsic (or mitochondrial) pathway is predominantly 
controlled by the Bcl-2 family proteins. BH3 only members (i.e. Bim, Bad, Bid, Noxa, 
Puma) either activate Bak and Bax directly (direct activation model) or indirectly (indirect 
activation model) through inhibition of the anti-apoptotic Bcl-2-like proteins, i.e. Bcl-2, Bcl- 
XL, and Mcl-1. Activated Bak/Bax homo-oligomerize and form mitochondrial pores that 
release pro-apoptotic factors such as ATP, cytochrome c, Smac, and Omi into the cytosol. 
Cytochrome c, ATP, APAF-1, and activated caspase-9 form the apoptosome, which can 
activate executioner caspases (i.e., −3, and −7). Smac and Omi further promote apoptosis by 
preventing IAPs, which are caspase inhibitors. Schematic modified from [11, 19]. 
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Figure 2. Mechanisms of RNA Interference 
(A) ODN silencing is believed to be induced by sterically blocking translation through 
hybridization with mRNA and RNAse-H mediated degradation of both the ODN and mRNA 
(B) Proposed mechanisms for RNA interference by miRNA, shRNA, dsRNA, and siRNA. 
Endogenous miRNA, which is made transcriptionally, and exogenously delivered shRNA/ 
dsRNA must all be first processed into siRNA, double stranded RNA molecules around 20 
base pairs in size. Exogenous siRNA can also be delivered that circumvents the need for 
dicer processing. siRNA is loaded onto the RISC complex and mediates degradation of 
mRNA complementary to the antisense siRNA strand. For each type of therapeutic RNAi, 
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the exogenous RNA must reach the cytoplasm to interact with mRNA and other intracellular 
machinery required for gene silencing. 
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Figure 3. Model representation of BH3-only protein peptidomimetic cancer cell pro-apoptotic 
activity 
Numerous cancers overexpress anti-apoptotic Bcl-2-like proteins, and BH3 domain-derived 
peptides can be utilized to antagonize Bcl-2-like protein activity to indirectly activate Bak/ 
Bax and overcome apoptotic resistance. 
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Figure 4. Intracellular delivery barriers 
1) Upon entering systemic circulation, the drug formulation must protect the 
biomacromolecule from enzymatic degradation and serum protein destabilization and/or 
opsonization. 2) Drug circulation half-life needs to be long enough such that the drug 
persists in the vasculature until it accumulates (through specific targeting or nonspecifically 
thorough the enhanced permeation and retention effect) in the tumor tissue. 3) The drug 
must interact with the cell membrane to initiate internalization, which can result in uptake 
into an endosomal (or pinocytic) vesicle. 4) If no endosomal escape mechanism is present, 
the drug can be degraded in the lysosome, remain in the late endosome, or undergo 
trafficking for exocytosis. 5) If the drug is able to escape the endo-lysosomal pathway, it is 
released where it can diffuse to molecular targets in the cytoplasm. 6) If attached to a carrier 
or loaded within a nanoparticle such as a liposome, polyplex, etc., the drug may need to be 
released from this formulation to become bioavailable. 
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Figure 5. Chemical structures of example pH-responsive “smart” polymers used for intracellular 
drug delivery 
(a) Anionic polymers thought to become more hydrophobic and lipophilic in acidic 
environments. (b) Cationic amine-containing polymers believed to disrupt endo-lysosomes 
through the proton sponge mechanism. 
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Figure 6. Multidrug Resistance 
Examples of cellular characteristics that enable cancer cell multidrug resistance to 
chemotherapeutics include reduced uptake, increased metabolism, and increased efflux of 
the drugs. Chemotherapeutics affected are also summarized. 
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Figure 7. Relationships of some of the genes involved in MDR phenotype 
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Cell Penetrating Peptides 
 
Peptide (abbreviation) Sequence Sequence Origin Ref 
 
Penetratin (PEN, pAntp) RQIKIWFQNRRMKWKK Drosophila antennapedia homeodomain [118] 
 
Trans-activating 
transcriptional factor (TAT) 
 
GRKKRRQRRRPPQ Human Immunodeficiency Virus type I 
(HIV-1) 
 
[118] 
 
pVEC LLIILRRRIRKQAHAHSK Murine vascular endothelial cadherin [118] 
 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Galanin (neuropeptide) and mastoporan (toxic 
peptide in wasp venom) 
 
[118] 
YARA YARAAARQARA Optimized TAT transduction domain [320] 
WLR WLRRIKAWLRRIKAWLRRIK synthetic [320] 
 
VP22 MTSRRSVKSGPREVPRDEYEDLYYIPSSGMAS 
PDSPPDTSRRGALQTRSRQRGEVRFVQYDESD 
YALYGGSSSEDDEHPEVPRTRRPVSGAVLSGP 
GPARAPPPPAGSGGAGRTPTTAPRAPRTQRVA 
TKAPAAPAAETTRGRKSAQPESAALPDAPAST 
APTRSKTPAQGLARKLHFSTAPPNPDAPWTPR 
VAGFNKRVFCAAVGRLAAMHARMAAVQLW 
DMSRPRTDEDLNELLGITTIRVTVCEGKNLLQ 
RANELVNPDVVQDDAATATRGRSAASRPTER 
PRAPARSASRPRRPVE 
 
Herpes Simplex Virus type I (HSV-1) [321] 
 
SynB vector RGGRLYRRRFVVGR Protegerin-I analogue without cysteine 
residues 
 
[322] 
 
Diatos Peptide Vector 3 
(DPV3) 
 
Diatos Peptide Vector 6 
(DPV6) 
 
Diatos Peptide Vector 7 
(DPV7) 
 
Diatos Peptide Vector 7b 
(DPV7b) 
 
Diatos Peptide Vector 3/10 
(DPV3/10) 
 
Diatos Peptide Vector 10/6 
(DPV10/6) 
 
Diatos Peptide Vector 1047 
(DPV1047) 
 
Diatos Peptide Vector 10 
(DPV10) 
 
Diatos Peptide Vector 15 
(DPV15) 
 
Diatos Peptide Vector 
15b(DPV15b) 
 
RKKRRRESRKKRRRES                                              Superoxide dismutase                                            [117] 
GRPRESGKKRKRKRLKP                                           Platelet-derived growth factor (PDGF)                 [117] 
GKRKKKGKLGKKRDP                                               Epidermal-like growth factor                                 [117] 
GKRKKKGKLGKKRPRSR                                          Epidermal-like growth factor                                 [117] 
RKKRRRESRRARRSPRHL                                         Superoxide dismutase and intestinal mucin           [117] 
SRRARRSPRESGKKRKRKR                                      Intestinal mucin and PDGF                                   [117] 
VKRGLKLRHVRPRVTRMDV                                    Apolipoprotein B and anti-DNA antibody            [117] 
SRRARRSPRHLGSG                                                    Intestinal mucin                                                     [117] 
LRRERQSRLRRERQSR                                               Cationic antimicrobial protein 37 (CAP37)           [117] 
GAYDLRRRERQSRLRRRERQSR                              Cationic antimicrobial protein 37 (CAP37)           [117] 
R8                                                 RRRRRRRR                                                                   Oligoarginine (synthetic)                                       [114] 
R12                                               RRRRRRRRRRRR                                                        Oligoarginine (synthetic)                                       [120] 
IRQ                                              IRQRRRR                                                                       Oligoarginine derivative (synthetic)                      [323] 
 
basic fibroblast growth factor 
1 (HbFGF-1) 
 
basic fibroblast growth factor 
2 (HbFGF-2) 
 
NYKKPKL Nuclear localization sequence in HbFGF-1 [324] 
 
HFKDPKR Nuclear localization sequence in HbFGF-2 [324] 
 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV HIV Gp41-SV40 nuclear localization 
sequence 
 
[121] 
 
Sweet arrow peptide (SAP) VRLPPPVRLPPPVRLPPP Proline rich motif [121] 
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Peptide (abbreviation) Sequence Sequence Origin Ref 
 
hCT (9–32) LGTYTQDFNKTFPQTAIGVGAP Human calcitonin [121] 
 
Pep-1 KETWWETWWTEWSQPKKKRKV Trp-rich motif-SV40 nuclear localization 
sequence 
 
[121] 
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Fusogenic Peptides 
 
Peptide 
(abbreviation) 
 
Model amphipathic peptide 
(MAP) 
 
 
 
Sequence Sequence Origin Ref 
 
KALAKALAKALA Chimeric [121] 
 
GALA                                       WEAALAEALAEALAEHLAEALAEALEALAA       Model amphipathic peptide derivative                     [135] 
KALA                                       WEAKLAKALAKALAKHLAKALAKALKACEA     Model amphipathic peptide derivative                     [141] 
EALA                                        EALAEALAEALA                                                         Chimeric                                                                   [142] 
4(6)                                            Ac-LARLLARLLARLLRALLRALLRAL                    Synthetic amphipathic peptide                                 [143] 
Hel 11-7                                    KLLKLLLKLWKKLLKLLK                                        Synthetic amphipathic peptide                                 [143] 
INF7                                          GLFEAIEGFIENGWEGMIWDYG                               23 mer Hemagglutinin (HA-2) derivative                [137] 
JTS-1                                         GLFEALLELLESLWELLLEA                                     INF7 mimic                                                              [137] 
ppTG1                                       GLFKALLKLLKSLWKLLLKA                                   JTS-1 mimic                                                             [144] 
ppTG20                                     GLFRALLRLLRSLWRLLLRA                                    JTS-1 mimic                                                             [144] 
LAH4 Analogues                      KKALLALALHHLAHLALHLALALKK                     Histidine rich amphipathic peptide                          [145] 
β-amyloid (29–42)                    GAIIGLMVGGVVIA                                                     Transmembrane β-amyloid protein derivative         [146] 
 
Influenza HA-2 GLFGAIAGFIENGWEGMIDGWYG N-terminal sequence of influenza 
hemagglutinin subunit HA-2 
 
[140] 
Influenza derivative I                GLFQAIAGFIQNGYQGMIDGGGC                            Hemagglutinin (HA-2) mimic                                  [138] 
Influenza derivative II               GLFEAIAEFIEGGWEGLIEGCA                                  Hemagglutinin (HA-2) mimic                                  [139] 
Mellitin                                     GIGAVLKVLTTGLPALISWIKRKRQQ                      Peptide component of bee venom                            [148] 
Penetratin (PEN, pAntp)           RQIKIWFQNRRMKWKK                                            Drosophila antennapedia homeodomain                  [118] 
 
Trans-activating 
transcriptional factor (TAT) 
 
GRKKRRQRRRPPQ Human Immunodeficiency Virus type I 
(HIV-1) 
 
[118] 
 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Galanin (neuropeptide) and mastoporan (toxic 
peptide in wasp venom) 
 
[118] 
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Application of Cationic Polymeric Carriers to Facilitate Endosomal/Lysosomal Escape. 
 
Cationic Polymer Gene Cell Efficacy Ref 
Cationic polymeric nanoparticles 
PEI STAT3 B16 melanoma ~5% gene silencing (25 nM);~25% 
gene silencing and 13% cell death 
(50 nM). 
[325] 
PEI-StA STAT3 B16 melanoma ~53% gene silencing (25 
nM);~68% gene silencing and 40% 
cell death (50 nM). 
[325] 
PDMAEMA VEGF PC3 prostate cancer cell 68 % gene silencing (N/P = 2) 
97 % gene silencing (N/P = 4) 
[173] 
PDMAEMA-b-PDbB 
complex with PSMA 
Plk1 MDR Ovarian cancer cell >70% transfection, 50% gene 
silencing, and 5%–10% apoptosis 
[272] 
PEI-b-PEG-RGD Luciferase gene VEGF-R2 Neuroblastoma 
In vivo, mice 
90% gene silencing 
Tumor size barely increased (6 fold 
bigger for untreated and ~12 fold 
bigger for siRNA negative control 
[326] 
EHCO Luciferase CHO-d1EGFP 84% cellular uptake and 87% gene 
silencing 
[211] 
Biodegradable cationic polymeric nanoparticles 
PAMAM dendrimer 
complexed with PEG-b- 
P(PrMA-co-MAA 
Bcl-2 PC-3 prostate cancer cell 62% gene silencing (50 nM) [226] 
PAMAM dendrimer Hsp27 PC-3 prostate cancer cell 75% gene silencing (50 nM) and 
~45% cell apoptosis 
[327] 
PEO-b-PBAE MDR-1 SKOV3 human ovarian 
adenocarcinoma 
Effective gene silencing (100 nM) 
and 10 – 25% greater cell apoptosis 
induced in SKOV3 cells, <5% 
greater cell apoptosis induced in 
SKOV3 MDR cells 
[328] 
PBAE Luciferase gene Hepatoma, primary hepatocytes ~38%–75% gene inhibition and 
10%–20% cell apoptosis in 
hepatoma 
50%–70% gene inhibition in 
primary hepatocytes 
[204] 
PHPMA-MPPM 
TMC 
Luciferase gene H1299 lung cancer cells 30%–40% gene silencing 
(compared with 50% with 
PDMAEMA nanoparticle and 60% 
with lipofectamine) 
[329] 
 
EHCO: N-(1-aminoethyl)iminobis[N-(oleicyl-cysteinyl-histinyl-1-aminoethyl)propionamide; RGD: Arg-Gly-Asp; Hsp27: heat-shock protein 27; 
PHPMA-MPPM: poly((2-hydroxypropyl)methacrylamide 1-methyl-2-piperidine methanol); TMC: O-methyl-free N,N,N-trimethylated chitosan; 
PBME: Poly(β-amino esters); PDbB: butyl methacrylate; PSMA: poly(styrene-alt-maleic anhydride). Concentrations provided in the “Efficacy” 
column refer to siRNA. 
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In vitro Success at Inducing Apoptosis through siRNA Knockdown. 
 
Gene Target Delivery Method Cell line Effect Ref 
Anti-Apoptotic 
Bcl-2 siRNA vector 
Cationic Lipid 
Lipofectamine™ 
HeLa 
HeLa, Lung adenocarcinoma, hepatoma, 
ovarian carcinoma, ocular melanoma 
Melanoma, renal carcinoma 
Stopped growth 
Stopped growth 
25–35 % apoptosis 
[250] 
[251] 
[253] 
Bcl-xL X-tremeGENE kit™ PHK, HaCaT Growth inhibition and 
apoptosis 
[330] 
BAXi Oligofectamine® Prostate carcinoma 45% apoptotic cells [331] 
Survivin Oligofectamine® 
Plasmid 
Human sarcoma ovarian carcinoma, ocular 
melanoma 
Melanoma, renal carcinoma 
10% apoptosis 
45–70% apoptosis 
[258] [253] 
Livin siRNA vector 
pSUPER 
HeLa 
HeLa 
8% apoptotic cells 
4% apoptotic cells 
[257] 
[332] 
XIAP Lipofectamine™ Ovarian cancer 75% apoptosis [260] 
c-myc Lipofectamine™ MCF-7 50% apoptosis [267] 
Oncogenes 
HER2/neu Oligofectamine® SKBr3, MCF7/HER2 tumor cell lines 20–50% apoptosis [267] 
Viral E6 oncogene pSUPER HPV+ cervical carcinoma Massive apoptosis of 
susceptible cells 
[333] 
Lyn Kinase (oncoprotein) electroporation Chronic Myelogenous Leukemia 40% apoptosis [334] 
PLK1 Oligofectamine® 
Plasmid vector 
Breast cancer, HeLa, colon cancer, lung 
cancer 
HeLa, prostate cancer, human 
glioblastoma, dermal fibroblasts 
13–50% apoptosis 
<5% apoptosis 
[271] 
[335] 
Protein kinase B Lipofectamine™ Bone marrow cells, HEK 293 20% apoptosis [336] 
HDAC3 Oligofectamine® HeLa 15% apoptosis [337] 
B-RAF Thymidine A375 Colo829 WM-266-4 23–52% apoptosis [338] 
OPA1 Oligofectamine® HeLa NIH-OVCAR-3 38% apoptosis [339] 
m-bcr/abl siRNA vector K562 leukemic cell 7.5 fold increase in 
apoptosis 
[340] 
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In vivo Success at Inducing Apoptosis through siRNA Knockdown. 
 
Gene Target Method Cell line / Animal Model Effect Ref 
Anti-Apoptotic 
 
 
c-myc 
Anisamide-targeted 
nanoparticles 
Plasmid polymerase III 
promoter 
Protamine-antibody fusion 
protein 
Melanoma in mice 
MCF-7 in mice 
B16 melanoma in mice 
Tumor growth decreased by 75% 
relative to control 
Increased tumor latency 
Tumor growth decreased by 75% 
relative to control 
[262, 265, 266] 
[263] 
[264] 
Bcl2 In vivo-jetPEI™ Melanoma in mice 15–50% apoptosis, decrease in tumor 
growth 
[252] 
BAXi Superfect HT1080 and B16F10 in 
mice 
Reduces cancer metastasis [341] 
Survivin DharmaFect® A549/DDP in mice Tumor growth decreased by 40% 
relative to control 
[259] 
XIAP Lipofectamine™ MCF-7 cells in mice Tumor growth decreased by 75% 
relative to control 
[261] 
Oncogenes 
Coagulation 
tissue factor 
mTF 
Lipofectamine™ Ex vivo 
transfection 
B-16 cells in Female 
C57BL/6 mice 
Tumor growth did not vary 
significantly 
[342] 
PAR-1 Neutral liposomes (DOPC) A375SM human melanoma 
cell line 
Female athymic nude mice 
(NCr-nu) 
Tumor growth decreased by 75% 
relative to control, reduced invasion of 
cancer cells 
[343] 
HIF-1alpha shRNA – Lipofectamine™ 
shRNA-Tf-PEI 
A375 and A875 cells 
Nude mice 
A375 – 50% reduction in tumor size 
A875 – no effect 
[344] 
STAT3 Lipid-substituted PEI Murine B16.F10 cells 
Male C57Bl/6 mice 
Significant increase in caspase 3 
activity, tumor growth decreased by 
70% relative to control 
[325] 
S100A4 pS100A4-shRNA gastric cancer cell line, 
BGC823, nude mice 
Tumor growth decreased by 75% 
relative to control 
[345] 
WT1 Aerosol PEI B16 F10 mouse melanoma Tumor growth decreased by 80%, 
survival time increased 
[346] 
Plk1 In vivo jetPEI™ C666-1 cells in mice Increase to 50% multinuclear cells and 
decrease in tumor growth 
[270] 
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Abstract 
 
Phospholipid bilayers that constitute endo-lysosomal vesicles can pose a barrier to delivery of biologic drugs to intracellular targets. To overcome 
this barrier, a number of synthetic drug carriers have been engineered to actively disrupt the endosomal membrane and deliver cargo into 
the cytoplasm. Here, we describe the hemolysis assay, which can be used as rapid, high-throughput screen for the cytocompatibility and 
endosomolytic activity of intracellular drug delivery systems. 
 
In the hemolysis assay, human red blood cells and test materials are co-incubated in buffers at defined pHs that mimic extracellular, early 
endosomal, and late endo-lysosomal environments. Following a centrifugation step to pellet intact red blood cells, the amount of hemoglobin 
released into the medium is spectrophotometrically measured (405 nm for best dynamic range). The percent red blood cell disruption is then 
quantified relative to positive control samples lysed with a detergent. In this model system the erythrocyte membrane serves as a surrogate for 
the lipid bilayer membrane that enclose endo-lysosomal vesicles. The desired result is negligible hemolysis at physiologic pH (7.4) and robust 
hemolysis in the endo-lysosomal pH range from approximately pH 5-6.8. 
 
Video Link 
 
The video component of this article can be found at http://www.jove.com/video/50166/ 
 
Introduction 
 
Although there are many potential high-impact therapeutic targets inside the cell, the intracellular delivery of agents poses a significant 
challenge. Frequently, drugs, especially biologics, are internalized by cells and trafficked into vesicles that either lead to degradation of their 
contents through the endo-lysosomal pathway, or are shuttled back out of the cell via exocytosis.
1 
In the latter process, the internal pH of the 
vesicles is acidified to approximately 5-6, which is the optimal pH for activity of enzymes that function in this compartment, such as lysozyme.
2
 
 
Recently, a number of materials have been specifically engineered to leverage the acidification of endosomes to facilitate cytosolic delivery of 
their cargo. One example of this approach uses synthetic, polymer micelle nanoparticles whose core is zwitterionic and charge-neutral at 
physiologic pH (i.e. 7.4). However, at pH 6.0 - 6.5, the polymers become protonated and acquire a net positive charge that destabilizes the 
micelle core, and the exposed polymer segments interact with and disrupt the endosomal membrane. This activity has been shown to promote 
the endosomal escape of peptide and nucleic acid-based therapeutics, allowing them to access their cytosolic targets.
3,4 
Other examples of 
methods developed to mediate endosomal escape that disrupt the membrane barrier include 'fusogenic' peptides or proteins that can mediate 
membrane fusion or transient pore formation in the phospholipid bilayer.
5 
Homopolymers of anionic alkyl acrylic acids such as poly(propylacrylic 
acid) are another well-studied approach, and in these polymers, the protonation state of pendant carboxylic acid dictates transition into a 
hydrophobic, membrane-disruptive state in endo-lysosomal pH ranges.
6,7
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One useful model system for screening endosomolytic behavior is the ex vivo pH-dependent hemolysis assay.
8 
In this model system, the 
erythrocyte membrane serves as a surrogate for the lipid bilayer membrane that enclose endo-lysosomal vesicles. This generalizable model has 
been used by others to evaluate the endosomolytic behavior of cell-penetrating peptides and other polymeric gene delivery systems.
8-11 
In this 
experiment, human red blood cells and test materials are co-incubated in buffers at defined pHs that mimic extracellular (7.4), early endosomal 
(6.8), and late endo-lysosomal (< 6.8) environments. The amount of hemoglobin released during the incubation period is quantified as a measure 
of red blood cell lysis, which is normalized to the amount of hemoglobin released in positive control samples lysed with a detergent. 
 
From screening a small library of potentially endosomolytic test materials, one can infer that samples that produce no hemolysis at pH 7.4, but 
significantly elevated hemolysis at pH < 6.5, will be the most effective and cytocompatible candidates for cytosolic drug delivery. Materials that fit 
these criteria would be expected to remain inert and not indiscriminately destroy lipid bilayer membranes (i.e. that could cause cytotoxicity) until 
being exposed to a drop in the local pH following internalization into endo-lysosomal compartments. 
 
In this protocol, erythrocytes are isolated from a human donor and co-incubated at pH 5.6, 6.2, 6.8, or 7.4 with experimental endosomolytic drug 
delivery agents. Intact erythrocytes are pelleted, and the supernatants (containing hemoglobin released from lysed erythrocytes) are analyzed for 
the characteristic absorbance of hemoglobin via a plate reader (Figure 1). 
 
Protocol 
 
1. Preparation and Sterilization of Buffers and Test Agents 
 
1.   150 mM NaCl buffer: Dissolve 4.383 g NaCl crystals in 500 ml of nanopure water. 
2.   pH Buffers: Prepare phosphate buffers at pH 5.6, 6.2, 6.8, and 7.4 by mixing appropriate amounts of monobasic and dibasic sodium 
phosphate. If samples are to be tested at lower pH values (i.e. pH < 5.6) then a more appropriate buffer, such as citrate buffer, should be 
used. Buffer recipes are readily available, and an example reference has been provided here.
12
 
3.   Sterilize all buffers noted above through a bottle-top vacuum filtration apparatus and re-check buffer pH's. 
4.   20% Triton X-100 (positive control): Mix 20 ml pure Triton X-100 in 80 ml of nanopure water. Vortex vigorously and sonicate to dissolve. 
Leave at room temperature overnight before use. 
 
2. Preparation of Erythrocytes 
 
1.   Obtain 25 ml of blood from an anonymous human donor, drawn directly into K2-EDTA-coated Vacutainer tubes to prevent coagulation. 
 
NOTE: All procedures must be pre-approved by the appropriate Institutional Review Board (IRB), and venipuncture and blood collection must 
be performed by a trained phlebotomist in order to minimize the risk to the donor. Standard phlebotomy procedures have been published 
elsewhere.
13
 
 
2.   Centrifuge blood at 500 x g for 5 min, and mark levels of hematocrit (red, lower layer) and plasma (yellowish, upper layer) on tube. 
3.   Aspirate plasma gently via a micropipettor, add into bleach, and discard into biohazardous waste. 
4.   Fill hematocrit tube to marked line (original level of plasma) with 150 mM NaCl solution. Cap and invert a few times to gently mix. Centrifuge 
at 500 x g for 5 min. 
5.   Repeat step 2.3-2.4 to wash blood cells again. Then aspirate supernatant and replace with PBS at pH 7.4. Invert to mix. 
6.   Split blood evenly into four tubes, corresponding to each pH that will be tested. Label the tubes according to each pH to be tested (5.6, 6.2, 
6.8, 7.4). 
7.   Centrifuge blood tubes at 500 x g for 5 min. Mark levels on tubes, then aspirate supernatant. 
8.   Fill each tube to marked line with buffer of appropriate pH (as indicated in 2.6). 
9.   Label four 50 ml conical tubes (one per pH to test), and pipet 49 ml of PBS of appropriate pH into each conical tube. 
10. Add 1 ml of erythrocytes (same pH) into corresponding tube for a 1:50 dilution. Visually inspect the diluted blood, which should be turbid and 
will settle if left undisturbed. If no pellet forms, cells have lysed. 
 
3. Lysis Assay 96 Well Plate Setup and Quantification 
 
1.   Prepare stock solutions of all experimental drug delivery agents, at 20x the desired final concentration to be tested (Assay will take 10 μl of 
drug delivery agent + 190 μl diluted red blood cells, leading to a 1/20 dilution of the original drug delivery agent into the final test mixture). 
Stocks of 20, 100, and 800 μg/ml are suggested, resulting in final test concentrations of 1, 5, and 40 μg/ml, respectively. 
2.   Pipet 10 μl of each stock solution into V-bottom 96-well plates. For optimal results, load each sample in triplicate or quadruplicate. 
 
NOTE: For ease, it is recommended that a separate 96-well plate should be prepared for each pH to be tested, with each sample (at each 
concentration) loaded at n=3-4 per plate. 
 
3.   For positive control wells, add 10 μl of 20% Triton X-100. 
4.   For negative control wells, add 10 μl of phosphate buffer. Use buffer at the same pH to be tested. 
5.   Pipet 190 μl of diluted erythrocytes (see 2.10) to each well, making sure cell stock solution remains homogenous during transfer. Hint: Use 
multi-channel pipette to simplify this task. 
6.   Incubate plates at 37 °C for one hour (Optional: Use an orbital shaker or rocker). 
7.   Centrifuge plates for 5 min at 500 x g to pellet intact erythrocytes. Note: when removing the plate from the centrifuge and transporting it to the 
next step, handle with care and be certain not to disrupt the cell pellet. 
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8.   Using a multichannel pipet, transfer 100 μl of supernatant from each well into a clear, flat-bottomed 96-well plate. Note: if the cell pellet is 
accidentally disturbed for any sample(s), one can re-centrifuge the plate and then proceed with supernatant transfer. 
9.   Measure absorbance of supernatants with a plate reader. Note that a range of wavelengths can be used (400 - 541 nm). 
 
NOTE: Different plate readers may have different saturation points and sensitivities, so the choice of a wavelength for measurements depends 
on whether or not hemolysis data from experimental samples can be reliably normalized against maximum hemolysis as induced by detergent 
treatment. This requires accurate measurement of absorbance values of the positive control samples. 
 
10. Using Microsoft Excel or a similar data analysis software, find the average of the background absorbance readings from the negative control 
samples set up for each pH (step 3.4). Subtract this background absorbance value from all other samples that were measured at that pH. 
11. After background subtraction, find the average absorbance of the positive control detergent-treated samples (step 3.3). Then normalize all 
experimental data points to this mean absorbance value, which should represent 100% hemolysis. Finally, multiply each well value by 100% 
to calculate % hemolysis that occurred in each individual well relative to the detergent control. 
 
Representative Results 
 
Typically, the agents that exhibit ideal pH-dependent hemolytic behavior have the highest potential for cytosolic delivery of drugs, nucleic acids, or 
other bioactive molecules. This is exemplified by Agent #1 as portrayed in Figure 2, which exhibits minimal hemolysis at pH 7.4, but a sharp 
increase in hemolytic behavior at endosomal pH ranges (< 6.5). Some agents may exhibit significant levels of hemolytic behavior at physiological 
pH ranges (Agent #2 at 40 μg/ml; Figure 2), suggesting that these agents may not be hemocompatible and could potentially be cytotoxic at 
these concentrations. 
 
In most cases, hemolysis is also dose-dependent, as increasing concentrations of the test materials correspond with higher levels of hemolysis, 
especially at the lower pH ranges tested (5.6 - 6.2). 
 
 
 
Figure 1. Schematic Diagram of Red Blood Cell Hemolysis Assay. Human erythrocytes are isolated and incubated with experimental 
endosomolytic drug delivery agents in a series of buffers simulating the pH range from physiologic (7.4) to late endosomes/lysosomes (5.6). 
The optimal drug delivery agents will not disrupt the erythrocytes at physiologic pH but will exhibit robust hemolysis in more acidic conditions. To 
assess percent hemolysis, the release of hemoglobin into the surrounding medium is measured via absorbance on a plate reader. 
 
 
 
Figure 2. Representative Results of a Hemolysis Assay Demonstrating Behavior of Two Experimental Endosomolytic Agents. First, 
the average A450 of the vehicle (PBS) control was subtracted from the other samples tested at that pH. Afterward, experimental samples were 
normalized to the A450 of Triton X-100-treated erythrocyte samples and multiplied by 100%. Based on these control samples, the ability of 
experimental transfection agents to lyse erythrocytes can be calculated. Typically, ideal endosomolytic agents exhibit dose-dependent and 
pH-dependent hemolytic behavior. Ideal agents (such as Agent #1) exhibit minimal hemolysis at pH 7.4, but a sharp increase in hemolytic 
behavior at endosomal pH ranges (< 6.5). Some agents exhibit substantial hemolytic behavior at physiological pH ranges (Agent #2 at 40 μg/ml), 
suggesting that these agents may be cytotoxic at these concentrations. Error bars indicate standard deviation of 4 independent measurements. 
 
Discussion 
 
pH-responsive polymers or other agents designed for endosomolytic function can be rapidly and effectively screened based on lysis of red 
blood cells at pH values encountered in the endosome (Figure 1; pH 6.8 - early endosome, pH 6.2 - late endosome, pH 5.6 - lysosome).
14-17 
pH-dependent hemolysis has been used to screen the ability of carriers to mediate endosomal release of biomacromolecular therapeutics (e.g. 
peptides, siRNA, ODNs, proteins), and results of this assay can be predictive of performance as an intracellular drug delivery vehicle.
3,4,8,18,19
 
Thus, this assay represents an effective screen to gauge the ability of polymeric drug carriers to mediate intracellular drug delivery based on their 
pH-dependent membrane disruption. 
 
As noted in the procedure, hemolysis is detected through spectrophotometric measurement of the supernatants of red blood cells treated 
with experimental agents. Therefore, in addition to hemoglobin, it is likely to contain other erythrocyte-derived cytosolic components, including 
proteins and carbohydrates. While these other components may contribute a small amount of signal to the spectrophotometric measurement, 
100% hemolysis was calibrated to the erythrocyte lysate resulting from treatment with Triton X-100. Assuming all erythrocytes from the same 
donor contain similar levels of hemoglobin and other biomolecules, we can safely conclude that the 'contaminating' components will not 
contribute any artifacts to the hemolysis measurement, especially if the same blood sample is used for all tests. However, this highlights the 
possibility that, for any given blood donor, there are likely to be small day-to-day variations in blood composition and hematocrit, and therefore, 
internal control samples (steps 3.3-3.4, 3.10-3.11) should be analyzed for all experiments. 
 
One should also always closely examine the raw absorbance data. Though it cannot be appreciated in the normalized example data shown in 
Figure 2, detergents such as Triton X-100 effectively destabilize erythrocyte membranes regardless of pH, and one should expect to see very 
little sample to sample variability in positive controls. The absorbance spectrum of Triton X-100 does not include peaks in the 400-600 nm range 
recommended for this assay, and therefore, should not interfere with the normalization of experimental data.
20 
Furthermore, for negative control 
samples, one should not observe significant hemolysis after the 1 hr incubation in any of the buffers used (i.e. even the most acidic buffer does 
not typically generate hemolysis on this timeframe). Background readings on negative control samples should closely approximate background 
absorbance readings taken on the fresh buffers. 
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Ideally, researchers will employ complementary strategies to characterize their experimental drug delivery systems. The hemolysis assay is 
advantageous for initial endosomolytic agent screening on naturally-occurring biomembranes, but should be considered as only one of the 
many tools in the drug delivery researcher's armamentarium for testing cytosolic delivery agents. For example, one potential shortcoming 
of the hemolysis assay is that it utilizes the red blood cell membrane as a biological model for endosomal membranes. However, the make- 
up and lipid content of endosomal membranes varies by cell-type and may not be accurately recapitulated by the blood cell membrane.
1 
A 
variety of other, complementary assays have been developed to mimic endosomal membrane composition and behavior.
21,22 
One alternative 
to is to utilize liposomes containing fluorescence resonance energy transfer (FRET)-quenched fluorophores, which become unquenched 
following destabilization of the liposomes and release of the fluorophores to the surrounding media. In studies that employ this method, 
the quantification of unquenched fluorophores has been found to correlate with the ability of a vehicle to mediate endosomal escape of its 
payload.
21,23 
Microscopy-based measurements can provide a more robust but lower-throughput method that is complementary to the hemolysis 
assay. For example, it is common to assess colocalization of the carrier or the drug itself with dye-labeled lysosomes (e.g. LysoTracker by Life 
Technologies), or the trafficking pathways can be characterized using pH-sensitive dyes conjugated the carrier or drug (e.g. pHrodo by Life 
Technologies).
24-26
 
 
Once an endosomolytic delivery system has been confirmed to achieve cytosolic cargo delivery, the hemolysis assay can also provide 
information on the mechanism through which endosomal escape occurs. For example, gene delivery vehicles based on polyethyleneimine (PEI) 
lack an inherent ability to disrupt phospholipid membranes at neutral or acidic pH's.
11,27 
Instead, PEI achieves cytosolic gene delivery through a 
'proton sponge' effect. After internalization, PEI buffers the endosome by "absorbing" protons that are pumped across the endosomal membrane 
to acidify these compartments. Eventually, this leads to buildup of excess protons and their counter-ions inside the endosome. This results in a 
rise in osmotic pressure, water influx, vesicle swelling, and endosomolysis. Therefore, the success of proton sponge effect necessitates the 
accumulation of a critical concentration of PEI into an endosome.
27 
Delivery vehicles that achieve endosomal disruption through the 'proton 
sponge' effect will not physically disrupt red blood cells or liposomes, and their efficacy in achieving intracellular drug delivery must be assessed 
through osmotic pressure calculations, or in vitro microscopy, or functional studies. 
 
In conclusion, the hemolysis assay described here is a reliable model for screening pharmaceutical agents designed for intracellular delivery of 
biologic drugs. This assay provides a high throughput means of drug delivery vehicle screening, enabling the rapid development of formulations 
that deliver biologics with intracellular targets. 
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Appendix D:  Scaling and systems biology for integrating multiple organs-on-a-chip 
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Scaling and systems biology for integrating multiple 
organs-on-a-chip 
 
John P. Wikswo,*abc  Erica L. Curtis,ab  Zachary E. Eagleton,ab  Brian C. Evans,ab 
Ayeeshik Kole,ab  Lucas H. Hofmeisterab  and William J. Matloffab 
 
Coupled systems of in vitro microfabricated organs-on-a-chip containing small populations of human cells 
are  being  developed  to  address  the  formidable   pharmacological  and  physiological  gaps  between 
monolayer cell cultures, animal models, and humans that severely limit the speed and efficiency of drug 
development. These gaps present challenges not only in tissue and microfluidic  engineering, but also in 
systems biology: how does one model, test, and learn about the communication  and control of biological 
systems with  individual  organs-on-chips that  are one-thousandth or one-millionth of the size of adult 
organs, or even smaller, i.e., organs for a milliHuman (mHu) or microHuman (µHu)? Allometric scaling that 
describes inter-species variation of organ size and properties provides some guidance, but given the desire 
to utilize these systems to extend and validate human pharmacokinetic  and pharmacodynamic (PK/PD) 
models  in  support of  drug  discovery and  development,  it  is more  appropriate  to  scale each organ 
functionally  to ensure that  it makes the suitable physiological contribution to the coupled system. The 
desire to recapitulate  the complex organ–organ  interactions that  result from  factors in the blood  and 
lymph places a severe constraint on the total circulating fluid (5 mL for a mHu and 5 µL for a µHu) and 
hence on the pumps, valves, and analytical instruments required  to maintain  and study these systems. 
Scaling arguments  also provide  guidance  on  the  design of  a universal cell-culture  medium,  typically 
without red blood cells. This review presents several examples of scaling arguments and discusses steps 
that should ensure the success of this endeavour. 
 
Introduction 
 
Organ-on-chip (OoC) microphysiological systems  (MPS) pro- 
grams  funded by a  variety  of  governmental agencies in  the 
United   States,   Europe,   and   Asia  are  developing individual 
organs-on-a-chip and,  more  important, coupling human-cell, 
multi-organ, organ-on-chip and  larger human organ  construct 
(HoC)  systems   for  drug   development  and   studies  of  drug 
toxicity and  efficacy. While  individual OoC technologies have 
advanced  considerably  in   the   past   decade,1–6    significant 
technical challenges must  be met  before  multiple organs  can 
be  integrated into  a single  system  of coupled  organs.1   Only 
limited reports describe coupled organs,2,3 and there  is not yet 
a full  understanding of how  biological  scaling  laws apply  to 
 
aVanderbilt Institute  for Integrative Biosystems Research and Education, Vanderbilt 
University, Nashville, TN 37235, USA. E-mail: john.wikswo@vanderbilt.edu;  Fax: +1 
615-322-4977; Tel: +1 615-343-4124 
bDepartment  of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, 
USA 
cDepartment  of Molecular Physiology & Biophysics and Department  of Physics & 
multiple, coupled OoCs. To replicate human physiology  and 
drug  response with  interconnected human OoCs/HoCs,  it  is 
critical   that   each   OoC/HoC   has   the   correct   relative   size. 
Extensive    literature   describes   differences   in   organ    size 
between  animal species  whose body mass,  Mb, spans 6 orders 
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in organs on chips. 
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Table 1 Allometric scaling coefficients and organ masses for a Hu, mHu, and mHu based upon primate data. Coefficients from Stahl, 196512 
 
Human milliHuman (mHu)  microHuman (mHu) Organ  mass  ratios 
 
 Body mass:  60 kg   60 g   60 mg  
Organ A B  M, g Organ/Body  M, g Organ/Body  M, mg Organ/Body  MmHu/MHu MmHu/MHu 
Liver 33.2 0.93  1496 2.5%  2.4 4.0%  3.9 6.6%  1.62E-03 2.63E-06 
Brain 85 0.66a  1268 2.1%  13 22%  139 232%  1.05E-02 1.10E-04 
Lungs 9.7 0.94  455 0.76%  0.69 1.2%  1.0 1.7%  1.51E-03 2.29E-06 
Heart 5.2 0.97  276 0.46%  0.34 0.57%  0.42 0.70%  1.23E-03 1.51E-06 
Kidneys 6.3 0.87  222 0.37%  0.54 0.91%  1.3 2.2%  2.45E-03 6.03E-06 
Pancreas 2.0 0.91  83 0.14%  0.15 0.26%  0.29 0.48%  1.86E-03 3.47E-06 
Spleen 1.5 0.85  49 0.081%  0.14 0.23%  0.39 0.64%  2.82E-03 7.94E-06 
Thyroid 0.15 1.12  15 0.025%  0.0064 0.01%  0.0028 0.0047%  4.37E-04 1.91E-07 
Adrenals 0.53 0.7  9.3 0.016%  0.07 0.12%  0.59 0.98%  7.94E-03 6.31E-05 
Pituitary 0.03   0.49 0.00081%  0.0044 0.0074%  0.040 0.067%  9.12E-03 8.32E-05 
a Coefficients for human brain  scaling:  80–90. The corresponding number for monkeys  is 20–30, and  great  apes  30–40. 
 
 
 
 
of magnitude from  shrew  to whale.  Organ  size does  not  scale 
proportionally (isometrically) with Mb, but  instead obeys a 
number of different allometric power  laws that  describe, for 
example,  how as the animal’s linear  dimension L increases, its 
mass  increases as L3, and  hence  the cross-sectional area of the 
bones  must  increase non-linearly.4 Metabolic  rates may exhibit 
Mb
3/4  scaling,5–8 pulmonary and vascular networks exhibit Mb 
1/4  11 
ii. Pros/cons. In  this  review, we follow a similar trajectory, 
beginning with  simple   allometric scaling  to  estimate organ 
size,  and  then   concluding that  the  requisite OoC and  HoC 
scaling  must   reflect  physiological activity  and  the  efficiency 
with  which  engineered tissues can  replicate human organ 
function in vivo. The power of allometric scaling is that there  is 
a rich literature to guide the OoC/HoC designer, as provided in 
the   Scaling   Spreadsheet  in   the   Electronic   Supplementary
 
scaling,9,10 and blood circulation time scales as Mb     . Table 1 
shows the coefficients A and B, derived from primates with body 
masses of 10 g to 100 kg,12  to compute organ  mass  M = AM B. 
When  multiple organs  are connected, their  relative  size could 
be normalized to mass,  surface  area,  volumetric flow, or other 
geometric measures. The challenge is to specify the appropriate 
scaling   law(s)  for   specific   applications,  whether  it   be   to 
construct a physically functional organ  (e.g., a pumping heart), 
a  pharmacodynamic model  (3D co-culture systems),  or  both 
simultaneously in a MPS. 
For convenience we select  three  scales  for our  discussion: 
Human (Hu), milliHuman (mHu), and microHuman (mHu); we 
assume an adult  Hu mass  of 70 kg and  hence  a mHu  mass  of 
70  g  and  a  mHu  mass   of  70  mg.  In  theory,  a  system  with 
multiple organs  could be designed to represent any fraction of 
a  human, possibly   a  nanoHuman (nHu).  In  this  paper   we 
discuss the  factors  that  guide  the  specification of the  size of 
each organ  in a coupled system. We hope that  this will provide 
guidance  to  the  ongoing   efforts   to  design   and   implement 
coupled organ  systems. 
 
Allometric  scaling 
 
i. Principle. Allometric  scaling  has  been  of great  academic 
interest, but  it is largely unexplored in the  design  of coupled 
microphysiological  systems.    As  reviewed   elsewhere,1    allo- 
metric   scaling   formed   the  early  foundation of  pharmacoki- 
netic  modeling of the  delivery and  activity of a drug  within  a 
human relative to experiments using  culture dishes and  small 
mammals, but  it has  been  supplanted by scaling  based  upon 
physiology  rather than simply  mass  or body surface  area.13–15 
Information  (ESI3).   As  we   will   show,   allometric  scaling 
provides    an   excellent    starting  point    for   specifying    and 
validating coupled OoC/HoC systems. 
However, this  scaling  may not produce valid parameters for 
mHu  and  mHu  systems.  The  most  notable observation from 
Table  1 is  that  the  large  human brain  size  (a = 85) and  its 
allometric scaling  exponent (b = 0.66) would produce a mBrain 
that  has  twice the  body  mass  of the  mHuman.  The nature of 
this  problem can  be  seen  in  Fig. 1. The  intersections of the 
allometric scaling  lines  for each  organ  with the  vertical  mHu 
and  mHu  lines  in  Fig. 1A indicate the  allometric mass  of the 
mHu  and  mHu  organ  in  Table  1. The  scaling  of each  organ 
relative  to  its  mass  for  a 1.0 Hu  is shown  in  Fig. 1B, which 
suggests that  allometric scaling  for  the  brain,  pituitary, and 
adrenals will produce larger  than average  organs,  while  that 
for the thyroid  will be smaller. Given its median position, one 
might  consider using  the pancreas scaling  as a starting point, 
with B = 0.91. 
There  would  be similar issues  were allometric scaling  used 
to set  the  heart  rates  and  blood  circulation times.  The heart 
rate of a mouse  is approximately one hundred times  that  of an 
adult  human,11 and  hence  one  would  not  want  to assemble a 
mHu   whose  organs   and   the  connecting  vasculature  would 
require perfusion at  rates  that  would  not  be  realistic   for  a 
human. Human cells might  not  function properly  or for long 
when  placed  in organs  sized to a mouse. 
Simple  scaling  will also  fail  for  other  reasons. A  working 
heart  cannot be less than one cardiomyocyte thick.  Key 
endothelial layers  must  be one  cell thick,  and  only one  cell, 
independent of organ  size. Certain  immune cells function at 
such  a low density  (3000 leukocytes  per  ml of cerebral  spinal 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3499 
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Fig. 1 How allometric scaling might (mis)inform mHu and mHu scaling when known power laws12  are used to extrapolate from humans. A) Organ mass in grams. B) 
The mass of each organ relative to that for a 1.0 Hu. Note the range in allometric slopes for different organs, and that a 106 reduction in body mass leads to only a 104 
reduction in the mass of the brain, pituitary, and adrenals, leading to a mBrain with twice the mass of the mHuman. 
 
 
fluid  (CSF)) that  the  breadth of  acquired immune response 
may not be replicable in a mBrain with a CSF volume of y1 mL 
that  would  contain about  3 leukocytes.  Cellular  heterogeneity 
should not  scale. 
 
Interconnected ‘‘histological  sections’’ 
 
i. Principle. Given that  cells in OoCs/HoCs  may not  operate 
with  the  same   efficiency  as  cells  in  vivo, it  may  be  more 
realistic  to construct an OoC/HoC system  that  reflects  a small 
fraction of an adult  human. Don Ingber  has  described this  as 
creating ‘‘living histological ‘sections’  of an adult  human’’ 
(personal communication). 
ii. Pros/cons. This approach is ideal for OoC/HoCs operated 
in isolation, in that  it effectively avoids the need  for scaling  by 
simply  observing a  small  portion of  an  organ.   The  rate  of 
perfusion can be determined by the number of cells being 
supported and  the  section  can  be  studied for  as  long  as  it 
survives. The first challenge occurs  if the media  is recirculated 
– what is the correct  volume for that  media?  The rate at which 
the  OoC/HoC  consumes nutrients, secretes  metabolites, and 
otherwise conditions that  media  is determined by this volume, 
and   to  overestimate  the  volume   might   lead  to  proportion 
delays in the appearance, for example,  of toxic metabolites, 
particularly if they have only limited lifetimes. It is necessary, 
however,  to make  the  ‘‘section’’ large enough and  sufficiently 
realistic   that  the  organ  functions in  a  more  physiologically 
realistic  manner than a simple  monolayer monoculture in  a 
Petri  dish  or well plate.  Building  a functional ‘‘section’’ from 
an  individual human’s cells may have  advantages over using 
real ones16 in that  it may be possible to create ‘‘sections’’ of an 
individual patient’s organs  that  are not  readily available. 
This  approach is  advantageous when  one  desires to 
recapitulate only a subset of an organ’s  function, for example, 
a  lung   alveolus   with  epithelial, endothelial, immune, and 
mechanical  interactions  but   without  requiring  gas   trans- 
fer,17,18   a  heart-on-a-chip  that   elucidates  drug   effects   on 
cardiac  electrophysiology or mechanical activity but doesn’t 
pump blood,19,20 or a gut-on-a-chip that  does not consider bile 
activity, nutrient and  water  uptake, or abluminal transport.21 
In this  case, the system  may scale linearly,  and  in effect one is 
creating a local system  with inputs, outputs, and  selected 
physiological controls.22 
However, the situation becomes more  complex  when two or 
more  ‘‘histological  sections’’  are coupled in series  or parallel. 
Correct  representation of organ-organ interactions is now 
determined by the size of each section  and the volume of their 
shared fluid. A scaling mismatch of the two organs  could make 
one  section  either  oblivious  of the  other  or dominated by it. 
Too large a fluid volume would delay or minimize organ-organ 
interactions.  Furthermore, a  small  histological section   may 
not be representative of the complexity of the organ  as a whole 
and  may be missing essential biological  features that  can alter 
biological  responses to stimuli. 
However, engineering all in vivo conditions artificially  would 
fundamentally eliminate the need to couple the organ systems, 
and the same  results could be achieved  by running each organ 
in its own microenvironment. This contradicts the purpose of 
coupling the  organ  systems  together, in  which  the  goal is to 
observe  the  most  physiologically accurate response and  intra- 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3500 
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organ  signaling to perturbations in the system  without a priori 
biases.  Hence  we need  functional scaling  of our ‘‘sections’’. 
 
Functional scaling 
 
i.  Principle. Given  the  shortcomings of  allometric scaling 
and  the uncertainties of how to scale coupled ‘‘histological 
sections’’,  it is worthwhile to examine  the obvious  alternative: 
functional or  physiological scaling  of  coupled organs.   With 
this  approach, one  identifies the  organ  functions that  are the 
most  important for the coupled system,  e.g., heart:  volume 
pumped; lung: gas exchanged; liver: metabolism; kidney: 
molecular filtering  and  transport; brain:  blood-brain barrier 
function and synapse  formation. The functional parameters to 
be achieved  for a particular implementation are specified, and 
then  the physical  milli- or micro-organ is sized, iteratively if 
necessary, to achieve the requisite functional activity given the 
constraints imposed by physical  architecture, materials, and 
available  cells. 
ii. Pros/cons. This is a rational approach to preserve  specific 
organ   functions  at   their   appropriate  relative   magnitudes, 
rather  than  relying   on   the   classical,   allometric approach. 
Given that  the  chosen functions should be quantifiable, this 
provides   a  straightforward approach  to  designing both   the 
device and  the functional readouts of a complete OoC system. 
One  limitation of  the  approach is  that  functional  scaling 
may   result   in   oversimplification  of   OoCs   and   limit   the 
translatability of the  results achieved.  Another  is that  it may 
not be possible to create an organ  that recapitulates more than 
one   organ   function.  Just   as   we  saw  in   Fig.  1,  different 
functions may  scale  differently  with  respect, for  example,  to 
surface-volume ratio.  One could  devise two-part  organs,  e.g., a 
heart  with  separate chambers for  recapitulating mechanical 
and  electrophysiological functions.19,20 
iii.  Example.  Fig. 2 shows  an  example  of a  coupled mHu 
HoC system  currently under development by a collaboration 
between   Los  Alamos  National  Laboratory,   Vanderbilt 
University,  the  University of California San Francisco, Charite´ 
Hospital Berlin, Harvard  University, and  the CFD Research 
Corporation.23  The  design  challenges are  to properly  size all 
organs  to provide  realistic  organ-organ interactions, including 
drug  metabolism, and  to do so with a low enough volume  of 
blood  surrogate that   the  autocrine and  paracrine signaling 
factors  released by each  organ  are  not  diluted to  below  the 
level of physiological effect for other  organs.  A working  heart 
and   a  functional  lung   are   desired.  Simple   scaling   would 
suggest  that  given  an  adult   blood  volume  of  y4.5  liters,  a 
mHu  and  a mHu  would  have  blood  volumes  of y4.5  ml and 
y4.5  ml,  respectively.  A  microfluidic cardiopulmonary assist 
system  might  be required as the system  is assembled and  the 
organs  grow and  stabilize, e.g., if the lungs  and  heart  have not 
yet achieved  their  needed level of gas exchange  and  pumping. 
Given that  every organ  in the body is not being  represented, it 
may be necessary to include a microformulator1,24,25 to add 
missing blood  components, as well as a means to neutralize 
ones that  are not removed  by a missing organ.  Finally, in 
recognition that complex biological  systems  tend  to oscillate,  a 
system   for   sensing  and   control22,26    will   be   required  to 
maintain organ   stability   and   simulate aspects   of  neurohu- 
 
 
 
 
Fig. 2 The mHu Advanced Tissue-engineered Human Ectypal Network Analyzer 
(ATHENA), a milliHuman (Homo chippus) being developed by Los Alamos 
National Lab, Vanderbilt University, Charite´ Universita¨tsmedizin Berlin, University 
of California–San  Francisco, Harvard University, and CFD Research Corporation 
with the support of the Defense Threat Reduction Agency (DTRA).23 Figure from 
Wikswo et al., 2013, with permission.1 
 
 
moral  physiological control  not explicitly included, thereby 
ensuring both   homeostasis and   the  requisite  physiological 
daily and  longer  biorhythms. 
 
 
Examples of organ scaling 
 
We now  present several  examples of  scaling  considerations 
that  might  apply  to the  creation of individual organs.  In the 
ESI3 Scaling Spreadsheet, we present an extensive compilation, 
with appropriate references from a vast and often inconsistent 
literature, of y250 anatomical and  functional parameters for 
the brain,  heart,  kidney, liver, lung, and blood that can be used 
to  guide  the  design,  modeling, and  validation of OoCs  and 
HoCs, using  either  allometric or functional scaling.  In the 
following paragraphs we provide a brief discussion of the 
importance of several  of the  parameters for each  organ. 
Our  examples  are  limited to  the  major   organs   that   are 
common therapeutic targets  and  do  not  include other 
significant tissues such  as adipose, bone,  endocrine, skeletal 
muscle, or  skin  tissues. When  attempting to  recapitulate  in 
vivo metabolic and  physiologic  demands of a coupled organ 
system,  one  must  consider that  these  tissues also  play a key 
role  in  metabolic demands and  biochemical signaling. As a 
result,  design  criteria  for OoC scaling  should take into 
consideration  the   presence,  absence,  and    simulation   of 
various  organs  when  scaling  certain physiologic  parameters. 
The  ESI3  Scaling   Spreadsheet  and   the   discussion  of  each 
example   below   should  provide   guidelines  for   a   rational 
approach to the  design  of integrated HoC/OoC systems. 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3501 
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Brain 
 
There  are a growing  number of reports on in vitro, flow-based 
models  of  the   neurovascular  unit   (NVU) and   blood-brain 
barrier (BBB),27–31  and  other  neural co-cultures.32–35 For this 
scaling   analysis,   we  choose   to  reduce   the   brain   from   its 
Functional scaling  of the  brain  is  largely  driven  by 
metabolism.  In  humans  the   brain   represents  20%  of  the 
overall   metabolic  load   and   2%  of  overall   body  mass.38,39 
Moreover,  the  relative  metabolic demand of the  brain  grows 
more  slowly than body  and  brain  mass  (allometric exponent 
40,41
 
extreme  structural and  functional complexity  and  focus  our 
0.873). The total  energy  consumption by the  brain  varies 
analysis  on  scaling  of the  NVU, which  is the  most  important 
linearly  with the  number of neurons in the  brain  at a rate  of 
functional unit  for ADMET (absorption, distribution, metabo- 
5.79 6 1029 mmol  glucose  min21 neuron 21.40 However,  it is 
lism,  and  excretion   toxicity)  studies and  functionally  repre- 
sents  the  BBB. The  NVU consists of a capillary  and  its 
surrounding cell types,  including endothelial cells,  pericytes, 
astrocytes, microglia, and  neurons. Correct  and,  importantly, 
feasible  scaling  of an NVU will require a unique combination 
of geometrical and  biochemical scaling. 
This is important because the brain  is particularly complex, 
and  the  literature is  riddled with  inconsistent  physiological 
data.  For example,  one  of the  most  common misconceptions 
of brain  physiology  is that  glial  cells  outnumber neurons by 
ten  to  one,  where  in  fact  the  ratio   for  neocortical  glia  to 
neurons is 1.2, and  the ratio of non-neuronal to neuronal cells 
ranges   from  0.2  to  1.5,  depending upon   the  brain   region. 
These  ratios  are of exquisite  importance when  constructing a 
brain-on-a-chip. 
Many of these  misconceptions arise from the difficulty of 
studying the  brain.  Brain tissue  is very diverse  across  species, 
and  therefore studying the physiological parameters of rodent 
or  other   brains will  not  give  an  accurate representation  of 
human physiology.  The best  understanding we can gain from 
non-human studies comes  from the primate brain.  The 
architectural  complexity   of  the   brain   also  complicates the 
analysis  of simple  parameters such  as  capillary  density  and 
cell numbers. Neurons can traverse  multiple brain  regions. 
Significant advances  have been  made  in this  regard  by 
Herculano-Houzel  et  al.,   with   their   isotropic  fractionator 
technique,36 and  improvements will continue to be made  with 
more  advanced analytical techniques such  as the  transparent 
brain  recently  developed  by Chung  et al.37 
As the  ESI3 Scaling  Spreadsheet indicates, gray matter and 
white matter may also contain different ratios  of cell types and 
orientations. These  parameters are  important for  scaling  in 
brain  region-specific ways. The task  of assembling these 
parameters is complicated because most  groups  studying the 
brain  make empirical measurements on a specific brain  region 
and  not  the  whole-brain scale.  In  addition,  metabolic para- 
meters such  as oxygen consumption are  difficult  to measure 
for   specific   brain   regions,  but   capillary   density   and   cell 
number distribution are  far  easier   to  measure for  isolated 
brain  regions. To further complicate gathering this  informa- 
tion,   many   of  these   parameters  had   to  be  assembled  by 
studying the  control  groups  from  manuscripts investigating a 
specific  disease  state.  Finally, it is unclear which of these 
parameters will be most  important for the end goal of creating 
and  integrating a brain-on-a-chip. Therefore, in the Scaling 
Spreadsheet  we   present  our   best   understanding  of   the 
necessary physiological parameters  and  their  sources  for the 
reader  to evaluate  and  employ  as necessary. We envision this 
table  of parameters as evolving alongside our  understanding 
of the  human brain  and  the  challenges of building HoCs. 
unclear if an in vitro brain-on-a-chip (BoC) can recapitulate the 
metabolic rate of the in vivo case. Therefore, we believe that  a 
mHu  and  mHu BoC, for example,  should be scaled  linearly  by 
the number of neurons in the adult  human brain,  and  the 
remaining components of the  brain  should be scaled  accord- 
ing to the metabolic demand of the number of neurons in the 
BoC. Autoregulation of the  BBB by all cellular  components of 
the  NVU also necessitates correct  scaling  of the  cell numbers 
in  the   BoC  and   capillary   surface   areas   in  relation  to  the 
metabolic demand of the  neurons which  they  support. 
According  to the  cellular  composition of the  cerebral  cortex, 
the NVU should consist of 1.2 astrocytes/neuron, 0.46 vascular 
cells/neuron, and  0.2 microglia/neuron.42 
The greatest challenge in geometrical scaling  of the brain  is 
realization of the capillary density  of the brain,  which has one 
of  the  largest  capillary  densities of  any  organ.  The  average 
human adult  has between  12 and  18 m2  of BBB, or 150 to 200 
cm2   g21   of  tissue.   The  necessity  of  providing neurons  with 
such   a  high   capillary   surface   area   per   neuron  (174  mm2 
neuron21)  will challenge fabrication techniques and  is most 
feasible  in microfluidic systems.42,43  In association with the 
vasculature, pericytes  cover around 30% (5 m2,  667 cm2   g21) 
and  astrocytes cover around 99% (18 m2,  200 cm2   g21) of the 
abluminal surface  of brain  microvasculature.44–46 
Scaling of blood  flow in a BoC relative  to other  OoCs could 
present significant challenges. The  human brain  has  a flow 
rate  of  7  L min21,  which  accounts for  13%  of  total  blood 
flow.47–50 This number should scale functionally with the size 
and   metabolism  of  the   BoC  in  order   to  supply   sufficient 
glucose,  oxygen, and  other  nutrients and  remove resulting 
metabolites.  Values  such   as  the  central   metabolic rate  for 
oxygen (CMRO2) of 3.2 mL/100 g min  should remain constant 
with  decreased  size  and   will  be  a  useful   readout  of  BoC 
success.47  Another  critical  factor  is maintenance of the  shear 
stress  at the endothelial barrier. Blood surrogate flow must  be 
supplied to  a  BoC with  a  sufficiently   small  capillary  cross- 
sectional area  to maintain a shear  of around 1.5 Pa without 
excessive volumetric flow rates.51–53  This value will also 
determine the pharmacokinetic parameters of the brain  by 
influencing the  residence time  and  Pe´clet number of the  BoC 
capillaries. 
In summary, the  scaling  of a BoC revolves around the  NVU 
and  is  focused  on  delivering   the  correct  metabolic demand 
relative to other  organs  and  the unique transport properties of 
the  BBB. As these  technologies develop  it will become  more 
clear  which  of these  scaling  laws are  critical  to success,  and 
also where scaling  can or must  be broken in favor of realistic 
implementation of these  technologies for routine studies. 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3502 
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Heart 
 
The  scaling  considerations that  apply  to the  development  of 
heart  tissue  revolve around tissue  architecture and  composi- 
tion,  electrical  conduction, biochemical factors,  metabolism, 
and  fluid flow. An important decision that  must  be addressed 
early in the development of an OoC/HoC heart  is whether it is 
to be a working  heart,  i.e., support the flow of blood  against a 
mechanical  load   (including  the   pulmonary  or   peripheral 
active   and   requires   sufficient  oxygenation.  Thus,   scaling 
cellular   metabolism is  another  concern, as  the  balance  of 
energy supply and demand is essential for maintaining cardiac 
pump  function. To  meet   this   demand, native  heart   tissue 
contains a dense, complex  network  of myocardial capillaries 
that  penetrate  orthogonally through  the  myocardium. 
However, recapitulating a complex  network  of small  diameter 
capillaries may  not  yet be  feasible  in  vitro,  although recent 
66,67
 
vasculature),54–58  or  serve  as  an  electromechanical  sensor of 
developments are promising. As a result,  the utilization of 
the effects of drugs  and  their  metabolites on cardiac 
performance.19,20 
The  cardiac   parameters  in  the   ESI3  Scaling  Spreadsheet 
support several of the major  cardiac  scaling  issues  we have 
discussed. For example, if a heart  construct is to be used as the 
fluidic pump that  provides  and supports circulation of a blood 
surrogate through  a  coupled  OoC  system,   then   functional 
parameters such  as transport capacity,  ejection  fraction, and 
fractional cell shortening become  scaling  issues  of paramount 
importance. The ESI3 Scaling Spreadsheet is constructed to 
circumvent the  need  to look up individual organ  parameters, 
which often  vary throughout the literature and  species  type. 
Furthermore, a  desired organ   size  can  be  used   to  quickly 
calculate approximate  parameter  values  for  an  organ   of  a 
certain  size   based    upon    both   allometric  and   functional 
scaling.  Thus  the  table  is a valuable  resource for quickly  and 
efficiently approximating functional and structural parameters 
for OoC design,  and  it also highlights a number of the scaling 
issues  that  must  be considered in terms  of design  criteria. 
Composition  and   biochemical  factors   are   of  significant 
import in  modeling mammalian heart  tissue,  which  is 
intrinsically heterogeneous, containing cardiomyocytes, fibro- 
blasts,  vascular  smooth muscle  cells, endothelial cells, and 
neuronal  cells   among    other    less   abundant   non-myocytic 
cells.59  These  cell types all interact through a variety of 
biochemical factors  and  signaling mechanisms to maintain 
cardiomyocyte phenotype and  tissue  function.60–65 In terms  of 
these   fundamental  signaling  pathways,   one   may  need   to 
consider exogenous   sources   of  biochemical factors  that  are 
scaled  to the targeted tissue  construct’s mass,  volume,  and 
composition. One must  also consider that the size of the organ 
construct will limit the ability to accurately  recreate features of 
the  mammalian heart  (e.g., if the  size of a heart  construct is 
limited to 1–2 cells thick,  as would  be required for a mHeart, 
then  the realization of an endocardium and  the incorporation 
of all native  cell types will not  be feasible,  whereas  this  might 
be possible with a 15-myocyte thick  mHeart). 
Tissue  architecture and  metabolism must  also  be  consid- 
ered.   The  specialized  cells  that   comprise  heart   tissue   are 
organized in a highly specific  structure that  results in a 
transendothelial  biochemical gradient that  forms  the  blood- 
heart  barrier. Furthermore, the fibers  in the  heart  are aligned 
in anisotropic, helically wound  layers that  impart unique, 
spatiotemporally dynamic biomechanical properties to  heart 
tissue.  This  issue  is of key importance when  considering the 
use of a scaffold  or substrate as a culture platform, since 
mismatched substrate and  tissue  properties can result  in a 
significant reduction in cardiac  pump function. In addition to 
its  complex   architecture,  heart   tissue   is  very  metabolically 
planar diffusion may suffice for now, as the reduced thickness 
of the  cultured myocardium of engineered heart  tissue  may 
allow for adequate oxygenation  without vascular  perfusion. 
Fluid  flow and  other  biomechanical stimulation of cardiac 
tissue  are  integral to a variety of the  heart’s  intrinsic control 
mechanisms.  Synchronized cardiomyocyte contraction results 
in complex  mechano-electrical feedback  mechanisms through 
the activation of stretch-activated channels and  modulation of 
cellular  calcium  handling, the endocardium responds to both 
fluid  shear  stresses and  pulsatile cyclical strain by releasing 
paracrine and  endocrine factors,  and  baroreceptors transduce 
sensory   feedback   into   various   forms   of  cellular   signaling. 
Under normal fluid shear  conditions, endothelial and vascular 
smooth muscle  cells have relatively  low rates  of proliferation, 
whereas  abnormal hemodynamic conditions result  in  patho- 
logical cellular  phenotypes that  are associated with a number 
of cardiovascular diseases.68  The proper  scaling  of biomecha- 
nical  properties in  conjunction with  fluid  dynamics is there- 
fore crucial to modeling both  normal and  pathological cardiac 
tissue.  In order  to achieve  physiologic  fluid  shear  stresses in 
miniaturized working   heart   constructs, one  must   appropri- 
ately  apply  volumetric and  resistance scaling  by modulating 
flow rates  and  blood  surrogate/media viscosity in accordance 
with  the   geometry   of  the   bioreactor  and   tissue   construct. 
These  scaling  issues  only gain  significance when  integrating 
heart-on-a-chip technologies into  multi-organoid constructs, 
especially  if the  heart  tissue  is to  be  responsible for cardiac 
output to  perfuse   the  entire   organ   network.   Here,  cardiac 
output (i.e., stroke  volume,  heart  rate,  ejection  fraction, etc.), 
tissue  size, metabolic and perfusion demands of other  tissues, 
total  peripheral resistance, and  resident blood  surrogate 
volume   are   all  variables   that   need   to  be  properly   scaled 
relative to each other.  However daunting it may be, the scaling 
of biological  variables  for the  integration of multiple human 
organ  constructs provides   a  basis  for  fabricating functional 
mHu  or mHu constructs that  would  streamline drug  develop- 
ment  and  discovery and  produce a more realistic  cellular 
microenvironment than monolayer monocultures in  Petri 
dishes or well plates. 
Overall, each of these  scaling  issues  merits  consideration in 
the design  of engineered heart  constructs, and optimization of 
heart-on-a-chip technologies, not  to  mention all  organ-on-a- 
chip  technologies, is  a  compromise between   verisimilitude 
and  a functional abstraction. 
 
Kidney 
 
Building  an in vitro kidney model  necessitates architectural, 
functional, and  biochemical scaling.  The nephron consists of 
three  structurally and  functionally distinct subunits – glomer- 
ular filtration, proximal  reabsorption and  secretion, and  urine 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3503 
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concentration–which must  scale individually as well as relative 
to one another in order  to preserve  whole organ  functionality. 
The   ESI3   Scaling   Spreadsheet   provides    examples and 
literature references for a range  of functional and  structural 
factors  that  need  to be considered in kidney scaling.  First and 
foremost, the kidney model  must  scale in order  to sufficiently 
filter the circulating volume of blood in the HoC construct and 
achieve  physiologically relevant  rates  of the  glomerular 
filtration. Second, the model  must  be manipulated to facilitate 
physiological rates  of  fractional reabsorption, a  challenging 
feat due to the wide discrepancies between  in vivo functionality 
and  in vitro performance. The kidney  also  provides  a unique 
example  of an organ  in which  the  preservation of geometrical 
features, such  as the  countercurrent mechanism and  exchan- 
ger,  is  critical  to  realizing  an  accurate model  of the  human 
kidney. 
Functional scaling begins in the glomerulus. The glomerular 
filtration rate (GFR) in a 70 kg human produces 125 mL min21 
of ultrafiltrate and  therefore 125 mL min21 in a functional 
milliHuman (mHu).39 The ratio of the surface area of the 
glomerular hemofilter to porous  surface  area can be optimized 
in  the  model  to  achieve  this  rate  of  filtration, given  that  a 
physical  filter will be different from  a biological  one. 
Recapitulation and  subsequent scaling  of the  specific 
transport,  metabolic,  endocrine,  and   immune  activities   of 
the renal  tubules pose formidable fabrication and  scaling 
challenges.69,70 A potential approach begins  with functional 
scaling   of  active  solute   reabsorption  rate   in  the   proximal 
tubule. For example,  a 70 kg human normally  filters  180 g per 
day  of  D-glucose,  almost   all  of  which  is  reabsorbed in  the 
proximal  tubule; therefore, a mHu  kidney  must  scale to filter 
and  subsequently reabsorb about  180 mg of glucose per day.71 
Because metabolic activity and  active transport abilities of the 
proximal  cells in vitro may differ significantly from in vivo 
quantities, preliminary in vitro studies must  be conducted to 
characterize the phenotype of human proximal  tubule cells in 
single  hollow  fibers.  From  these  results, we can  predict the 
number  of  cells  and   surface   area   required  for  functional 
scaling  of solute  reabsorption. Manipulation of geometric 
dimensions or the use of parallel  proximal  tubule modules can 
ensure that  the  proximal  tubule model  can  receive the 
appropriate volume  of ultrafiltrate from  the  glomerular unit. 
Although  the scaling  of the urine-concentrating mechanism 
must   encompass functional scaling   concepts, the  approach 
must  also pay particular attention to scaling  the  critical 
architecture of  the  loop  of  Henle.  Although   the  relation  of 
absolute loop  length  and  urine-concentrating ability  between 
species  is highly debated, the creation of the corticomedullary 
osmotic gradient is unequivocally linked  to active reabsorption 
of  Na+    as   well  as   the   complex   geometry   of  the   loop   of 
Henle.72,73   In  an  approach  similar to  that   of  the  proximal 
tubule model,  functional scaling  in the  loop  of Henle  can  be 
achieved  by scaling  the rate of Na+  reabsorption. Active 
reabsorption of  Na+   by  Na/K-ATPase pumps located   in  the 
thick  ascending limb  of  the  loop  of  Henle  (TAL) effectively 
drives  the  passive  H2O reabsorption in  the  descending limb. 
Additionally,  the Na/K-ATPase pump has  been  extensively 
characterized  and    is   tunable  with   a   variety   of   solutes, 
hormones, and  drugs,  and  therefore may serve as a point  of 
modulation for scaling  purposes.74  Successful  scaling  may be 
impossible without the  preservation of architectural features 
such  as the countercurrent mechanism and  exchanger. 
Computational modeling can  be used  to optimize the  length 
and  surface  area to volume ratios  needed to establish a 
physiologically relevant  osmotic gradient for a human, 300 to 
1200 mOsm  regardless of size.75  Additionally,  ‘‘precondition- 
ing’’ of long loops with short  loops, as seen in vivo in a ratio of 
85 short  to 15 long  in humans, may help  to maximize  urine- 
concentrating ability.73,76 
The kidney is an excellent example of a key OoC/HoC design 
concept:  while   functional  and    biochemical  scaling    may 
provide  the  best  approach to scaling  a histological section  of 
a  human,  some   organ   functionalities  cannot  be  achieved 
without reproduction and  scaling  of certain physiological 
architectures. 
 
Liver 
 
The ESI3 Scaling Spreadsheet provides  an overview of the 
available  allometric scaling  laws for the liver and  a basis  from 
which  we can  evaluate  parameters that  will scale  and  those 
that  will not.77 Intuitively,  we can  identify  certain parameters 
that  will not  scale.  For example,  cellular  parameters such  as 
sinusoidal endothelial cell (SEC) fenestration size will remain 
100–1000 nm  in  diameter.78  Additionally,  hepatocyte density 
(1.39 6 108  cells g21  liver), protein concentration (90 mg g21 
liver), and  liver density  (1.03 g liver mL21) are not  expected  to 
show appreciable scaling  in our milli/microliver.39,79 
There  are,  however,  central   design   parameters for  which 
there   are  allometric  scaling   laws,  but   from   which   we  can 
justifiably    deviate    for   functional  scaling.    For   functional 
scaling,  we argue  that  the hepatic mass  will not follow the 
allometric power  law and  instead represent 1/103   or 1/106   of 
what  is found  in a normal human. For example,  although an 
allometric  power   law  exists   for   oxygen   consumption,  we 
instead  use   functional  scaling   given   that   the   metabolic 
demand per  hepatocyte—approximately 0.3 to  0.9 nmol  s21/ 
106    cells—will  be  equivalent  in   our   scaled   OoC.80,81   The 
allometric value  for  oxygen  consumption in  the  mHu  (O2  = 
0.035 Mb
0.69,  with Mb in g, such  that  a 60 g mHu  would have a 
hepatic  oxygen  consumption of  0.59  ml  min21)  underesti- 
mates  consumption when  compared to  a functional propor- 
tion  of a normal human (2.06 ml min21).9  Note that  if oxygen 
transport through the blood  surrogate is insufficient, a system 
of hydrophobic hollow  fibers  could  be  used  to  increase the 
interstitial oxygen concentration without affecting  interstitial 
or blood volumes,  as has been done  quite  successfully  for liver 
HoCs.82,83 
In addition to proper  oxygen delivery, there  is also a need  to 
seed  the  appropriate number of cells with sufficient exposure 
to a blood  surrogate. In vivo hepatocytes sit adjacent to the 1.4 
mm   perisinusoidal  space   (i.e.,  the   space   of  Disse),   which 
separates the hepatocytes from the sinusoidal capillary that 
averages 10 mm in diameter and 275 mm in length. Appropriate 
concerns are  whether a longer  and  larger  in vitro model  of a 
hepatic sinusoid unit  via  hollow  fiber  (HF) bioreactors  will 
affect  nutrient delivery,  create   unwanted  oxygen  gradients, 
and/or add to necessary volume given the limitations of HF 
fabrication. Although  the number of hepatocytes needed for a 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3504 
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functional mHu  is calculated to be 3 6 108  cells, it is unclear if 
current  HF  technology  can   support  this.83–85   Neither   3-D, 
planar microfabricated, or hollow-fiber livers have yet achieved 
collection of bile,  generated by the  liver canaliculi, into  bile 
ducts. 
Validation  of the milli- and  microliver  models will primarily 
occur  via iterative  in vitro–in vivo correlation of xenobiotic 
clearance. Several groups  have conducted correlation studies, 
with  a  general   belief  that  each  drug  compound, unsurpris- 
ingly,  may  have  its  own  allometric power  law across  species 
(due to metabolic variations) and also a different scaling  factor 
(due to assumptions made  in their  model  such  as diffusional 
barriers).86–93  For  example,   Naritomi et  al.  found   that   they 
could  predict human in vivo clearance rates  of eight  model 
compounds from  human in  vitro  data  by  using   an  animal 
scaling  factor  (Clin   vivo/Clin   vitro)  from  either   a  rat  or  a  dog. 
Scaling factors were similar across species  for each of the eight 
compounds, but varied from 0.3 to 26.6-fold among  the 
compounds.89 
While this variation may prove to be troublesome in the 
analysis  of unknown compounds during drug  evaluation and 
discovery stages,  awareness of the  properly  scaled  input 
parameters and  thorough analysis  of a wide  range  of model 
compounds (e.g., acetaminophen, diazepam) will assist  in 
building predictive pharmacokinetic/pharmacodynamic (PK/ 
PD) models of the  OoC system. 
Lastly,  Boxenbaum notes  in  an  early  paper  on  allometric 
scaling  of clearance rates  that  these  models may not  prove to 
be accurate, particularly at  small  masses, as the  intercept  of 
the allometric equation predicts a non-zero  clearance rate at 0 
g.  This   collapse   of  allometric  theory   at   the   micro-   and 
milliscale gives  credence to  the  necessity  to  scale  based  on 
organ  function.22 
 
Lung 
 
Within   the  lung,  the  bronchial tree  and  the  alveoli  can  be 
scaled  separately. The main  structures in the lung  that  do not 
scale with system  size are the individual cell parameters, such 
as cell volume and  radius. While one might  not expect to scale 
the  percent distribution of cells, this  may be necessary if the 
efficiency of a particular cell type in a mHu or mHu differs from 
that  in a Hu. 
The ESI3 Scaling  Spreadsheet provides  a collection of both 
functional  and    structural  lung    variables.    Inconsistencies 
between  the  allometric exponents show a disconnect between 
structure and  function, illustrating a novel problem when 
constructing HoCs. As we have discussed, additional support 
systems,  such  as assistance from  a microformulator, may be 
necessary  to   ensure  the   most   accurate  structure/function 
mLung  construct incorporated onto  a HoC. A  robust table  of 
scaling   values  is  therefore  a  valuable   reference  tool  when 
making the inevitable compromises while designing a coupled 
OoC system. 
Allometric scaling  in the bronchial region  is found  in the 
diameters of the  trachea and  bronchioles. Allometrically,  the 
diameter of the terminal bronchiole scales with an exponent of 
0.21, while the radius of the trachea scales with an exponent of 
0.39. However, this presents a problem: allometrically scaled, a 
mHu  would  have  a  terminal bronchiole diameter of  30  mm, 
which is near the limit of current soft-lithographic micro- 
fabrication technology;  were hollow  fibers  used  for the  larger 
bronchial tubes,  with a minimum diameter of 200 mm, the 
microfluidic network  would  require approximately six binary 
splittings to  achieve  a 240 mm  diameter. Either  scaling  laws 
must  be broken or novel  fabrication techniques94  utilized  to 
accommodate   and    create    a   viable   mHu   trachea/bronchi 
system.9 
Allometric  scaling  in the alveoli is critical  as well. The most 
important function of the  alveolus  is oxygenation, so scaling 
should be addressed to meet oxygenation  needs, if required for 
the MPS. The critical parameter to be properly scaled is surface 
area,  as it is the  main  component of Fick’s law and  governs 
diffusion  capacity   across   the   alveolar-capillary barrier. 
Pulmonary diffusing capacity  (DLO2) scales  linearly  with body 
mass  with  an  exponent of y1.
95   
This  means that  the  DL02/ 
body   mass   ratio   is   relatively   constant  in   all   mammals. 
Diffusing   capacity  is  related   to  alveolar  surface   area,  mean 
barrier thickness, and  capillary  blood  volume,  and  the 
allometric  coefficients  are   0.95  for  surface   area,   0.05  for 
barrier thickness, and  about  1 for capillary  blood  volumes.95 
To replicate a mHu,  alveolar  diameter would  be  21 mm–an 
order  of magnitude less than the average 200 mm diameter of a 
human. The diameter of a type 1 epithelial cell is around 20 
mm.  Thus  any  individual mHu  alveolus  would  require only a 
single  epithelial cell,9,96  but  the  entirety  of alveolae  for a 0.1 
mHu might  well be modeled by a rectangular membrane of the 
appropriate area.17,18 
Another  scaling  argument that  should be considered is the 
mass-of-tissue to volume-of-media, in this case lung tissue 
volume  to blood  volume.  Blood  volume  is linearly  related  to 
body  mass   in  mammals  (allometric exponent  of  1).  Thus 
scaling  lung  tissue  surface  area  and  blood  substitute volume 
in  the  HoC depends on  the  total  mass  of the  system,  and  if 
both  are scaled  correctly then  oxygen concentration should be 
sufficient. If scaling  is ignored, problems could  arise with the 
surface   area   required  to  supply   the   blood   with   sufficient 
oxygen for metabolic needs.95 
A  mLung  would  have  184 000  cells  in  the  alveolar  region. 
Around  37%  of  those  (the  interstitial cells)  could  be 
eliminated, since only endothelial, type I and  II cells, and 
macrophages  are   needed  to   create   a  functional   alveolar- 
capillary unit.  The correct  percentage breakdown of cells is 
important to assure  sufficient paracrine factors  and  surfactant 
production.97–99 
The scaling  factor that  appears to present the greatest 
challenge  to  a  mLung  is  respiration  rate.   Were  we  to  use 
allometric scaling,  a mLung  would  have  to  inspire 643 times 
per minute to maintain proper  oxygenation. Due to the strain 
this  would put on a 1 mm thick  polymer  membrane, it is likely 
that   this   frequency   would   have   to  be   slowed   to  prevent 
rupture. As a result,  more surface  area would need  to be added 
or higher oxygen concentrations used  to compensate for the 
loss of rate  in order  to maintain a minute volume  of 0.17977 
mL   min21     consumption  of   oxygen.   This   highlights  the 
challenges of  scaling,   especially  into  the  micro-  and  nano- 
scales, where the limitations imposed by non-biological 
fabrication technologies prevent  meeting design  parameters 
without violating  scaling  laws,100  which  could  result  in a less 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3505 
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accurate abstraction. Hence  it is critical  to specify the desired 
lung  functions and  scale the  device to achieve  them. 
 
Blood 
 
A  universal media, or  blood  surrogate, for  HoCs  and  OoCs 
must  be able  to support each  cell type in addition to 
recapitulating the blood’s  critical  role in homeostasis through 
the  transport of dissolved gases,  carrier  proteins with  bound 
molecules, soluble  nutrients, metabolites, and  signaling 
molecules. Since blood  ‘‘maintenance’’ is dynamic but  tightly 
controlled by several organs  and  biochemical processes, 
development of a blood  surrogate is non-trivial. 
Allometric  scaling  of blood  components gives some  insight 
into how the surrogate should be constructed. The ESI3 Scaling 
Spreadsheet corroborates the scaling  issues  that  must  be 
considered in designing a blood surrogate. First, it can be seen 
that  the  concentrations of blood  remain virtually the  same  in 
organisms of all sizes: conveniently, the concentrations of a 
remarkably large  number of blood  components do  not  scale 
with  body  mass.101  This  means that  the  creation of a blood 
surrogate can  benefit from  the  large  body  of work  that  has 
been   completed on  creating cell  media. Second,   it  can  be 
noted  that  blood  volume  scales  linearly  with  mass;  thus,  the 
total  volume  of  the  blood  surrogate in  an  OoC/HoC  device 
should be proportional to the entire  size of the device. For all 
non-aquatic mammals, the blood volume is about  6–7% of the 
total body volume.100 Scaling the blood  surrogate volume with 
the  size  of  the  OoC/HoC  device  is  necessary to  ensure that 
signaling and  other  transported molecules are not  excessively 
diluted and  that  the total mass  of transported blood  surrogate 
components is enough to support the organs.  Third,  the 
spreadsheet shows  the  critical  functional parameters for 
ensuring that   the  cells  behave   in  a  physiological  manner. 
The epithelial cells in contact with  the  blood  surrogate must 
have the same  shear  stress  that  cells experience in the body to 
achieve  the  requisite polarization. In addition, the  cells must 
experience  the  same   levels  of  oxygen  and   carbon  dioxide, 
which  are  dictated by  the  gas  transport  capabilities of  the 
blood  surrogate, in order  to maintain the physiological 
metabolism of the  cells. The physical  properties of a number 
of different oxygen carriers  are also shown.  The spreadsheet is 
based  upon  the  scaling  of  a  complete system;  as  discussed 
above, it may be necessary to correct  for the hydrodynamic, 
metabolic,  and   chemical  activity   of  organs   that   are   not 
included in the  system. 
Hence,  little  should be changed in normal blood  to form  a 
blood  surrogate. However, there  are  other  scaling  issues  that 
must  be considered to ensure that  the  cells in the  mHu  and 
mHu behave  physiologically. 
First, the blood  surrogate must  recapitulate physiological 
oxygen transport properties. Experiments have shown  that  the 
rate  of oxygen delivery to the  cells affects  the  cells’ metabolic 
rate.102 There  are programmatic differences relative to the 
suitability of serum in an OoC/HoC system: the Defense Threat 
Reduction Agency (DTRA) program announcement23  precludes 
the  use  of  serum, whereas   the  Defense  Advanced  Research 
Projects   Agency  (DARPA) program103   does   not.   If  simple 
serum-free aqueous culture media  is used,  the  low concentra- 
tion  of  dissolved oxygen  in  the  media   may  limit  metabolic 
rates  and  affect capillary  surface-to-volume scaling.  Therefore, 
the  level of oxygen transport that  cells  experience in vivo as 
enabled by hemoglobin must  be functionally mimicked with 
the  blood   surrogate.  Were  erythrocytes   not  used,   perfluor- 
ocarbons and  hemoglobin-based oxygen carriers  may be very 
effective for achieving  this.104–106 If human or animal serum is 
not  utilized, appropriate  concentrations  of  carrier   proteins 
such  as albumin may be required to replicate organ-organ 
chemical communication. 
For  the  purpose of supporting HoCs,  the  blood  surrogate 
must  maintain multiple cell types while also optimizing 
physiological processes.  While  there   is  no  known  universal 
serum-free media, a number of different formulations of 
minimal media  can be used as a starting point  for the creation 
of a medium that  can support multiple cell types.107,108  To 
achieve  optimal cell functionality and  longevity,  supplements 
must  be added to this  minimal medium.109 
Although  a  number of effective  medium  formulations for 
the  growth  and  maintenance of multiple cell types have been 
developed, these  media  mixtures have not  been  widely tested 
for  interconnected HoCs.  For  OoC/HoC  systems,  this  repre- 
sents  a significant challenge due to differential scaling, 
simultaneous maintenance of multiple cell types, and  the 
recirculatory nature of HoCs. Logic dictates that  during flow- 
through of the  blood  surrogate within  a HoC,  some  compo- 
nents will be absorbed or metabolized, while others will be 
added to the blood  surrogate, with a negative  impact  on 
downstream HoCs. 
One  method that   has  been  successfully   used  to  create  a 
common blood  surrogate for a number of different cells in an 
OoC/HoC first involves combining the  established serum-free 
mediums  of  each   cell  type,   which   can   be   found   in   the 
literature, to create  a base medium. Next, various  other 
components, such   as  growth  factors   and   supplements,  are 
added to optimize for physiological functionality, based  on  a 
number  of  different  physiological measures.  Finally,  since 
some  of the  components of the  medium support one  type of 
cell but  hinder others, one  of several  different techniques is 
used  to ensure that  each  organ  receives  an  optimal subset of 
the   components  of  the   blood   surrogate.  Zhang   et  al.  108 
demonstrated this  method by creating a blood  surrogate that 
supported four  cultured cell  types:  liver  (C3A), lung  (A549), 
kidney  (HK-2), and  adipose (HPA). Another  option is to grow 
cells in isolated OoC/HoCs on their  preferred media, and  then 
gradually,  through controlled valves, wean  them  slowly from 
this  media  to the  universal one. 
In addition, some properties of blood and  related  structures 
that  exist physiologically cannot yet be replicated with  HoCs. 
For  example,  capillaries, which  have  relatively  constant  size 
across species,  are too small to be recreated at present, so care 
must be taken to design the HoCs such that the physical 
characteristics of the  blood  surrogate, such  as  flow, volume, 
and shear  stress,  match those found  in the tiny capillaries. It is 
imperative to match the  wall shear  stress  in  HoCs to that  of 
microvessels to  achieve  the  same  mechanotransduction and 
gene  expression  in  endothelial  cells  as  in  humans.52   This 
might  be addressed by self-organizing on-chip  microvascula- 
ture.66,67 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3506 
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Furthermore, it is important to understand PK/PD scaling  in 
order to add drugs  to the HoC/OoCs at proper  levels and to use 
the  HoC/OoCs to predict the  pharmacokinetics in humans.2,3 
 
Table 2 Heterogeneity of cell types in different  organs 
 
# of cell 
The classical  scaling  relationship for drug/signal dosing  is that Organ types, N Cell type  % 
the  body’s ability  to use  and  metabolize drugs/signals  varies 
with surface  area.110  But these  scaling  laws are critically 
dependent on the  biochemical mechanisms and  physical 
properties of the  organs.111  If the  organs  do not  functionally 
mimic   physiology,  they  could   fail  to  predict the  PK/PD  of 
humans. Differences  in drug  transport and  metabolism in the 
HoC can render typical allometric PK/PD scaling  useless. This 
can  be seen  clearly by the  fact that  PK/PD varies significantly 
between  infants and  adults.112 
Finally, the blood  surrogate will require supporting systems 
that  can provide  missing functionality required for blood 
surrogate and  organ  maintenance. As required, a microformu- 
lator108  can  provide  media  supplements specific  to each 
organ.108  The  microformulator could  be  used  to  locally add 
media  components to a particular organ.  A size-exclusion filter 
or  an   affinity   capture  chamber  or  matrix   (Donna   Webb, 
personal communication) could  be used  to remove  any toxic 
molecules produced  by  one  organ   before  they  reach   other 
organs.  Computer-controlled microformulators could  also 
provide the regulated injection of molecules that  cannot be 
maintained by the system  alone  and  those  from organs  not in 
the  HoC.24,113 
 
Cellular  heterogeneity 
 
In contrast to the  common monocultures and  occasional co- 
cultures used  in  much  of cellular  biology,  organs  present a 
 
Brain (neocortex)42 4 Glia 41% 
Neurons  33% 
Vascular  17% 
Microglia  8% 
Total  100% 
 
Heart59,60                               5                  Cardiomyocytes                     55% 
Fibroblasts  25% 
Vascular  smooth muscle       10% 
Endothelial  7.0% 
Neuronal 3.0% 
Total  100% 
 
Liver116                                       4                  Hepatocyte                            60% 
Sinusoidal endothelial          20% 
Kupffer  15% 
Hepatic  stellate                       5.0% 
Total  100% 
 
Lung (alveolar) 97  5 Endothelial  39% 
Interstitial  29% 
Type II epithelial  18% 
Type I epithelial  11% 
Alveolar macrophages  3% 
Total  100% 
 
Blood117 6 Erythrocytes  99% 
Neutrophils  0.50% 
Lymphocytes  0.30% 
Monocytes  0.050% 
Eosinophils  0.025% 
Basophils 0.007% 
Total  99.9% 
much richer cellular heterogeneity. Cellular heterogeneity is a    
key issue  to  consider when  applying  scaling   laws  to  OoCs, 
since  downscaling an  organ  may result  in  a reduction in  the 
number  of   cell   types   present.  Furthermore,  achieving    a 
complex co-culture  system that  preserves native cellular 
heterogeneity in  an  organ,  much  less  coupled organs,  is still 
far from  realization. As a result,  in addition to scaling  issues, 
the  choice  of cell types  used  to develop  an  OoC may also  be 
altered   in  order   to  focus  on  a  biological   response  that   is 
specific  to a certain cell population in  the  organ  of interest. 
Table  2 indicates the  relative  fractions of the  most  common 
cells in each of the organs  considered. In the ESI3, we present 
these  data  in  terms  of Shannon-Wiener Index  (SWI),114,115 a 
useful   method to  quantify   cellular   heterogeneity.  We  were 
unable to identify  from  the  literature a self-consistent set  of 
cell distributions for the kidney. One could also argue that  the 
erythrocytes  and  leukocytes  could  be treated separately. 
 
 
Engineering  challenges 
 
We have discussed a number of criteria  for scaling  mHu  and 
mHu   organs   as   required  to  design   and   validate   realistic, 
coupled HoC/OoC systems.  That said, there  are also a number 
of  engineering  challenges  that   must   be  met   before   it  is 
possible to construct a realistic  mHu  as shown  in Fig. 2 or a 
mHu  as  shown  schematically in  Fig. 3. These  challenges are 
cataloged in  detail  elsewhere,1  and  include determining the 
proper   size  of  each   organ,   fluidic   control   of  mL  and   mL 
volumes,  analytical chemistry in mL and nL volumes,  including 
comprehensive molecular characterization in real time,  main- 
taining and  controlling coupled organ  systems,  vascularizing 
organs  with appropriate surface-to-volume ratios,  developing a 
universal blood  surrogate, accounting for missing organs  and 
the  adjustment of blood  surrogate, modeling coupled organ 
systems,   characterization of  organ   health and  disease, and 
minimizing  organ   cost   to   enable   high-content  screening. 
Several  of  these   can  be  revisited   based   upon   our  detailed 
scaling  analysis. 
The  circulating volume  of perfusate of an  OoC/HoC  must 
match organ  size, lest  metabolites, hormones, and  paracrine 
signals  be diluted to the  point  that  each  organ  operates in  a 
large reservoir  independent of the other  organs,  thereby 
precluding accurate study  of the  desired organ-organ interac- 
tion so necessary for PK/PD,120  ADMET,121 and drug safety/ 
toxicity studies.122,123 The aforementioned y4.5 mL and  y4.5 
mL   blood   volumes   for  a  mHu   and   mHu  will  place   severe 
constraints on not only the fraction of an organ  bioreactor that 
must  be occupied by cells, but also limits  the size of in-system 
sensors and  the volume  that  can be withdrawn for analysis  of 
the  system’s  state  and  subsequent control  adjustments.  The 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3507 
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Fig. 3 A concept drawing of a four-organ mHu (Homo chippiens). A) An on-chip 
peristaltic ventricular assist, B) Right heart, C) Lung, D) Left heart, E) Liver 
(courtesy of Kapil Pant), F) Peripheral circulation118 (courtesy of Kapil Pant), G) 
Microchemical analyzer of metabolic activity.119  The system would operate on a 
single microfluidic chip, with on-chip pneumatic valves controlling system 
functions and connections. 
 
 
 
scaling   arguments  applied to  the  organs   also  apply  to  the 
instruments that  will analyze  their  performance. 
One   might    also   wonder   whether  the   ratio   of   cell-to- 
perfusate volumes   alone  precludes the  use  of  conventional 
well plate  cell culture in  creating properly  coupled HoC/OoC 
systems:  blood  and  interstitial fluid volumes  for organs  in vivo 
are  a small  fraction of the  volume  of the  organ  itself.  Well- 
plate  tissue  cultures without internal vascularization can 
seldom support tissues thicker than 100 to  300 mm  without 
necrosis, so the  height  of fluid  above such  tissues grown in a 
well plate would have to be a small fraction of the thickness of 
the cell layer to maintain the proper  tissue-fluid volume ratios. 
Because of surface  tension effects, it is difficult  to pipette fluid 
from   such   a   thin    layer   of   fluid   without  damaging  the 
underlying cells. This argues  for flow-based  HoC/OoC systems 
that   can  function  within   the   aforementioned  volume   con- 
straints.  The   capabilities  of  microfluidic  systems   will  be 
critical to produce compact organs  with both  appropriate 
temporal responses and  the  ability  to  produce and  react  to 
circulating cytokines,124–126  and  to work with small  quantities 
of rare  or expensive  human cells.127 
Another issue that  has been largely overlooked  yet is critical 
to   consider  in   OoC/HoC   design    is   temporal  scaling    in 
reference to disparate cell growth  and  turnover rates  between 
tissues and between  in vivo and in vitro conditions, particularly 
when  studying drugs  with  slow kinetics. It is well recognized 
that  cellular  co-cultures are subject  to being  overrun  by one of 
the  two  cell  types,  although components can  be  added  to 
culture media  to retard proliferation of one  species128 or 
accelerate the growth of the other.  It may be possible to design 
a mechanical means to address cellular  turnover, for example 
by adding or removing sections of cells from  an organ  as the 
entire  MPS ages. 
While fluorescence sensors can be used to record  metabolic 
signals  such as acidification and oxygenation, it may be wise to 
reserve optical  bandwidth for intracellular fluorescent probes, 
and  instead utilize  miniature, wide-bandwidth electrochemi- 
cal sensors matched to small  cell populations129–131  or single 
cells.132–135 It is a great advantage that,  typically, the signal-to- 
noise  ratio of electrochemical sensors does not increase as the 
electrodes are miniaturized,136 and it has been shown  possible 
to  make   electrochemical measurements  of  single  cells  and 
small  cell populations.134,135,137,138 
A  larger  problem is  to  characterize the  circulating  mole- 
cules  either  consumed or produced by each  organ,  given the 
small  volumes  and  the  need  to track  concentrations of many 
molecules over long periods of time.  Nanospray injection, ion 
mobility-mass spectrometry (nESI-IM-MS) may prove to be the 
key technique for rapid  OoC state  monitoring, given that  IM 
separations require milliseconds rather than the hour  or so of 
high  pressure liquid  chromatography,139,140  with the  recogni- 
tion that  nESI requires desalting of the media  that  can now be 
done  on-line.141 Ultimately,  the sensors and  controllers might 
be  interconnected in  a  way that   would  lead  to  automated 
inference of model-based control  algorithms.22,142 
An additional implication of the  small  fluid  volumes  in  a 
mHu  or  mHu  is  that  adjustment of the  chemical concentra- 
tions  of the perfusion media, for example to simulate humoral 
control  of organ  function, requires injection of small  volumes 
of precisely mixed fluids. While a high-throughput screening 
fluidic robot  or droplet injector can handle nl to pl volumes,  it 
is   a   non-trivial  to   connect  one   of   these   into   a   closed, 
circulating system of coupled HoCs/OoCs. It is yet another 
problem to achieve the dynamic range  of concentrations of 
different chemical species  found  in typical cell culture media 
without the  use of large volumes  of media  and  serial  dilution 
techniques. It will also  be necessary to provide  the  signaling 
molecules and  metabolites from  missing organs,   as  well as 
apply  localized  biochemical perturbations to  assess  the 
response of  the  other   organs,   but  note  that  this  has  to  be 
done  as a small  perturbation of the  mL to mL volume  of the 
blood  surrogate with a temporal resolution guided  by the 
requisite controller bandwidth. A microfluidic microformula- 
tor as we discussed earlier  may meet  these  needs. 
As the  complexity  of a coupled OoC system  increases with 
the  number of organs  integrated, organ  scaling  will become 
more  complicated, since  the  metabolic demands and  relative 
This journal is © The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3496–3511 |  3508 
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scaling  between  organs  will undoubtedly be affected.  We also 
believe that  the scaling  in multi-organ OoC/HoC systems, 
particularly for dynamic metabolic phenomena, will require 
systematic design  such that the functional scaling of any organ 
system  is not  significantly altered  by another organ,  and  no 
single    organ    receives   a   substantial,   unintended   scaling 
priority. 
Coupled  non-linear biological  systems  can spontaneously 
oscillate  and  may require external  stabilization, which  in turn 
will require the use of sensors and  controllers, possibly  at the 
level of each organ.  The neurohumoral control  of human 
homeostasis may in fact be simulated by a properly configured 
sensor and  control  system,  which  in  turn  will benefit from 
both   properly   scaled   sensors  and   the   ability   to   rapidly 
Conclusions 
 
It is reasonable to assume that  the  many  issues  addressed in 
this  review can be resolved  through careful  attention to 
engineering and   physiological details,  particularly  with  the 
large number of well-funded investigators now working on this 
worldwide.  Clearly,  this  does  represent a Lab-on-a-Chip 
challenge of unprecedented complexity  and  significance. It is 
most  important to recognize  that  there  are obvious  trade-offs 
between  realism and  simplicity,  since  the  ability to sense  and 
control    the    microscale   environment   in    microfabricated 
organs-on-a-chip  may   provide   a   solution  to   the   current 
impasse in extending existing  in vitro models, most  of which 
are  based  upon  single-layer  cellular  monoculture, to  greater 
150
 
reformulate the  perfusion media. That  said,  regulatory  noise 
may  contain useful   information about   system   interconnec- 
tions. 
It will be interesting to determine whether cellular 
heterogeneity in mixed cultures, critical  to cellular  signaling 
mechanisms in vivo, can be maintained for long times  in vitro 
in coupled HoC/OoC systems.  Given the regulatory  role of the 
cellular microenvironment in vivo,143,144 there  would be reason 
to  expect  that   it  might   in  fact  become   easier   to  maintain 
heterogeneity  as  multiple  cell  types  are  grown  together in 
realism and  utility. 
There will undoubtedly be requests to make these  OoC/HoC 
systems  ever-more realistic, and to criticize them  for their 
shortcomings. There have been  similar drives for perfect 
reductionist representations, particularly in the  regulatory 
networks and  systems  biology  communities, where  computa- 
tional  models continue to grow in complexity and may operate 
at a very small  rate  compared to real  time.  It is important to 
realize  that  OoC/HoC systems  reside  in a niche  of abstraction 
that  will improve   constantly with  technology but  will never 
9
 
balanced  environments  with   self-conditioned  media.  The 
exactly recreate a full human, which  represents y10 years of 
Shannon-Wiener  Index   may  prove   important  in   assessing 
and  controlling this. 
We  have  not  yet  addressed in  detail   the  scaling   issues 
associated with microfluidics, oxygen carrying  capacity  of the 
blood  surrogate, and  the  distributed  hydraulic impedance of 
both  the individual organs  and  the coupled system.  This is of 
evolutionary engineering. It may be most  useful  if OoCs and 
HoCs are  viewed as simplified model  systems  for PK/PD and 
systems  biology studies, not  small  humans. 
The drive  to perfect  reductionism is put  in  perspective by 
both Jorge Luis Borges and Lewis Carroll, in which a map of an 
empire/country the  size  of  an  empire/country is  not  found 
151,152
 
particular   significance  for   mHu    and    mHu   systems    with 
useful. Just as a perfect  map  resolves  few problems and 
working   hearts.  One  would   expect   that   designing around 
these  constraints would benefit greatly from multiphysics, 
computational biology modeling tools.145,146  Optimized micro- 
fluidic  design  using  a first-principles optimization of vascular 
produces  others,  the   creation  of  a  near-to-perfect  in  vitro 
replica  of a human may accomplish little at great expense.  We 
believe  that   with  the   proper   application  of  scaling   and   a 
balance between  abstraction and realism, we should be able to 
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branching147–149  may  be  better  suited than approaches that 
learn  much  about  the complexity  of human biology and  its 
assume a particular scaling  law.9 
Ultimately,   there   may  be  significant  technical  and   eco- 
nomic  advantages to  creating a  mHuman on  a  single 
microfluidic chip as shown  schematically in Fig. 3. Simpler 
implementations are already being  developed.108 The total 
volume  of fluidic  interconnects is minimized. On-chip  valves 
can  be utilized  to bypass  individual organs  while  the  organs 
are being seeded  and grown to a stable  state,  and  to adjust the 
duty cycle by which they are connected to the entire  system  so 
that conditioning of media  can be gradual rather than sudden, 
providing  time   for   cellular    up-   and    down-regulation   of 
signaling and  control  genes.  Multi-organ integration  is  not, 
however,   a  practical  approach  until   each   organ   has   been 
perfected individually, albeit  at the  correct  size. Hence  as we 
gain  experience in this  field, we need  to make  our  HoCs and 
OoCs small,  but  not  too small. 
interaction with  drugs  from  each  implementation of a HoC/ 
OoC. Ultimately,  we may be able to create OoC/HoC surrogates 
for specific genetic  or disease  subgroups for drug development 
or for individual patients to optimize their  treatment. 
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